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INTRODUCTION AND OVERVIEW OF THE THESIS 
Intracoronary stent replacement is being used increasingly for the treatment of athero-
sclerotic coronary artery disease and has gained widespread acceptance. Although stent 
implantation itself has been shown to reduce restenosis compared to balloon angioplas-
ty, in-stent restenosis still occurs in 10-40% of patients.1,2 In-stent restenosis has long 
been considered the main limitation hampering the long-term efficacy of coronary stent-
ing. Restenosis after stent occurs secondary to the accumulation of smooth muscle cells 
and extracellular matrix which consists of proteoglycans, hyaluronan and collagen.3,4 
To overcome this major limitation, drug-eluting stents were developed. Drug-elut-
ing stents consist of a drug (immunosuppressive, antiproliferative, or anti-inflammatory 
drug), a polymer, and a stent platform. Several drugs with durable or erodable polymers 
were tested in clinical trials and showed that drug-eluting stents significantly inhibit neo-
intimal growth compared with bare metal stents.5-7 Currently, drug-eluting stents have 
been widely distributed all over the world and become main-stream of percutaneous 
coronary intervention. However, (1) long-term efficacy and chronic vascular response af-
ter drug-eluting stents implantation in humans (Part 1 of this thesis) (2) effect of drug-
eluting stents for patients with high in-stent resteonsis risk factors, such as diffuse lesion, 
diabetes mellitus, left main coronary artery lesion, chronic total occlusion or bifurcation 
lesion (Part 2 of this thesis), have not been fully investigated. Furthermore, problem of 
stent thrombosis is still observed in drug-eluting stent era. Drug-eluting stents interferes 
with the natural healing response by preventing or significantly delaying the formation 
of a functional endothelial lining over stent. The early establishment of a functional en-
dothelial layer after stent implantation may resolve this issue. Recently, the existence of 
circulating endothelial progenitor cells has been identified as a key factor for re-endo-
thelialization.8,9 New concept stent using immobilized antibodies targeted at endothelial 
progenitor cell surface antigens has been developed. (Part 3 of this thesis) 
Part 1 Long term tissue growth inside and outside drug-eluting stent in 
humans
In animal models, the inhibition of neointimal hyperplasia after deployment of poly-
mer-coated sirolimus-eluting stents and gelatin coated paclitaxel-eluting stents was not 
sustained at 90 days due to delayed cellular proliferation. Although long term follow-
up after drug-eluting stents implantation shows a sustained clinical benefit in several 
randomized trials, little is known about neointimal growth and vessel reaction out of the 
stent beyond the first 6 to 9 months. In chapter 2, four-year coronary artery response 
inside and outside the stent after sirolimus-eluting stent implantation was evaluated by 
Chapter  1
14
using serial quantitative IVUS (post-procedure, 4 months, 1 year, 2 years and 4 years) and 
computer assisted grey-scale value analysis for plaque composition in 23 patients in the 
Firs-in-man trial. In chapter 3, two-year coronary artery response inside and outside the 
stent after bare metal stents and paclitaxel-eluting stent implantation were evaluated 
by using serial quantitative IVUS (post-procedure, 6 months and 2 years) in the TAXUS 
II Study. In chapter 4, one-year coronary artery response after various doses and phar-
macokinetic release of paclitaxel-eluting stents with an erodable polymer was evaluated 
by using serial quantitative IVUS (post-procedure, 4 months and 1 year) in the Paclitaxel 
In-Stent Controlled Elution Study (PISCES). In chapter 5, vessel reaction against several 
kinds of drug-eluting stents (sirolimus, paclitaxel, everolimus and ABT 578-eluting stents 
were summarized. 
Part 2 Efficacy of drug-eluting stent for high risk patients
Many randomized trial showed that sirolimus-eluting stents and paclitaxel-eluting stents 
are dramatically reduced in-stent restenosis and target lesion revascularization, com-
pared to bare metal stents. However, these trials had exclusion criteria. The efficacy of 
drug-eluting stents for high risk patients and lesions for restenosis with conventional 
bare metal stents has not been evaluated in detail. At the Thoraxcenter, Erasmus univer-
sity, the safety and efficacy of unrestricted utilization of sirolimus and paclitaxel-eluting 
stents in the real world were analyzed. (RESEARCH: Rapamycin-Eluting Stent Evaluated 
At Rotterdam Cardiology Hospital Registry and T-SEARCH: Taxus-Stent Evaluated At Rot-
terdam Cardiology Hospital Registry). In these registries, sub-analyses for “high risk pa-
tients” such as patients with diffuse lesion (chapter 6), diabetes mellitus (chapter 7 and 
8), chronic total occlusion of left main bifurcation lesion (chapter 9), left main coronary 
artery lesion (chapter 10 and 11), chronic total occlusion lesion (chapter 12 and 13) or 
bifurcation lesion (chapter 4 and 15) were analyzed.
Part 3 Endothelial progenitor cell – alternative to drug-eluting stents
In chapter 16, stent thrombosis is still observed in daily practice, using drug-eluting 
stents and it is associated with a high morbidity and mortality. EPC capture coating stent 
using monoclonal anti-human CD34 antibodies has been developed and this device may 
have the potential to reduce stent thrombosis and in-stent restenosis (chapter 17). In 
chapter 18, the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointi-
mal Growth - First In Man) Registry which is the first clinical investigation using this tech-
nology, was reported.
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Part 4 Future direction to the interventional cardiology
Despite the advances in the treatment of patients with coronary artery disease, sudden 
cardiac death is still unacceptably prevalent. Patients with ischemic heart disease usually 
require a combination of therapies (drugs and coronary intervention) and may continue 
to experience symptoms. Recently, numerous percutaneous interventional treatments 
and diagnostic tools have been developed to diagnose the vulnerable plaque and to 
treat the large number of patients with myocardial ischemia. In chapter 19, catheter 
based bypass graft, therapeutic angiogenesis and myogenesis, and the catheter based 
devices to detect the plaque vulnerability and composition were summarized. 
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CLINICAL RESEARCH Interventional Cardiology
Evaluation of Four-Year Coronary
Artery Response After Sirolimus-Eluting Stent
Implantation Using Serial Quantitative Intravascular
Ultrasound and Computer-Assisted Grayscale Value
Analysis for Plaque Composition in Event-Free Patients
Jiro Aoki, MD,* Alexandre C. Abizaid, MD, PHD, FACC,† Patrick W. Serruys, MD, PHD, FACC,*
Andrew T. L. Ong, MBBS, FRACP,* Eric Boersma, PHD,* J. Eduardo Sousa, MD, PHD, FACC,†
Nico Bruining, PHD*
Rotterdam, the Netherlands; and São Paulo, Brazil
OBJECTIVES This study sought to evaluate the long-term arterial response after sirolimus-eluting stent
implantation.
BACKGROUND Sirolimus-eluting stents are effective in inhibiting neointimal hyperplasia without affecting
plaque volume behind the stent struts at six months.
METHODS Serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis
over four years were performed in 23 event-free patients treated with sirolimus-eluting stents.
RESULTS In the first two years, the mean plaque volume (155.5 � 42.8 mm3 post-procedure and
156.8 � 57.7 mm3 at two years, p � 0.86) and plaque compositional change expressed as
mean percent hypoechogenic tissue of the plaque behind the stent struts (78.9 � 8.6%
post-procedure and 78.2 � 8.9% at two years, p � 0.67) did not significantly change.
However, significant plaque shrinking (change in plaque volume � �18.4 mm3, p � 0.02)
with an increase in plaque echogenicity (change in percent hypoechogenic tissue � �7.8%,
p � 0.0001) was observed between two and four years. The mean neointimal volume
increased over four years from 0 to 8.4 � 5.8 mm3 (p � 0.0001). However, no further
statistically significant change occurred between two and four years (7.0 � 6.7 mm3 vs.
8.4 � 5.8 mm3, p � 0.25).
CONCLUSIONS Between two and four years after sirolimus-eluting stent implantation, peri-stent tissue
shrank with a concomitant increase in echogenicity. These intravascular ultrasound findings
suggest that late chronic artery responses may evolve for up to four years after sirolimus-
eluting stent implantation. In addition, the fact that the neointima does not significantly
change from two to four years may suggest that the biological phenomenon of a delayed
healing response has begun to subside. (J Am Coll Cardiol 2005;46:1670–6) © 2005 by the
American College of Cardiology Foundation
Polymer-based drug-eluting stents reduce in-stent neointi-
mal hyperplasia in randomized trials and registries (1–3).
However, concern exists that the non-erodable polymer, as
well as the presence of the drug within the polymer, may
exert long-term detrimental biological effects (4,5). Little
data are available on long-term arterial responses after either
sirolimus-eluting stent (SES) or paclitaxel-eluting stent
(PES) implantation. A recent report showed that PES
implantation was associated with an increase in plaque
volume behind the stent struts at six months (6). Although
SES do not affect the plaque volume behind the stent struts
at six months, no data at later time points have been
reported (7,8). The goal of this study was to evaluate the late
progression of the intra-stent neointima as well as the
long-term arterial remodeling process and changes in plaque
composition inside and outside the stent after SES implan-
tation. To investigate these changes, serial quantitative
intravascular ultrasound (IVUS) and computer-assisted
grayscale value analyses for plaque compositional imaging
over a four-year follow-up period were performed in event-
free patients who were treated with SES.
METHODS
Study population. Thirty patients with de novo coronary
artery lesions were treated with a single 18-mm sirolimus-
eluting Bx-Velocity stent (Cordis, Miami Lakes, Florida) in
São Paulo, Brazil, in the first human study of SES as
described elsewhere (9). After the procedure, proper risk
factor management was mandated for all patients. Of the 30
patients, 26 patients underwent IVUS examination at four
years by protocol, three patients had target vessel revascu-
larization before scheduled four-year follow-up angiogra-
phy, and one asymptomatic patient refused repeat angiog-
From the *Erasmus Medical Center, Rotterdam, the Netherlands; and the
†Institute Dante Pazzanese of Cardiology, São Paulo, Brazil.
Manuscript received December 9, 2004; revised manuscript received June 22, 2005,
accepted June 28, 2005.
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raphy. Of these 26 patients, three were excluded: two
patients did not undergo IVUS at two-year follow-up, and
plaque behind the stent on the immediate post-procedure
IVUS could not reliably be assessed in one patient. Thus,
serial coronary angiography and intravascular ultrasound
analysis were performed post-procedure, at four-month, one-
year, two-year, and four-year follow-up in 23 patients who
were event-free throughout the four-year follow-up period.
Serial quantitative IVUS analysis. All follow-up IVUS
were performed using an automated pull-back system at 0.5
mm/s and recorded on VHS videotapes. Images were
digitized for quantitative analysis. The lumen, stent, and
external elastic membrane contours were detected with
CURAD QCU analysis software (Curad B.V., Wijk bij
Duurstede, the Netherlands) (7). The stented segment and
the 5-mm segments proximal and distal to the stent were
analyzed. Over the four-year follow-up period, different
IVUS catheters and ultrasound consoles were used. Post-
procedure, four-month, and one-year follow-up, 20- or
30-MHz non–electrocardiogram (ECG)-gated IVUS were
performed. At two-year follow-up, 30- or 40-MHz ECG-
or non–ECG-gated IVUS were performed. At four-year
follow-up, 30- or 40-MHz non–ECG-gated IVUS were
performed. Three IVUS consoles were used (In-Vision
[Volcano Therapeutics, Rancho Cordova, California],
Clearview, and Galaxy [both Boston Scientific Corp.,
Natick, Massachusetts]). To analyze and compare the IVUS
data consistently, all IVUS examinations were retrospec-
tively ECG-gated using the Intelligate method, which
automatically selects the end-diastolic frames from pre-
recorded non–ECG-gated IVUS data (10). In addition, an
automatic adjustment for 30-MHz Boston Scientific cath-
eters that were connected to a Clearview console was
applied as previously described (11).
Image-based plaque characterization (echogenicity). We
used a computer-aided, in-house–developed grayscale value
analysis program for plaque characterization (12). Based on
the mean gray level (brightness) of the adventitia, plaque was
classified as more (hyperechogenic) or less bright (hypoecho-
genic) in relation to the adventitia (Fig. 1A). The volume
bounded externally by the surface that lies 0.5 mm outside the
media and internally by the surface that lies 0.2 mm outside the
media was defined as the adventitia. In cross-sectional images,
it appears as a 0.3-mm thick band just outside the media.
Upper tissue was defined as tissue that has a mean gray value
higher than the mean adventitial intensity plus two times its
standard deviation (12). Calcified plaque and stent struts
were in this upper tissue range. The percentage of hypo-
echogenic plaque was calculated for the entire region of
interest, excluding upper tissue (Fig. 1B) (12).
Statistical analysis. Continuous variables were expressed
as mean values � standard deviations and compared by
means of the paired t test. Overall IVUS parameters
(volume and echogenicity) across all time points were
compared using repeated-measure analysis of variance
(ANOVA). Two post-hoc tests (between post-stent and
two years, and between two years and four years) were
performed with Bonferroni corrections (p value for signifi-
cance �0.025) for p values �0.05 on ANOVA.
RESULTS
Patient characteristics. Mean age of patients was 57 years,
and two-thirds were male (Table 1). The left anterior
descending artery was treated in 14 patients, right coronary
artery in 6 patients, and left circumflex artery in 3 patients.
After stent implantation, risk factor management was insti-
tuted in all patients. Aspirin and statins were prescribed in
all patients during the four years.
Plaque volume behind the stent struts. Table 2 shows the
serial quantitative IVUS data. Plaque volume behind the
stent struts did not change significantly in the first two years
(p � 0.86), but showed a significant change between two
and four years because of a decrease in plaque volume
behind the stent struts at four years (156.8 � 57.7 mm3 vs.
138.4 � 42.2 mm3, p � 0.02). Although plaque volume
at the proximal edge of the stents increased significantly
at four-month follow-up compared with post-procedure
(32.5 � 12.2 mm3 vs. 39.8 � 15.8 mm3, p � 0.005), it did
not differ significantly between post-procedure and four-
year follow-up (32.5 � 12.2 mm3 vs. 33.0 � 11.7 mm3,
p � 0.81). At the distal edge, no significant changes in
plaque volume were observed at any time point (p � 0.18).
Neointimal volume. Neointimal volume increased at each
measured time point, and was 8.4 � 5.8 mm3 at four-year
follow-up (p � 0.0001). Between post-procedure and two-
year follow-up, a significant change in neointimal volume
was noted (0 mm3 vs. 7.0 � 6.7 mm3, p � 0.0001).
However, between two-year and four-year follow-up, the
increase in neointimal volume was not statistically different
(7.0 � 6.7 mm3 vs. 8.4 � 5.8 mm3, p � 0.25). Figure 2A
shows the correlation between neointimal volume and
plaque volume behind the stent struts over four years.
Plaque composition. Serial computer-assisted grayscale
value analyses for plaque composition are shown in Table 3.
With respect to the plaque behind the stent struts, there was
a significant decrease in percent hypoechogenic tissue, that
is, an increase in percent hyperechogenicity up to four years
(p � 0.0001). Between post-procedure and two years, there
were no significant changes in plaque echogenicity (78.9 �
8.6% vs. 78.2 � 8.9%, p � 0.67). However, between two
Abbreviations and Acronyms
ANOVA � analysis of variance
ECG � electrocardiogram/electrocardiographic
IVUS � intravascular ultrasound
PES � paclitaxel-eluting stent
SES � sirolimus-eluting stent
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and four years, significant changes were noted (78.2� 8.9%
vs. 70.4 � 10.6%, p � 0.0001). A similar pattern was
observed for plaque at the proximal stent edge with a
significant reduction in percent hypoechogenic tissue at
four-year follow-up (p � 0.02). At the distal stent edge, no
significant changes in plaque echogenicity were observed
across time points (p � 0.78). Figure 3 is a representative
example of a patient with plaque shrinkage and reduction of
hypoechogenic plaque composition from two-year to four-
year follow-up.
Neointimal echogenicity. The echogenicity of the neoin-
tima increased over the four-year follow-up period (p �
0.0001) (Fig. 2B). On post-hoc testing with Bonferroni
corrections, the decrease in hypoechogenicity between four
Figure 1. (A) The adventitia is defined as tissue outside the external elastic membrane contour. For all non-shadowed adventitia pixels, the mean value and
standard deviation are calculated. To observe the suitability, a normal distribution curve based on the same mean and standard deviation histogram is
created. (B) Cross-sectional image of echogenicity and distribution graph of plaque echogenicity behind the stent struts. Hyperechogenic areas are colored
green. Hypoechogenic areas are colored red. ROI � region of interest.
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months and two years was not significant (74.9 � 12.7% vs.
66.7 � 19.1%, p � 0.03), but was significant between
two-year and four-year follow-up (66.7 � 19.1% vs. 57.0 �
22.6%, p � 0.01).
DISCUSSION
Previous reports have shown that SESs are effective in
inhibiting neointimal hyperplasia without affecting total
vessel volume or plaque volume behind the stent struts at six
months (7,8). In the present study, this pattern of tissue
growth inhibition inside and outside the SES was main-
tained at two years. However, at four-year follow-up, a
significant negative remodeling (shrinking) of the plaque
behind the stent struts with an increase in hyperechogenic-
ity was observed.
Several studies have shown that plaque echogenicity in
the carotid artery is related to the histologic components of
plaques and that echolucency (low echogenicity) can predict
clinical events (13,14). For coronary plaque studies, plaque
echogenicity has also been related to the histologic compo-
nents of plaque (15–17). Hyperechogenic tissue has been
shown to be associated with a predominance of dense
fibrous or elastic tissue, whereas hypoechogenic plaque was
correlated with predominance of loose fibrous, lipid, or
necrotic tissue. Recently, other analysis systems such as
IVUS elastography, IVUS palpography, IVUS radiofre-
quency analysis (so-called virtual histology), and optical
coherence tomography have been used to evaluate plaque
vulnerability and plaque composition (18–20). However,
these methodologic approaches require prospective acquisi-
tion of data, for which their respective devices were not
available for human use at the time of initial assessment.
Plaque echogenicity analysis by computer-assisted grayscale
value is currently the only method that has the potential to
analyze plaque composition in a retrospective manner.
Table 1. Patient Characteristics
n � 23
Age, yrs (mean � SD) 57 � 9
Male, % 65.2
Hypertension, % 69.6
Hyperlipidemia, % 47.8
Diabetes mellitus, % 26.1
Family history, % 30.4
Current smoking, % 65.2
Treated vessel
LAD, % 60.9
LCX, % 13.0
RCA, % 26.1
LAD � left anterior descending artery; LCX � left circumflex artery; RCA � right
coronary artery.
Table 2. Serial Three-Dimensional Intravascular Ultrasound Analysis of Neointima and Plaque Volume
After
Procedure 4 Mo 1 Yr 2 Yrs 4 Yrs
ANOVA*
p Value
Post Hoc After
Procedure to
2 Yrs
Post Hoc
2 to 4 Yrs
Neointima, mm3 0 2.1 � 1.7 3.8 � 3.3 7.0 � 6.7 8.4 � 5.8 �0.0001 �0.0001 0.25
Plaque (stented segment), mm3 155.5 � 42.8 160.4 � 60.4 153.5 � 61.6 156.8 � 57.7 138.4 � 42.2 0.04 0.86 0.02
Vessel (stented segment), mm3 305.1 � 53.7 310.8 � 99.4 305.4 � 83.8 309.8 � 84.1 290.5 � 65.3 0.09 — —
Plaque (proximal edge), mm3 32.5 � 12.2 39.8 � 15.8 36.5 � 11.9 37.4 � 13.0 33.0 � 11.7 0.006 0.03 0.05
Vessel (proximal edge), mm3 82.6 � 21.9 88.6 � 23.8 80.1 � 17.2 82.6 � 22.1 78.3 � 21.6 0.001 0.98 0.10
Plaque (distal edge), mm3 26.2 � 15.4 28.6 � 11.1 28.6 � 14.0 31.1 � 13.4 25.8 � 11.3 0.18 — —
Vessel (distal edge), mm3 63.3 � 22.0 68.5 � 20.8 66.5 � 26.3 67.3 � 21.8 61.4 � 22.7 0.07 — —
*Repeated-measures analysis of variance (ANOVA) was performed among five periods. Post hoc analysis between after the procedure and two years, and between two and four
years were performed with Bonferroni corrections (significant level of p value is 0.025).
Figure 2. (A) Correlation between neointimal volume and plaque volume
behind the stent struts over four years. (B) Correlation between neointimal
percent hypoechogenicity and plaque percent hypoechogenicity behind the
stent struts over four years. Error bars indicate 95% confidence interval.
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For SES, 80% of the drug load is eluted within 30 days of
stent implantation (1). However, concern has arisen about
long-term biological reactions to the non-biodegradable
polymer (5). Long-term exposure to these polymers may
cause chronic inflammation. Complete natural healing (i.e.,
re-endothelialization and a reduction in proteoglycan con-
tent) may take three to six months after bare metal stent
implantation (21). In this present study, plaque volume
behind the stent struts decreased between two and four
years, and this shrinkage was accompanied by a change in
plaque echogenicity, suggestive of a change in plaque
composition. This may indicate that the peri-stent area has
undergone a slower healing process after SES implantation
that results in a more fibrous content at four-year follow-up.
In animal experiments, it has been documented that the
exuberant proliferative process observed after stenting is
largely inhibited in the early stage with SES, but the normal
healing process is also delayed with persistence of fibrin
deposition and inflammatory cells (22). In humans, one
study reported the histologic findings of atherectomy spec-
imens of restenotic lesions after implantation of a paclitaxel
derivative-eluting polymer stent in which persistent fibrin
accumulation with smooth muscle cells and proteoglycan
and collagen type III-rich matrix with inflammation was
observed at 12 months (4,5). An autopsy performed on a
patient four years after SES implantation showed complete
healing, indicating that the delayed healing response had
abated, concurring with our findings (23).
In this study, neointimal volume continued to increase
over the four-year period. However, the increase between
two and four years failed to reach statistical significance (7.0
vs. 8.4 mm3, p � 0.25), and the change in neointimal
volume between two years and four years was significantly
less than between the post-procedure and two-year mea-
surements (1.4 vs. 7.0 mm3, p � 0.04), which possibly
indicates that the delayed tissue proliferation has subsided.
Carter et al. (24) reported long-term effects of SES in a
porcine coronary model. They found that inhibition of
neointimal hyperplasia was not sustained at 90 days com-
pared with the bare metal stent, and the mean neointimal
area was similar between 90 days and 180 days. These
results differ from observations seen in clinical trials, includ-
ing this study. Several trials have reported low target vessel
revascularization rates up to three years (25). This discrep-
ancy is likely explained by different monocyte and lympho-
cyte responses to similar concentrations of sirolimus in
human and porcine vessels, and the different anatomical
Table 3. Percent Hypoechogenic Tissue Component in the Plaque and Neointima
After
Procedure 4 Mo 1 Yr 2 Yrs 4 Yrs
ANOVA*
p Value
Post Hoc After
Procedure to
2 Yrs
Post Hoc
2 to 4 Yrs
Neointima, % — 74.9 � 12.7 68.9 � 17.1 66.7 � 19.1 57.0 � 22.6 0.0001† 0.03‡ 0.01
Plaque (stented segment), % 78.9 � 8.6 79.4 � 6.7 81.3 � 7.4 78.2 � 8.9 70.4 � 10.6 �0.0001 0.67 �0.0001
Plaque (proximal edge), % 88.7 � 6.9 87.2 � 6.5 87.1 � 6.0 87.7 � 7.9 81.7 � 9.3 0.02 0.67 0.008
Plaque (distal edge), % 86.1 � 9.8 86.8 � 6.0 87.0 � 10.4 88.5 � 9.5 85.9 � 9.4 0.78 — —
*Repeated-measures analysis of variance (ANOVA) was performed among five periods. Post-hoc analysis between after the procedure and two years, and between two and four
years were performed with Bonferroni corrections (significant level of p value is 0.025). †Repeated-measures ANOVA was performed among four periods, except after the
procedure. ‡Post-hoc analysis was performed between four months and two years.
Figure 3. A representative example of a patient with plaque compositional changes between two-year and four-year follow-up. Top row shows
cross-sectional vessel image at (A) post-procedure, (B) four months, (C) one year, (D) two years, and (E) four years. Red line indicates lumen. Light blue
line indicates stent. Green line indicates media. Dense blue line indicates adventitia. Bottom row shows cross-sectional echogenicity images.
Hyperechogenic areas are colored green. Hypoechogenic areas are colored red. (A’) Percent plaque behind stent hypoechogenicity was 84.0%
post-procedure, (B’) 85.3% at four months, (C’) 88.4% at one year, (D’) 84.2% at two years, and (E’) 74.8% at four years.
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features of normal porcine coronary arteries versus athero-
sclerotic human coronary arteries (26).
Furthermore, the increase in neointimal echogenicity as
observed in this study would also suggest that a fibrotic
process is now operative and predominant. The rate of
growth of the neointima has slowed—both features suggest
that the completion of the healing process may be expected
in the near future.
Study limitations. This study is limited by the sample
size of 23 patients. Secondly, patients without events
were used for the serial IVUS analysis. Consequently,
these results may not apply to all patients treated with
SES. Different IVUS catheters and consoles were used
over the four-year period, and most data were acquired
without ECG gating. These differences may have ham-
pered the consistency of volumetric and echogenic anal-
ysis (27). For instance, BSC 30-MHz catheters con-
nected to a Clearview console underestimates true
dimensions (11). To correct for these discrepancies, the
results from the 30-MHz catheter were adjusted using a
previously reported mathematical model (11), and image
artifacts resulting from cardiac cycle motion observed in
non–ECG-gated images were circumvented by the use of
the Intelligate method, which converts non–ECG-gated
data to ECG-gated data retrospectively (10,28).
The adventitia was taken as a reference to determine the
change in echogenicity occurring in the peri-stent and
intrastent tissue. Any alterations to the adventitia (e.g.,
inflammatory and fibrotic reactions) after stent deployment
may alter the echogenicity during the follow-up period.
Because any potential increase in echogenicity of the adven-
titia cannot be totally excluded or measured, the change in
echogenicity of the peri-stent and intra-stent tissue may be
underestimated and the interference of stent struts with
plaque echogenicity may not be completely excluded. Fi-
nally, any remaining bias after correction from the use of
different IVUS systems cannot be totally excluded in the
present study. Despite the inherent limitations, plaque
echogenicity analysis by computer-assisted grayscale value is
to date the only method with the potential to analyze plaque
composition retrospectively.
Conclusions. After SES implantation, negative plaque
remodeling and a decrease of hypoechogenic plaque
composition were observed at four-year follow-up. In
addition, the fact that the neointima does not signifi-
cantly change from two to four years may suggest that the
biological phenomenon of a delayed healing response has
begun to subside.
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Chronic arterial response to PES 
Peristent Remodeling and Neointimal Suppression 2 Years
After Polymer-Based, Paclitaxel-Eluting Stent Implantation
Insights From Serial Intravascular Ultrasound Analysis in the
TAXUS II Study
Jiro Aoki, MD; Antonio Colombo, MD; Dariusz Dudek, MD; Adrian P. Banning, MD;
Janusz Drzewiecki, MD; Krzysztof Zmudka, MD; Francois Schiele, MD; Mary E. Russell, MD;
Joerg Koglin, MD; Patrick W. Serruys, MD, PhD; for the TAXUS II Study Group
Background—The purpose of this study was to evaluate long-term vascular responses as long as 2 years after implantation
of polymer-based, paclitaxel-eluting stents in contrast to uncoated stents.
Methods and Results—TAXUS II is a randomized, double-blind trial comparing slow-release (SR) and moderate-release
(MR) TAXUS stents with bare-metal control stents (BMSs). One hundred sixty-one event-free patients (SR, 43; MR,
41; and BMS, 77) underwent serial intravascular ultrasound (IVUS) analysis after the procedure and at 6 months and
2 years. At 2 years, neointimal responses continued to be significantly suppressed in the SR and MR groups when
compared with the BMS group (BMS, 1.49�1.12 mm2; SR, 0.94�0.76 mm2 [P�0.004]; and MR, 1.06�0.90 mm2
[P�0.02]). Between 6 months and 2 years, the BMS group showed compaction of the neointima (�, �0.22�1.05 mm2
[P�0.08]). In contrast, both the SR and MR groups exhibited an increase (� SR, 0.30�0.76 mm2 (P�0.01); MR,
0.41�0.94 mm2 [P�0.009]). Between 6 months and 2 years, the initial increase in plaque outside the stent regressed
in the BMS and SR groups to levels comparable to those after the procedure, whereas expansive remodeling partially
regressed in the MR group (� between after the procedure and 2 years BMS, �0.34�1.28 mm2 [P�0.05]; SR,
�0.02�1.40 mm2 [P�0.93]; MR, 0.32�1.56 mm2 [P�0.27]).
Conclusions—The 2-year follow-up demonstrates that neointimal suppression was dose independent and that this effect
was still sustained at 2 years. However, the increase in area outside the stent seen at 6 months regressed to different
extents in a dose-dependent manner at 2 years. (Circulation. 2005;112:3876-3883.)
Key Words: stents � remodeling � restenosis
Both slow-release (SR) and moderate-release (MR)polymer-based, paclitaxel-eluting stents prevent in-stent
neointimal growth compared with bare-metal stents (BMSs).1
In the patient population studied in TAXUS II, these antir-
estenotic effects were comparable for both dose formulations.
However, at 6 months, this inhibition was associated with
expansive, peristent remodeling.2 The extent of peristent
remodeling was more pronounced with the MR formulation,
implying dose-dependent differences in vascular responses
outside but not inside the stent.
Clinical Perspective p 3883
In animal studies, the mechanism of action of drug-eluting
stents on neointimal proliferation after stent implantation
seems to be partially explained by a delay in vascular
responses. For polymer-based, paclitaxel-eluting stents, inhi-
bition of in-stent neointimal growth is associated with a delay
in intimal healing up to 28 days, as indicated by initially
increased fibrin deposition, inflammation, and delayed endo-
thelialization.3 By 90 days, peristrut changes associated with
paclitaxel were resolving, but in-stent neointimal growth
suppression was no longer present.
TAXUS II is an international study of 2 consecutive
cohorts designed to evaluate 2 formulations of a polymer-
based, paclitaxel-eluting stent. The primary end point in the
original protocol was the percent net volume obstruction,
providing a unique opportunity to evaluate serial intravascu-
lar ultrasound system (IVUS) changes over time.
The objective of this study was to evaluate long-term arterial
responses both inside and outside the stent as long as 2 years
after implantation of polymer-based, paclitaxel-eluting stents by
using serial quantitative IVUS analysis in event-free patients.
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Methods
Patient Selection
The original study design, procedure, and IVUS results have been
described previously.1,2,4 The design of the TAXUS II study is a
randomized, double-blind, controlled trial. In brief, 536 patients with
single de novo coronary lesions (�50% stenosis on visual assess-
ment) treatable with a single stent (3.0- or 3.5-mm diameter and
15 mm long) were randomly assigned to 2 consecutive, independent
cohorts. The first cohort of patients was randomized to be treated
with either a control BMS or a TAXUS-NIRx SR formulation stent.
A second cohort of patients was randomized to control BMSs versus
a TAXUS-NIRx MR formation. The primary end point was met with
a significant 66% (SR) and 62% (MR) reduction in 6-month percent
net volume obstruction as assessed by IVUS in both groups, without
an apparent difference between the SR and MR groups.
To further evaluate the natural history of vascular responses to
TAXUS, the study protocol was amended to include a 2-year IVUS
long-term follow-up. Of the initial 536 patients, 161 patients without
any clinical events through the 2-year follow-up and with serial
(postprocedure, 6 months, and 2 years) and analyzable IVUS data
were selected for this substudy (BMS, 77; SR, 43; and MR, 41). This
patient population represents a highly selected subgroup of patients
successfully treated with either a BMS, a TAXUS SR stent, or a
TAXUS MR stent. Because the 2-year quantitative coronary angiog-
raphy (QCA) and IVUS substudy was added as an amendment to the
original study protocol, it required additional approval from the local
regulatory agencies and ethics committees before being implemented
at the sites. The 2-year substudy was not approved by the appropriate
regulatory authorities or ethics committees at 9 of the 38 sites. As a
result, of the original 536 intent-to-treat patients, 154 were not
eligible to participate in the 2-year substudy. Additionally, 122
patients did not consent to the 2-year substudy, whereas 30 patients
were excluded for clinical reasons, resulting in 230 patients who
were eligible to participate in the substudy. In 34 of the 230 patients,
IVUS either was not performed or was not of adequate quality to be
included in the qualitative and quantitative analysis. An additional 23
patients were excluded because they had either a target-vessel
revascularization before 6 months or had a target-vessel revascular-
ization after 6 months but did not have IVUS before the target-vessel
revascularization. Finally, 12 patients were excluded from this
analysis because paired IVUS data were not available at all 3 time
points (postprocedure, 6-month, and 2-year data). Written, informed
consent was obtained from all patients.
TAXUS Stent System
The 15-mm NIR Conformer stent of 3.0- or 3.5-mm diameter was
used in this study (Boston Scientific Corp and Medinol Ltd). All
TAXUS NIRx stents were coated with 1.0 �g/mm2 paclitaxel in an
SR or MR formulation as previously described.1 The SR and MR
dose formulations are characterized by differences in the amount of
drug released during the initial 48-hour burst phase as well as the
amount of drug remaining embedded in the polymer at 30 days.
Study Procedure
Stents were implanted after balloon predilatation as described in the
initial reports. Per study protocol, all patients were to receive 75
mg/d aspirin indefinitely. Clopidogrel (300 mg) was administered,
preferably 48 hours before the procedure, followed by 75 mg once
daily for 6 months.
Quantitative IVUS and Angiographic Analysis
The quantitative IVUS and QCA analyses were performed by an
independent core laboratory that remains blinded to treatment
allocation during the ongoing 5-year follow-up (Cardialysis). Serial
IVUS (postprocedure, 6-month, and 2-year follow-up) procedures
were performed after administration of 200 �g intracoronary nitro-
glycerin with an automated pullback at 0.5 mm/s. All IVUS
procedures were recorded on VHS videotape, and images were
digitized for analysis. A computer-based contour-detection program
was used for automated 3-dimensional reconstruction of the stented
segment.5,6 Reconstruction and quantification of 3-dimensional
IVUS images have been validated previously.5 In brief, a series of
tomographic images is continuously acquired during an IVUS
pullback procedure. With use of a 40-MHz ultrasound probe, 25
frames per second are available from a motorized pullback procedure
recorded on videotape. In this study, an average of 714 sections in
the stented lesion were obtained per patient. All acquired cross-
sectional frames were analyzed by semiautomatic contour tracing in
several reconstructed, longitudinally cut planes, as developed and
tested in cooperation with Cuard B.V. The applied approach focuses
on the tracing of contours in the reconstructed, longitudinally cut
planes (L-mode view). The number of L-mode contours to be traced
is independent of the number of frames in the analysis. As many as
72 L-mode views at 5° intervals can be selected for display and
subsequent analysis. Contours of vessel, lumen, and stent structures
can then be traced. Instead of trying to find the structures completely
automatically, the program uses starting points as defined by the
user, followed by autotracing of the contour segment in either of 2
possible directions. Pieces of the contours can be retraced in a
semiautomatic procedure to optimize the interaction between oper-
ator and algorithm. In this way, all cross-sectional areas are ana-
lyzed, and the 3-dimensional nature of the data set is fully used. The
interobserver correlation coefficients for lumen, stent, and vessel
volumes resulted in R2 values of 0.96, 0.99, and 0.99, respectively.
In the stented segment, mean peristent area and mean neointimal
area were calculated. Incomplete stent apposition (ISA) was defined
as 1 or more stent struts clearly separated from the vessel wall with
evidence of blood speckles behind the strut without overlapping side
branches.6–8 ISA was classified into 3 groups. Resolved ISA was
defined as ISA that disappeared during follow-up. Persistent ISA
was defined as ISA that was evident both after the procedure and at
follow-up. Late acquired ISA was defined as ISA that was absent
after the procedure but present at follow-up.
Statistical Analysis
The BMS groups of the 2 cohorts were combined because the
baseline and 6-month follow-up data showed no significant differ-
ences, as previously described.1 Therefore, 3 groups are reported in
this study: The combined BMS, the TAXUS-SR, and the
TAXUS-MR groups. Discrete variables are displayed as percentages
and were tested with Fisher’s exact test. Continuous variables are
expressed as mean�SD. When 3 groups were compared, overall
probability values were derived from 1-way ANOVA or Fisher’s
exact test. Comparisons between postprocedure and follow-up data
were performed with a 2-tailed, paired t test, whereas comparisons
between 2 groups were performed with Fisher’s least significant
difference test. Linear regression was performed to assess the
correlation between different IVUS outcomes. A value of P�0.05
was considered statistically significant.
Results
Patients and Procedural Characteristics
Table 1 presents the patient and procedural characteristics for
the group that had serial (after the procedure, at 6 months, and
at 2 years) IVUS examinations compared with the entire
TAXUS II study cohort. Comparable baseline demographic
and angiographic data with the exception of the prevalence of
males (P�0.03) indicate that the data in the serial IVUS
cohorts are representative of the overall randomized study
population.
Area Inside the Stent (Neointimal Area)
As shown in Table 2, the neointimal area at 6 months was
significantly suppressed in the SR and MR groups, as
detected by serial IVUS when compared with the BMS group
(1.71�1.38 mm2 in the BMS group versus 0.64�0.81 mm2 in
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the SR group, P�0.0001; 0.66�0.83 mm2 in the MR group,
P�0.0001). This reduction relative to the BMS group was
also present at 2 years (1.49�1.12 mm2 in the BMS group
versus 0.94�0.76 mm2 in the SR group, P�0.004;
1.06�0.90 mm2 in the MR group, P�0.02). When relative
changes within the 3 groups were compared, the BMS group
showed compaction of the neointima between 6 months and
2 years, as demonstrated by a trend toward a decrease in
neointimal area (�, �0.22�1.05 mm2, P�0.08). In contrast,
the SR and MR groups both exhibited a significant increase in
neointimal area between 6 months and 2 years when com-
pared with controls (SR �, 0.30�0.76 mm2, P�0.01 versus
BMS; MR �, 0.41�0.94 mm2, P�0.009 versus BMS; Table
2). However, according to QCA analyses, the average mini-
mal lumen diameter (MLD) in the SR and MR groups did not
decrease from 6 months to 2 years (2.30�0.33 to
2.36�0.28 mm in the SR group; 2.30�0.38 to
2.31�0.35 mm in the MR group; Table 3).
TABLE 1. Baseline and Procedural Characteristics
BMS
(n�77)
SR
(n�43)
MR
(n�41) P*
All Randomized
Patients (N�536)
Age, y 57.2�9.0 59.4�1.3 57.5�10.9 0.50 60.1�10.0
Male, % 85.7 65.1 73.2 0.03 75.6
Current smoker, % 29.9 14.0 24.4 0.14 25.0
Diabetes, % 13.0 9.3 9.8 0.85 14.7
Hypertension, % 46.8 62.8 51.2 0.24 61.4
Hypercholesterolemia, % 72.7 83.7 80.5 0.35 75.9
Unstable angina, % 27.3 27.9 14.6 0.26 34.3
Previous MI, % 50.7 41.9 51.2 0.63 39.7
Target vessel, %
LAD 52.0 41.9 39.0 0.34 44.6
LCX 11.7 20.9 19.5 0.31 19.6
RCA 36.4 37.2 41.5 0.89 35.8
RVD, mm 2.73�0.50 2.78�0.38 2.76�0.45 0.88 2.75�0.46
Target lesion length, mm 10.5�4.15 10.0�3.69 11.0�6.27 0.68 10.4�4.23
Stent size, mm 3.29�0.25 3.31�0.24 3.23�0.25 0.31 3.26�0.25
MI indicates myocardial infarction; LAD, left anterior descending coronary artery; LCX, left circumflex artery; RCA,
right coronary artery; and RVD, reference vessel diameter. Other abbreviations are as defined in text. Values are
mean�SD or percentages.
*ANOVA among the 3 groups.
TABLE 2. Quantitative IVUS Data
BMS (n�77) SR (n�43) MR (n�41) P*
Neointimal area, mm2
6 Months 1.71�1.38 0.64�0.81 0.66�0.83 �0.0001
2 Years 1.49�1.12 0.94�0.76 1.06�0.90 0.006
Difference 2 years�6 months �0.22�1.05 0.30�0.76 0.41�0.94 0.001
Plaque area outside the stent
(peristent area), mm2
After procedure 7.97�2.00 8.18�2.11 8.38�2.52 0.71
Difference 6 months�after 0.68�1.19 1.18�1.66 1.52�1.68 0.04
Difference 2 years�6 months �1.02�0.92 �1.21�1.39 �1.19�1.56 0.74
Difference 2 years�after �0.34�1.28 �0.02�1.40 0.32�1.56 0.11
Vessel area, mm2
After procedure 16.43�3.07 17.25�2.93 16.79�3.36 0.50
Difference 6 months�after 1.03�1.41 1.21�1.84 1.60�1.94 0.34
Difference 2 years�6 months �1.18�1.23 �1.33�1.74 �1.38�1.78 0.50
Difference 2 years�after �0.15�1.49 �0.12�1.76 0.21�1.80 0.60
Abbreviations are as defined in text. Values are mean�SD.
*ANOVA among the 3 groups.
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Area Outside the Stent (Peristent Area)
Changes up to 6 Months
In the first 6 months, significant increases in mean peristent
area (calculated as mean vessel area minus mean stent area),
consistent with expansive vessel remodeling, were observed
in all 3 groups (Table 2). In the BMS group, the peristent area
increased by 8.5%, from 7.97�2.00 to 8.65�1.91 mm2
(P�0.0001). This contrasted with an increase by 14.4% in the
SR group (8.18�2.11 mm2 after the procedure versus
9.37�2.79 mm2 at 6 months; P�0.0003) and by 18.1% in the
MR group (8.38�2.52 mm2 after the procedure versus
9.90�2.45 mm2 at 6 months; P�0.0001).
Changes From 6 Months to 2 Years
From 6 months to 2 years, a significant regression of the
peristent area was observed in all 3 groups. In the BMS
group, the peristent area decreased by 11.8%, from
8.65�1.91 to 7.63�1.56 mm2 (P�0.0001). Similarly, the
peristent area decreased by 12.9% in the SR group
(9.37�2.79 mm2 versus 8.16�2.09 mm2; P�0.0001) and by
12.0% in the MR group (9.90�2.45 mm2 versus
8.70�2.20 mm2; P�0.0003).
At 2 years, this regression in the BMS and SR groups
resulted in absolute peristent areas that were comparable to
those observed after the procedure (difference between post-
procedure and 2-year measurements,�0.34�1.28 mm2 in the
BMS group and �0.02�1.40 mm2 in the SR group). In the
MR group, regression of the initial increase was incomplete,
with a remaining net increase at 2 years with respect to the
postprocedure value of 0.32�1.56 mm2 (Table 2).
Assessment of the peristent area showed that the expansive
vessel remodeling observed at 6 months regressed from 6
months to 2 years in all 3 groups. The incidence of this
remodeling pattern was observed in the vast majority of
patients (67.5% in the BMS, 74.4% in the SR, and 78.0% in
the MR groups; Figure 1).
Correlation Between Area Inside the Stent
(Neointimal Area) and Area Outside the Stent
(Peristent Area)
Figure 2 presents the changes of the area inside the stent
versus the correlating changes outside the stent for 2 years to
illustrate the natural history of vascular responses around and
within the stent. This graph illustrates that for the BMS, there
was a reduction in neointimal area as well as a reduction in
the peristent area between 6 months and 2 years. For the SR
group, the neointimal area increased, yet there was a reduc-
tion in peristent area, similar to that seen with the BMS.
Finally, for the MR group, the neointima significantly in-
creased between 6 months and 2 years, with a partial decrease
in peristent area.
For all 3 groups, there were no correlations between
peristent area after the procedure and neointimal area at 6
months (R��0.016, P�0.70 in the BMS group; R��0.021,
P�0.55 in the SR group; and R��0.037, P�0.93 in the MR
group) and 2 years (R��0.011, P�0.51 in the BMS group;
R�0.11, P�0.037 in the SR group; and R��0.036, P�0.88
in the MR group). In addition, there were no correlations
between relative changes in peristent area and changes in
TABLE 3. QCA Data
After Procedure 6 Months 2 Years
BMS (n�77)
RVD, mm 2.89�0.39 2.64�0.49 2.64�0.46
MLD, mm 2.61�0.35 1.91�0.45 2.05�0.40
DS, % 9.50�5.45 27.19�13.36 21.49�11.41
SR (n�43)
RVD, mm 2.87�0.30 2.81�0.40 2.78�0.33
MLD, mm 2.59�0.29 2.30�0.33 2.36�0.28
DS, % 9.53�5.44 17.63�8.78 14.64�6.96
MR (n�41)
RVD, mm 2.89�0.38 2.75�0.37 2.79�0.42
MLD, mm 2.58�0.33 2.30�0.38 2.31�0.35
DS, % 10.24�5.25 16.05�9.59 16.24�9.56
RVD indicates reference vessel diameter; DS, diameter stenosis. Other
abbreviations are as defined in text. Values are mean�SD.
Figure 1. The incidence of increasing (I) or decreasing (D) peris-
tent area up to 2 years after stent implantation within each
group. I/D indicates that peristent area (PSA) increased during
the first 6 months and decreased from 6 months to 2 years; D/D
indicates that PSA decreased up to 2 years; I/I indicates that
PSA increased up to 2 years; and D/I indicates that PSA
decreased during the first 6 months and increased from 6
months to 2 years. Other abbreviations are as defined in text.
Figure 2. Correlation between neointimal area and peristent
area for 2 years. Probability values for peristent area from after
the procedure to 6 months are 0.0001 for BMS, 0.0003 for SR,
and �0.0001 for MR. Probability values for peristent area from 6
months to 2 years are �0.0001 for BMS, �0.0001 for SR, and
0.0003 for MR. The probability value for neointimal area from
after the procedure to 6 months is �0.0001 for all 3 groups,
whereas probability values for neointimal area from 6 months to
2 years are 0.08 for BMS, 0.01 for SR, and 0.009 for MR.
Abbreviations are as defined in text.
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neointimal area over time at 6 months (R��0.013, P�0.57
in the BMS group; R�0.028, P�0.18 in the SR group; and
R��0.018, P�0.48 in the MR group) and 2 years
(R��0.017, P�0.72 in the BMS group; R��0.021, P�0.54
in the SR group; and R�0.021, P�0.22 in the MR group).
Incomplete Stent Apposition
As shown in Figure 3, the incidences of ISA at 2 years were
similar among the 3 groups (10.4% in the BMS group, 7.0%
in the SR group, and 7.3% in the MR group; P�0.82). The
incidences of late acquired ISA at 2 years in all groups were
lower than at 6 months (2.6% versus 6.5% in the BMS group,
0% versus 9.3% in the SR group, and 2.4% versus 9.8% in the
MR group).
Discussion
This article presents the first long-term (up to 2 years) serial
IVUS analysis after deployment of BMSs or drug-eluting
stents in a series of 161 patients. To assess long-term IVUS
outcomes in response to the original study stent implanted
during the index procedure, neointimal area analyses had to
exclude patients with target-lesion revascularization before
the follow-up IVUS examination. Thus, neointimal hyperpla-
sia in the overall population might be underestimated when
compared with this analysis. The major findings of this study
are as follows: (1) Neointimal suppression is maintained for
as long as 2 years in both the SR and MR groups when
compared with the BMS group. (2) Whereas the BMS group
showed compaction of the neointima over time, there were
very modest increases in neointima in the SR and MR groups
between 6 months and 2 years, with significant reductions
relative to the control. (3) The initial increase in peristent area
that coincides with neointimal suppression in both TAXUS
groups during the first 6 months regressed completely in the
SR group and partially in the MR group during the following
18 months to 2 years.
Change in Plaque Area Outside the Stent
In both paclitaxel groups, a significantly increased peristent
area was observed at 6 months. This expansive remodeling
regressed at 2 years, resulting in comparable levels of
peristent area to the BMS group. One might hypothesize that
this could be a result of the “drug effect” associated with a
potentially delayed healing process. The mode of action of
polymer-based, paclitaxel-eluting stents is believed to be
associated with a delay in cellular processes within the vessel
wall. This effect is exemplified in animal models by later
endothelialization, reduced smooth muscle cell proliferation,
and increased fibrin disposition around the stent struts.3
Long-term follow-up beyond 2 years may provide more
insight regarding the possibility of a continued delay versus a
persistent alteration of the remodeling processes outside the
stent.
Mean peristent area is driven by vessel area minus stent
area. Thus, ISA area influences peristent area. The occurrence
of late acquired ISA at 6 months that was resolved at 2 years
can also explain the plaque remodeling pattern outside the
stent in this study. However, the incidences of late acquired
ISA at 6 months that were resolved at 2 years were low (1.3%
in the BMS, 4.7% in the SR, and 4.9% in the MR groups). In
addition, because the change in vessel area was similar to the
change in peristent area, plaque remodeling outside the stent
can be mainly accounted for by changes in plaque area, not
ISA.
The current in vivo findings are limited to areal compari-
sons between groups and do not account for potentially
different cellular compositions of the areas inside and outside
the stent among the groups. New IVUS technologies, such as
computer-assisted gray-scale value analysis and virtual his-
Figure 3. Incidence of ISA for as long as
2 years after stent implantation. Abbrevi-
ations are as defined in text.
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tology, may offer advances in the detection of plaque com-
position to help confirm this hypothesis in future studies.9,10
Long-Term Effect of Inhibition of
Neointimal Growth
Both neointimal area from IVUS analyses and the change in
MLD from QCA analyses are parameters of neointimal
growth. In the present study, there are apparent discrepancies
between the change in neointimal area and the change in
MLD from 6 months to 2 years, especially in the TAXUS
groups. Although average neointimal area increased in both
TAXUS groups from 6 months to 2 years, average MLD did
not decrease during the same time period. Neointimal area is
calculated by considering neointimal growth in the entire
stented segment. The change in MLD is calculated by
considering the worst region, regardless of axial location.
Thus, MLD does not account for diffuse neointimal growth
over the entire length of the stent. These differences demon-
strate that neointimal area is a better index of the magnitude
and distribution of neointimal growth within the stent seg-
ment and may account for some of the discrepancies between
the change in neointimal area and the change in MLD in this
study.
Carter et al11 reported that the inhibition of neointimal
hyperplasia after deployment of polymer-coated, sirolimus-
eluting stents was not sustained at 90 and 180 days owing to
delayed cellular proliferation associated with increased levels
of proliferative cell nuclear antigen. Farb et al3 reported that
neointimal suppression after deployment of chondroitin sul-
fate– and gelatin-coated, paclitaxel-eluting stents was also not
maintained at 90 days. In this human IVUS study, from 6
months to 2 years, there was a small but significant increase
in neointima of unclear clinical significance observed in the
TAXUS group. At variance with the animal studies men-
tioned earlier, the present study of a distinctly different
polymer and dose-release formulation shows that a signifi-
cant effect on neointimal suppression was still present at the
2-year follow-up when compared with the BMS.
In this large IVUS 2-year substudy, neointimal regression
in the BMS group confirmed findings previously reported
from other long-term follow-up assessments of the natural
healing process after stent implantation. Kimura et al12
reported that mean in-stent luminal diameter as measured by
serial QCA analysis was improved from 1.95 to 2.09 mm
between 6 months and 3 years. This observation is in
agreement with a postmortem human coronary artery analy-
sis.13 A hypercellular neointima, rich in type III collagen,
versican, and hyaluronan but relatively little type I collagen,
was observed as long as 18 months after BMS implantation in
humans. After 18 months, neointimal tissue regressed be-
cause of the replacement of water-trapping proteoglycans
(hyaluronan and versican) by decorin and type I collagen.
After drug-eluting stent implantation, this pathological
change may be delayed owing to chronic vessel responses
induced by the presence of a durable polymer that still
contains the drug. The histological findings of atherectomy
specimens of neointimal tissue after implantation of a pacli-
taxel derivative–eluting polymer stent showed persistent
fibrin accumulation with smooth muscle cells and a
proteoglycan- and type III collagen–rich matrix associated
with inflammation at 12 months.14
Although long-term follow-up after drug-eluting stent im-
plantation has shown a sustained clinical benefit in several
randomized trials, little is known about neointimal growth
beyond the first 6 to 9 months.15,16 The longest available
angiographic follow-up after drug-eluting stent implantation
(sirolimus-eluting stents) is 4 years. From 2 to 4 years,
neointimal growth was still observed.16 When neointimal
growth after drug-eluting stent implantation begins to subside
is unknown. The issue of a “late catch-up phenomenon”
(delayed restenosis), which was observed after brachyther-
apy, has not been fully investigated with drug-eluting-
stents.17–20 Longer follow-up with serial angiographic and
IVUS analyses are needed to resolve this issue.
Interestingly enough, this phenomenon of long-term com-
paction of the neointima was not observed in the TAXUS arm
of this substudy up to 2 years. One might argue that this can
also be attributed to the mode of action of paclitaxel, as
discussed earlier, resulting in a general delay in vascular
responses. In contrast to the findings outside the stent, no
potential dose-dependent differences could be identified in-
side the stent. This raises the interesting question of different
dose thresholds and time kinetics for paclitaxel-induced
effects on different cellular compartments. Longer-term
follow-up studies will be needed to further understand these
phenomena.
Change of Plaque Area Outside the Stent and
Neointimal Growth
The relation between peristent remodeling and neointimal
growth after BMS implantation has been a controversial
topic. Nakamura et al21 reported an inverse correlation
between percent peristent volume change and percent intras-
tent neointimal volume change (r��0.517, P�0.0001),
whereas Hoffman et al22 reported a weak positive correlation
(r�0.282, P�0.058)). However, the remodeling of the peris-
tent area observed in the present study had no relation to
neointimal growth inside the stent in all groups.
Incomplete Stent Apposition
Regional expansive remodeling has been established as the
cause of late ISA after BMS implantation.23 In this study,
plaque outside the stent shrank from 6 months to 2 years. As
a result, the incidence of late acquired ISA at 2 years was
lower than at 6 months. After drug-eluting stent implantation,
the multiple effects of the eluted drugs also influence the
phenomenon of ISA; the antiproliferative effect may preclude
the growth of tissue in the void between the struts, and the
antimetabolic effect may induce either necrosis or apoptosis,
which may generate a new empty space between the struts.6,7
However, the incidences of ISA in both the SR and MR
paclitaxel stent groups for 2 years were similar to those
observed in the BMS group. In other words, the antiprolif-
erative and antimetabolic effects of the drug did not affect the
incidence of ISA at 2 years, and the clinical relevance of ISA
is dubious.8 Previously, one case of ISA at 6 months that
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evolved into a coronary aneurysm at 18 months after
sirolimus-eluting stent implantation was reported.7 However,
such a phenomenon was not observed in this study.
Limitations
The virtual impossibility of analyzing exactly the same
ultrasonic cross sections is a major limitation in serial
ultrasound studies. To minimize this limitation, the
3-dimensional IVUS reconstruction with semiautomatic con-
tour tracing in several reconstructed, longitudinally cut planes
was adapted for this study.
In addition, this study is a substudy of the TAXUS II trial,
which is analyzing outcomes in a highly selected subgroup of
event-free patients with focal, de novo lesions, and serial
2-year data were obtained in approximately half of the
original 6-month cohort of 314 patients. Although the serial
data at 6 months were comparable to the original 6-month
cohort data, this selection might theoretically limit transfer-
ability to the overall patient cohort.
Conclusions
Increased plaque outside the stent 6 months after paclitaxel-
eluting stent implantation regressed completely in the SR
group and partially in the MR group by 2 years. Neointimal
suppression with both SR and MR paclitaxel-eluting stents
was sustained for as long as 2 years. Whereas neointima
decreased in the BMS group between 6 months and 2 years,
neointima continued to increase in the SR and MR groups
without effect on clinical events. Although plaque outside the
stent began to shrink by 2 years, longer-term follow-up will
be required to establish the natural history of local paclitaxel
delivery.
Acknowledgment
The TAXUS II Study was supported by Boston Scientific Corp.
Disclosure
Dr Russell is a full-time employee of and stockholder in Boston
Scientific Corp. Dr Koglin is a full-time employee of Boston
Scientific Corp. Dr Dudek has a consultant/advisory board position
with Boston Scientific Corp and has received fees for speaking at
interventional cardiology meetings from Boston Scientific Corp. Dr
Banning has received a research grant and other research support
from Boston Scientific Corp. Dr Drzewiecki has received a research
grant from Boston Scientific Corp. The other authors report no
conflicts.
References
1. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S,
Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME.
Randomized study to assess the effectiveness of slow- and moderate-
release polymer-based paclitaxel-eluting stents for coronary artery
lesions. Circulation. 2003;108:788–794.
2. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C,
Munzel T, Belardi J, Ruzyllo W, Bilodeau L, Kelbaek H, Ormiston J,
Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME, Colombo
A. Chronic arterial responses to polymer-controlled paclitaxel-eluting
stents: comparison with bare metal stents by serial intravascular
ultrasound analyses: data from the randomized TAXUS-II trial. Circu-
lation. 2004;109:196–200.
3. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS,
Froehlich J, Virmani R. Pathological analysis of local delivery of pac-
litaxel via a polymer-coated stent. Circulation. 2001;104:473–479.
4. Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb
J, Hamburger J, Rutsch W, Kaiser C, Whitbourn R, Camenzind E,
Meredith I, Reeves F, Nienaber C, Benit E, Disco C, Koglin J, Colombo
A. Vascular responses at proximal and distal edges of paclitaxel-eluting
stents: serial intravascular ultrasound analysis from the TAXUS II trial.
Circulation. 2004;109:627–633.
5. Hamers R, Bruining N, Knook M, Sabate M, Roelandt JRTC. A novel
approach to quantitative analysis of intra vascular ultrasound images.
Comput Cardiol. 2001;28:588–592.
6. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A,
Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice
MC. Intravascular ultrasound findings in the multicenter, randomized,
double-blind RAVEL (RAndomized study with the sirolimus-eluting
VElocity balloon-expandable stent in the treatment of patients with de
novo native coronary artery Lesions) trial. Circulation. 2002;106:
798–803.
7. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A,
Morice MC, Ligthart JM, de Feyter PJ. Long-term follow-up of
incomplete stent apposition in patients who received sirolimus-eluting
stent for de novo coronary lesions: an intravascular ultrasound analysis.
Circulation. 2003;108:2747–2750.
8. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek
W, Bonnier J, Lablanche JM, Siminiak T, Nordrehaug J, Figulla H,
Drzewiecki J, Banning A, Hauptmann K, Dudek D, Bruining N, Hamers
R, Hoye A, Ligthart JM, Disco C, Koglin J, Russell ME, Colombo A.
Incomplete stent apposition after implantation of paclitaxel-eluting stents
or bare metal stents: insights from the randomized TAXUS II trial.
Circulation. 2005;111:900–905.
9. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J,
Hausmann D, Beckmann S, Gross M. Use of intravascular ultrasound to
compare effects of different strategies of lipid-lowering therapy on plaque
volume and composition in patients with coronary artery disease. Circu-
lation. 2001;104:387–392.
10. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG.
Coronary plaque classification with intravascular ultrasound radiofre-
quency data analysis. Circulation. 2002;106:2200–2206.
11. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC,
Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based,
slow-release, sirolimus-eluting stents in a porcine coronary model. Car-
diovasc Res. 2004;63:617–624.
12. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y,
Sato Y, Hamasaki N, Nosaka H, Nobuyoshi M. Three-year follow-up
after implantation of metallic coronary-artery stents. N Engl J Med.
1996;334:561–566.
13. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight
TN, Virmani R. Extracellular matrix changes in stented human coronary
arteries. Circulation. 2004;110:940–947.
14. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A,
Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after
implantation of a paclitaxel derivate–eluting polymer stent system in
humans. Circulation. 2002;106:2649–2651.
15. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W,
Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D,
Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F,
Guagliumi G, Colombo A, Ban Hayashi E, Wulfert E. Maintenance of
long-term clinical benefit with sirolimus-eluting coronary stents:
three-year results of the RAVEL Trial. Circulation. 2005;111:
1040–1044.
16. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF,
Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG.
Four-year angiographic and intravascular ultrasound follow-up of patients
treated with sirolimus-eluting stents. Circulation. 2005;111:2326–2329.
17. Meerkin D, Joyal M, Tardif JC, Lesperance J, Arsenault A, Lucier G,
Bonan R. Two-year angiographic follow-up of intracoronary Sr-90
therapy for restenosis prevention after balloon angioplasty. Circulation.
2002;106:539–543.
18. Teirstein PS, Massullo V, Jani S, Popma JJ, Russo RJ, Schatz RA,
Guarneri EM, Steuterman S, Sirkin K, Cloutier DA, Leon MB,
Tripuraneni P. Three-year clinical and angiographic follow-up after intra-
coronary radiation: results of a randomized clinical trial. Circulation.
2000;101:360–365.
3882 Circulation December 20/27, 2005
Chapter  3
38
19. Grise MA, Massullo V, Jani S, Popma JJ, Russo RJ, Schatz RA, Guarneri
EM, Steuterman S, Cloutier DA, Leon MB, Tripuraneni P, Teirstein PS.
Five-year clinical follow-up after intracoronary radiation: results of a
randomized clinical trial. Circulation. 2002;105:2737–2740.
20. Waksman R, Ajani AE, White RL, Chan R, Bass B, Pichard AD, Satler
LF, Kent KM, Torguson R, Deible R, Pinnow E, Lindsay J. Five-year
follow-up after intracoronary gamma radiation therapy for in-stent reste-
nosis. Circulation. 2004;109:340–344.
21. Nakamura M, Yock PG, Bonneau HN, Kitamura K, Aizawa T, Tamai H,
Fitzgerald PJ, Honda Y. Impact of peri-stent remodeling on restenosis: a
volumetric intravascular ultrasound study. Circulation. 2001;103:
2130–2132.
22. Hoffmann R, Mintz GS, Popma JJ, Satler LF, Pichard AD, Kent KM,
Walsh C, Mackell P, Leon MB. Chronic arterial responses to stent
implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz
stents in native coronary arteries. J Am Coll Cardiol. 1996;28:
1134–1139.
23. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of
late stent malapposition. Circulation. 2003;107:2660–2663.
CLINICAL PERSPECTIVE
Although long-term follow-up after drug-eluting stent implantation has shown a sustained clinical benefit in several
randomized trials, little is known about neointimal and plaque growth beyond the first 6 to 9 months. In the IVUS analyses
of the TAXUS II study, neointimal suppression with both SR and MR paclitaxel-eluting stents was sustained for as long
as 2 years. Whereas neointima decreased in the BMS group between 6 months and 2 years, neointima continued to increase
in the SR and MR groups without affecting clinical events. Although plaque outside the stent began to shrink by 2 years,
a longer-term follow-up will be required to establish the natural history of local paclitaxel delivery. The issue of delayed
restenosis, which has been observed after brachytherapy, has not been thoroughly evaluated with drug-eluting stent.
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Abstract
Aims: The one year clinical benefit of various doses and release durations of paclitaxel eluted from an erod-
able polymer has not been evaluated so far.
Methods and results: Conor paclitaxel-eluting stents have intra-stent wells in which drug and polymer are
deposited. Stents with six different release formulations (dose: 10 µg or 30 µg, duration: 5, 10 or 30 days,
direction: mural or bidirectional) were implanted in 6 patient cohorts. Clinical follow-up was conducted at
4 and 12 months. Quantitative angiography and IVUS were performed at 4 months, and additional angio-
graphic and IVUS follow-up were performed for groups D5 (10µg/30days/mural) and D6
(30µg/30days/mural), as they had shown the most favorable results at 4 months. At one year, the lowest
major adverse cardiac event rates were observed in the slow release (30 day) group (5.1% in D5 and 6.9%
in D6). One-year in-stent late loss was 0.52±0.34 mm in D5 and 0.36±0.50mm in D6 (p=0.20) while
neointimal area was 0.99±0.54 mm2 in D5 and 0.77±0.92 mm2 in D6 (p=0.42). Corresponding in-stent
binary restenosis at one year was 0% and 5.6% respectively (p=0.36).
Conclusions: Patients who received the slow release formulation stent had better clinical outcome at one
year than those who received the fast release formulation. However, the effect on neointimal suppression
requires investigation in a larger population to determine whether the high dose formulation confers an
additional clinical benefit.
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Elution release 
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Introduction
Drug-eluting stents consist of a drug, a polymer, and a stent plat-
form. Several drugs with durable or erodable polymers have been
tested in clinical trials and show that drug-eluting stents significant-
ly inhibit neointimal growth compared to bare metal stents1-4.
However, the most effective drug dose and pharmacokinetic release
formulation have not been evaluated thoroughly in humans.
The Paclitaxel In-Stent Controlled Elution Study (PISCES) has
demonstrated that kinetic variations play a key role in the efficacy of
a drug-eluting system5. At 4 months, the inhibition of in-stent neoin-
timal hyperplasia was better in the slow release groups compared to
the fast release groups. The present study evaluates (1) the one-
year clinical outcome in all 6 groups and (2) neointimal growth in
the two slow release groups, using serial quantitative coronary
angiography (QCA) and intravascular ultrasound (IVUS) analysis; in
order to understand the long-term impact of drug dose and phar-
macokinetic release.
Methods
Patient selection 
The PISCES trial was a prospective, multi-center, sequentially
enrolled, non-randomized, open-label trial in which patients were
treated with a Conor paclitaxel-eluting stent in one of six different
release formulations, and the results of each group was compared
(Table 1). The study device and protocol have been described previ-
ously5,6. In brief, 191 patients with single de novo lesions with a ref-
erence diameter of 2.5-3.5 mm and a lesion length that could be cov-
ered by a single 17mm stent were enrolled. Conor drug-eluting stents
were loaded with 10 or 30 µg of paclitaxel within a bioresorbable poly-
lactide-co-glycolide (PLGA) matrix. The drug and polymer were
deposited in the wells. The in-vitro drug release period was either 10
or 30 days. The PLGA polymer is fully erodable and neither polymer
nor drug is retained in the stent after several months of implantation.
Follow-up and endpoints 
The study protocol required all patients to have follow-up clinic vis-
its with an electrocardiogram (ECG) at one, four and twelve months.
An independent clinical event committee adjudicated clinical
events and ECGs. Quantitative angiography and IVUS were per-
formed at 4 months. Clopidogrel was discontinued per protocol at 6
months following stent implantation.
Additional angiographic and IVUS follow-up was performed at
12 months in groups D5 and D6 which showed the best results at
4 months (Figure 1)5,6.
The safety endpoint of the present study is a composite of major
adverse cardiac events (MACE) defined as cardiac death, Q-wave
or non-Q-wave myocardial infarction, and target lesion revascular-
ization (TLR) at 12 months. If the cause of death was undeter-
mined, it was categorized as cardiac death. Myocardial infarction
(MI) was diagnosed by a rise in the creatine kinase level to more
than twice the upper normal limit with an increased creatine kinase-
MB accompanied by new abnormal Q-waves in the surface electro-
cardiogram (Q-wave MI) or not (non-Q-wave MI). TLR was defined
as revascularization of the stented and the peri-stent segments
(5mm proximal and distal). Target vessel revascularization (TVR)
was defined as revascularization due to narrowing (>50% diameter
stenosis) of any portion of the target vessel outside the peri-stent
segment but was not included as an event in the MACE rate.
The efficacy endpoints included the in-stent and peri-stent (in-stent
+ 5 mm proximal edge + 5 mm distal edge) angiographic late loss
and binary restenosis rate as well as percent in-stent volume
obstruction as determined by quantitative intravascular ultrasound
(IVUS).
Quantitative Coronary Angiography (QCA)
evaluation
The quantitative ultrasound and coronary angiographic (QCA)
analyses were performed by an independent core laboratory that
remained blinded to treatment allocation (Cardialysis, Rotterdam,
The Netherlands). Quantitative coronary angiography was per-
formed by means of the CAAS II analysis system (Pie Medical BV,
Maastricht, The Netherlands). In each patient, the in-stent and peri-
stent segments were analyzed. Binary restenosis was defined in
every segment as diameter stenosis >50% at follow-up. Late loss
was defined as the difference between MLD post-procedure and
MLD at follow-up
Quantitative Intravascular Ultrasound (IVUS)
Post-procedure and follow-up stented vessel segments were exam-
ined with intravascular ultrasound (Cardio Vascular Imaging
System, CVIS, Sunnyvale CA, U.S.A.) using an automated pullback
at 0.5 mm per second. A computer-based contour detection pro-
gram was applied using CUARD QCU analysis software (Cuard BV,
Wijk Bij Duurstede, The Netherlands) for 3-D reconstruction of the
stented and adjacent segments7,8. The intrastent neointimal area
was calculated as the stent area minus lumen area, and plaque
area outside the stent was calculated as the vessel area minus stent
area. The percentage in-stent volume obstruction was calculated as
intrastent neointimal volume/stent volume*100. 
Table 1. Release formulations 
D1 D2 D3 D4 D5 D6
Paclitaxel dose 10 10 10 30 10 30
(µg/17mm stent)
Duration of elution (days) 5 10 10 10 30 30
Direction of elution Abluminal and luminal Abluminal and luminal Abluminal Abluminal and luminal Abluminal Abluminal
(bidirectional) (bidirectional) (mural) (bidirectional) (mural) (mural)
Key 10/5/b 10/10/b 10/10/m 30/10/b 10/30/m 30/30/m
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Statistical analysis
The analyses of MACE, angiographic and IVUS parameters were per
protocol based, in patients who received the allocated Conor pacli-
taxel-eluting stents. Continuous variables are expressed as
mean±standard deviation. Discrete variables are presented as per-
centages. For patient demographics, the following tests were
applied to calculate the differences among the six groups: F-test
from an analysis of variance, two-sample t-test, likelihood ratio chi-
square test, Fisher’s exact test and Cochran-Mantel-Haenszel test.
For QCA and IVUS parameters, continuous variables were com-
pared between groups D5 and D6 with the Student t test, and com-
parisons between 4 months and 12 months within the same group
were performed with a paired t test. The Fisher exact test was used
for categorical variables. All statistical tests were two-tailed, and 
p values less than 0.05 were considered statistically significant.
Results
Patient and lesion characteristics
In the PISCES trial, 191 patients were enrolled. The investigational
device could not be implanted in four patients. In total, 187 patients
were treated with one of the six different formulations of paclitaxel-
eluting Conor stents. The average age was 59.1±9.2 years and the
prevalence of diabetes was 18.2% in the total population. The base-
line demographic and angiographic data was similar among the six
groups, except for the incidence of a positive smoking history
(Tables 2 and 3).
Clinical events
Clinical follow-up was complete for all patients at one year (Table 4).
At four months, the slow release groups had a relatively lower inci-
dence of MACE compared to the fast release groups (2.6% in D5
and 3.4% in D6). This tendency did not change at one year (5.1%
in D5 and 6.9% in D6; Figure 2). Between 4 months and 1 year, a
MACE occurred in two patients in the slow release groups (D5 and
D6): one patient in D5 suffered a non Q-MI due to a non-TVR (max-
imum CK level of 356 U/L), and one patient in D6 had diffuse in-
stent restenosis (binary restenosis of 68%) at 4-month angiographic
follow-up with a positive exercise tolerance test. This patient was
placed on the waiting list for a repeat intervention. Two weeks after
the angiography, she was admitted with a Q-wave MI (maximum CK
level of 1687 U/L) and underwent re-catheterization which demon-
strated total occlusion at the inlet of the stent. This patient was sub-
sequently treated with a sirolimus-eluting stent. Notwithstanding this
patient who had angiographic restenosis, a positive functional test for
ischemia but delayed re-intervention at the 4 month follow-up, there
were no instances of abrupt, delayed stent thrombosis in the PISCES
patients.
Serial QCA analysis
A total of 50 patients (74%) in groups D5 and D6 underwent seri-
al QCA analysis at 4 months and 1 year. The baseline and post-pro-
cedure QCA data were similar in the two groups (Table 4). At
4 months, in-stent late loss was not significantly different between
Figure 1: 4-month QCA and IVUS results.
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D5 and D6, although in-stent late loss was lower in D6 than in D5
(0.32±0.40 mm versus 0.40±0.32 mm respectively, p=0.43).
From 4 months to 1 year, the late loss increased in both groups but
the trend remained in favor of D6; no statistical difference between
the two groups could be established although D6 showed a lower 
in-stent late loss at 1 year (0.52±0.34 mm in D5 and 0.36±0.50 mm
in D6, p=0.20). Overall peri-stent binary restenosis at 1 year was
observed in one patient in each group (3.1% in D5 and 5.6% in
D6, p=1.00). 
Serial IVUS analysis
A total of 45 patients (66%) underwent serial IVUS analysis at
4 months and 1 year. The IVUS results showed no statistical differ-
ences between groups D5 and D6 (Table 5). The percent in-stent
obstruction at 1 year was 12.46±7.60 in D5 and 8.37±9.10 in D6
(p=0.12). However, in D5, the neointimal area increased significant-
ly from 4 months to 1 year (delta=0.38mm2, p=0.0003) whereas
the difference between 4 months and 1 year in D6 failed to be sig-
nificant (delta=0.21 mm2, p=0.36, Figure 3). 
At 4 months, significant expansive remodeling (an increase in the
plaque area outside the stent) was observed in both groups (7.75±1.93
mm2 vs 9.09±2.45 mm2, p<0.0001 in D5; 8.04±1.76 mm2 vs
8.95±1.67 mm2, p=0.0015 in D6). Between 4 months and 1 year, a
significant regression of the expansive plaque area outside the stent
was observed in both groups (9.09±2.45 mm2 vs 8.46±2.15 mm2,
p=0.045 in D5; 8.95±1.67 mm2 vs 8.37±1.74 mm2, p=0.0023 in D6).
Discussion
The main findings of this study are the following: first, the slow
release (30 day) groups have better clinical outcomes at 1 year
compared to the fast release (5 or 10 day) groups. Second, com-
pared to the low dose (10 µg) group, the high dose (30 µg) group
had lower late loss and neointimal volume at one year without sta-
Table 2. Patient characteristics (per protocol)
D-1 D-2 D-3 D-4 D-5 D-6 P-Value P-Value 
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m comparing between
N=30 N=29 N=30 N=30 N=39 N=29 6 groups D5 and D6
Age (mean±SD) 57.4±9.90 61.8±8.9 59.7±9.6 60.2±8.8 56.7±7.6 58.5±10.5 0.23 0.41
Male, % 60.0 (18/30) 72.4 (21/29) 76.7 (23/30) 60.0 (18/30) 82.1 (32/39) 69.0 (20/29) 0.28 0.21
Smoking, % 53.3(16/30) 86.2 (25/29) 76.7 (23/30) 73.3 (22/30) 89.7 (35/39) 72.4 (21/29) 0.01 0.06
Diabetes, % 16.7 (5/30) 17.2 (5/29) 23.3 (7/30) 13.3 (4/30) 10.3 (4/39) 31.0 (9/29) 0.31 0.03
Hypertension, % 40.0 (12/30) 62.1 (18/29) 63.3 (19/30) 56.7 (17/30) 35.9 (14/39) 62.1 (18/29) 0.08 0.03
Dyslipidemia, % 66.7 (20/30) 62.1 (18/29) 73.3 (22/30) 63.3 (19/30) 61.5 (24/39) 65.5 (19/29) 0.93 0.74
Prior MI, % 40.0 (12/30) 44.8 (13/29) 33.3 (10/30) 30.0 (9/30) 41.0 (16/39) 41.4 (12/29) 0.85 0.98
Prior CABG, % 3.3 (1/30) 3.5 (1/29) 0.0 (0/30) 0.0 (0/30) 2.6 (1/39) 6.9 (2/29) 0.59 0.39
Prior PCI 6.7 (2/30) 6.9 (2/29) 10.0 (3/30) 13.3 (4/30) 15.4 (6/39) 17.2 (5/29) 0.71 0.84
Table 3. Lesion and procedural characteristics (per protocol)
D-1 D-2 D-3 D-4 D-5 D-6 P-Value P-Value 
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m comparing between
N=30 N=29 N=30 N=30 N=39 N=29 6 groups D5 and D6
Treated vessel
LAD 50.0% 41.4% 56.7% 50.0% 48.7% 27.6% 0.30 0.08
LCX 16.7% 20.7% 13.3% 23.3% 23.1% 37.9% 0.30 0.28
RCA 33.3% 37.9% 30.0% 26.7% 28.2% 34.5% 0.94 0.58
ACC/AHA classification 
A/B1/B2 100.0% 100.0% 100.0% 100.0% 94.9% 96.6% 0.34 0.74
C 0.0% 0.0% 0.0% 0.0% 5.1% 3.4% 0.34 0.74
Angiographic features
Reference vessel 
diameter, mm 2.76±0.40 2.70±0.52 2.82±0.43 2.64±0.43 2.73±0.41 2.70±0.41 0.71 0.79
Lesion length, mm 9.73±3.68 9.08±3.60 10.60±3.83 10.62±3.09 9.35±3.24 10.31±3.36 0.37 0.24
Minimal lumen 
diameter, mm 1.10±0.35 1.06±0.38 0.97±0.37 1.05±0.25 1.03±0.28 1.00±0.31 0.70 0.64
Diameter stenosis, % 60.32±9.57 61.02±11.54 65.72±11.77 59.89±7.77 62.05±8.19 63.17±9.63 0.21 0.61
Procedural characteristics
Stent/patient 1.2±0.38 1.1±0.35 1.1±0.43 1.1±0.25 1.2±0.43 1.0±0.00 0.41 0.13
Stent length, mm 19.03±4.90 18.80±4.80 18.20±3.90 17.60±2.28 18.38±3.88 17.0±0.0 0 0.39 0.13
Stent diameter, mm 3.18±0.24 3.18±0.24 3.25±0.25 3.21±0.25 3.31±0.24 3.25±0.25 0.26 0.44
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Table 4. MACE (Patients with events, per protocol)
D-1 D-2 D-3 D-4 D-5 D-6
10/5/b 10/10/b 10/10m 30/10/b 10/30/m 30/30/m
N=30 N=29 N=30 N=30 N=39 N=29
Post procedure ~ 4-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
Q-wave MI 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.3%) 1 (2.6%) 1 (3.4%)
Non Q-wave MI 1 (3.3%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
TLR 5 (16.7%) 4 (13.8%) 2 (6.7%) 1 (3.3%) 0 (0.0%) 1 (3.4%)
TVR 0 (0.0%) 1 (3.4%) 1 (3.3%) 0 (0.0%) 2 (5.1%) 1 (3.4%)
MACE 5 (16.7%) 5 (17.2%) 2 (6.7%) 2 (6.7%) 1 (2.6%) 1 (3.4%)
4-month ~ 12-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Q-wave MI 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.4%)
Non Q-wave MI 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
TLR 0 (0.0%) 1 (3.4%) 2 (6.7%) 1 (3.3%) 0 (0.0%) 1 (3.4%)
TVR 0 (0.0%) 1 (3.4%) 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.4%)
MACE 0 (0.0%) 1 (3.4%) 2 (6.7%) 1 (3.3%) 1 (2.6%) 1 (3.4%)
Post procedure ~ 12-month
Cardiac death 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
Q-wave MI 1 (3.3%) 0 (0.0%) 0 (0.0%) 1 (3.3%)† 1 (2.6%) 2 (6.9%)
Non Q-wave MI 1 (3.3%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
TLR 5 (16.7%) 5 (17.2%) 4 (13.3%) 2 (6.7%) 0 (0.0%) 2 (6.9%)
TVR 0 (0.0%) 2 (6.9%) 2 (6.7%)? 0 (0.0%) 2 (5.1%) 2 (6.9%)
MACE 5 (16.7%) 6 (20.7%) 4 (13.3%) 3 (10.0%) 2 (5.1%) 2 (6.9%)
*TVR was not included as an event in the MACE rate
Figure 2: 4-month and 1-year MACE.
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tistically significant difference. Third, between 4 months and 1 year,
modest neointimal growth continued in both the low and high dose
groups without new instances of in-stent angiographic restenosis or
target lesion revascularization, and this neointimal growth was sta-
tistically significant in the low dose group only. Fourth, plaque out-
side the stent increased during the first 4 months following Conor
paclitaxel-eluting stent implantation, but by 1 year it had partially
regressed in both the low and high dose groups.
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Various drug elution processes have reported conflicting clinical
results3,9-12. In the SCORE trial, QuaDDS stents with a total of
4000 µg paclitaxel and a durable acrylate polymer were found to
have an unacceptable safety profile9. In the DELIVER trial, the Multi-
Link PENTA stent with a coating of 45-150µg paclitaxel (a dose den-
sity of 3.0µg/mm2 stent surface area) without a polymer showed no
impact in reducing clinical revascularization or restenosis compared
to bare metal stents, presumably due to the rapid elution of the
drug10. In the ELUTES and ASPECT trials, the high-dose non poly-
mer paclitaxel-eluting stent has the better outcomes compared to
the low dose group11,12. In the TAXUS IV trial, a slow-release (7.5%
at 30 days), polymer-based paclitaxel eluting stent with a total of
106 µg paclitaxel (a dose density of 1.0 µg/mm2 stent surface area)
eluted from a durable polymer showed significantly better inhibition
of neointimal growth and clinical outcomes when compared to bare
metal stents3. In the light of this study and other paclitaxel–eluting
stent trials, the drug release profile is a key factor in the clinical effi-
cacy, and drug-eluting stents with a slow release formulation seem
to be more efficient. In the present study, the slow release groups
demonstrate the best 1-year clinical outcomes, mainly due to better
outcomes in the first 4 months. The drug and polymer are com-
pletely removed from the wells after several months, thus this novel
drug-eluting stent may potentially preclude the chronic vessel reac-
tion usually observed with a durable polymer and persistent drug on
the stent13,14. Further, there were no instances of late stent throm-
bosis. Though more data from larger studies is required to draw
definitive conclusions, these results support the hypothesis that
complete drug elution and polymer resorbtion may confer safety
benefits with respect to delayed thrombosis. 
In this study, the expansive vessel remodeling observed at 4 months
seems similar to the remodeling observed after implantation of
Taxus polymeric paclitaxel-eluting stents15. The expansive vessel
shrinkage observed at 1 year also suggests that the chronic vessel
reaction to mechanical injury and biological reaction to the drug and
polymer have subsided in that period of time. 
However, the chronic vessel reaction inside the stent differs from
the reaction observed behind the stent struts. Although this study
showed a regression of tissue growth outside the stent between
4 months and 1 year, compaction of neointima was not observed in
either the low dose or the high dose group over the same time peri-
od. The precise reason for this phenomenon is unclear. One might
hypothesize that this could be a result of different tissue composi-
tion inside and outside the stent. The tissue growth inside the stent
is composed of smooth muscle cells in a proteoglycan rich matrix,
whereas the tissue growth behind the stent struts consists of sever-
al components: 1) intracellular matrix and cell proliferation such as
smooth muscle cells and lymphocyte cells, 2) oedema due to
mechanical injury and biological reaction against the drug, polymer
and stent, and 3) growth or regression of existing atherosclerotic
plaque. Thus, the direction of volumetric change (regression or
expansion) from 4 months to 1 year may not be similar inside and
outside the stent.
In this study, the actual late loss and neointimal area were smaller
in the 30 µg group than in the 10 µg group. These differences were
not statistically different and did not influence the clinical outcomes.
The 10 µg paclitaxel dose may be sufficient to suppress neointimal
growth in humans at least for a period of one year. It may also be
argued that the sample size is too small to detect a biological differ-
ence between the low and the high dose. 
In animal studies, paclitaxel polymer coated stents have been found
to inhibit in-stent neointimal growth but with signs of delayed intimal
healing at 28 days, such as fibrin deposition, inflammation and
increased cellular proliferation. By 90 days, local toxicity associated
with paclitaxel resolves but in-stent neointimal growth suppression
is no longer present16. In humans following bare metal stent implan-
tation, the neointima does not keep growing beyond 6 months and
Table 5. Serial QCA analysis 
(post procedure, 4 months and 12 months)
D5 D6 P-value
(10/30/m) (30/30/m)
N=32 N=18
Pre
Lesion length 9.39±3.37 10.04±2.80 0.49
RVD, mm 2.71±0.43 2.69±0.42 0.84
MLD, mm 1.05±0.29 1.02±0.33 0.73
DS, % 61.5±7.7 62.5±9.2 0.67
Post stenting
In-stent
MLD, mm 2.68±0.35 2.51±0.38 0.12
DS, % 12.4±6.5 13.6±6.2 0.56
In-peristent*
MLD, mm 2.31±0.41 2.18±0.38 0.29
DS, % 22.3±9.1 23.5±8.9 0.65
4-month
In-stent
MLD, mm 2.28±0.32 2.19± 0.53 0.53
DS, % 19.9±9.3 21.7±9.7 0.63
Late loss, mm 0.40±0.32 0.32±0.40 0.43
Binary restenosis, % 0.0 5.6 0.36
In-peristent*
MLD, mm 2.10±0.36 1.97±0.48 0.27
DS, % 25.3±8.7 29.9±13.6 0.20
Late loss, mm 0.21±0.29 0.21±0.39 0.95
Binary restenosis, % 0.0 5.6 0.36
12-month
In-stent
MLD, mm 2.16±0.34 2.15±0.65 0.93
DS, % 21.3±10.3 23.2±20.6 0.72
Late loss, mm 0.52±0.34 0.36±0.50 0.20
Binary restenosis, % 0.0 5.6 0.36
In-peristent*
MLD, mm 2.01±0.35 1.94±0.61 0.69
DS, % 27.5±9.67 29.3±20.8 0.73
Late loss, mm 0.30±0.26 0.24±0.50 0.62
Binary restenosis, % 3.1 5.6 1.00
* In-peristent = In-stent + 5 mm proximal + 5 mm distal
47
Chronic arterial response to PES with erodable polymer 
- 171 -
instead begins to regress due to the replacement of water-trapping
proteoglycans (hyaluronan and versican) by decorin and type I col-
lagen17. In this study, compaction of neointima was not observed
and it is unknown whether neointimal tissue will keep growing or
stop beyond one year. Further follow-up is warranted to evaluate the
long-term efficacy of these devices and to find the best elution peri-
od and drug dose.
Limitations
At one year, 26% and 34% of the patients in the groups of D5 and
D6 respectively did not undergo serial invasive QCA or IVUS follow-up
evaluation. Following completion of patient enrolment, the protocol
was subsequently amended to allow one year angiographic and IVUS
follow-up, necessitating a new informed consent. Patients who did not
undergo one-year angiography reported no anginal symptoms at one
year. The sample sizes for groups D5 and D6 were insufficient to
detect a difference in outcome between the low and high doses in the
slow release formulation. However, they served as the basis for the
development of a large randomized trial (the EuroSTAR trial) which is
evaluating both doses (10 µg and 30 µg per 17mm stent) of slow-
release paclitaxel using the reservoir-based technology on an ultra-
thin cobalt-chromium stent in 270 patients.
Conclusions
The PISCES trial suggests that the pharmacokinetics of drug-eluting
stents is important for both neointimal suppression and for clinical
outcomes at 1 year. The slow release (30 day) formulation had bet-
ter clinical outcomes compared to the fast release (5 or 10 day) for-
mulation. The drug dose (10 µg or 30 µg) did not seem to influence
the amount of neointimal suppression but the sample sizes in this
pilot dose-finding study were insufficient to detect a beneficial dif-
ference in dose. 
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Serial assessment of tissue growth inside and outside 
the stent after implantation of drug-eluting stent 
in clinical trials. – Does delayed neointimal growth exist?
Although long term follow-up after drug-eluting stent (DES)
implantation shows a sustained clinical benefit in several random-
ized trials, delayed neointimal growth beyond the first 6 to 9 months
has been reported in serial intravascular ultrasound (IVUS) analy-
ses in some trials. The issue of a delayed restenosis which was
observed after brachytherapy has not been thoroughly evaluated
with DES.
Tissue growth inside the stent (Neointima)
Drug-eluting stents (DES) dramatically reduce neointimal growth at
6 or 9 months compared to bare metal stents (BMS).1-3 Although
long term follow-up after DES implantation shows a sustained clini-
cal benefit in several randomised trials,4,5 little is known about neoin-
timal growth beyond the first 6 to 9 months. The issue of a “late
catch up phenomenon” (delayed restenosis) which was observed
after brachytherapy has not been fully investigated with DES.6
In porcine models, the inhibition of neointimal hyperplasia after
deployment of polymer-coated sirolimus-eluting stents was not
sustained at 90 and 180 days due to delayed cellular proliferation,
and neointimal suppression after deployment of chondroitin sul-
fate and gelatin coated paclitaxel-eluting stents was also not main-
tained at 90 days.7,8
In humans, neointimal tissue does not keep growing after BMS
implantation. During long-term angiographic follow-up, com-
paction of neointima has been described in several reports.9-11
Histological analyses of post-mortem coronary arteries demon-
strate that compaction of neointima occurs due to the replacement
of water-trapping proteoglycans by decorin and type I collagen.11
Following DES implantation, neointima continues to grow during
the follow-up period in some trials in which serial IVUS analyses
were performed (Table 1). A chronic arterial response towards the
durable polymer and to the remaining drug within the polymer has
been imputed to explain this phenomenon. However, this was also
observed with Conor paclitaxel-eluting stents in which neither
polymer nor drug is retained at the end of the programmed
release period.12 The precise reason for this observation is thus
still unclear, but may be related to the delayed healing response
and persistent biological reaction caused by the drug soon after
the implantation of DES. In view of the results of animal studies
and clinical studies, DES may delay restenosis, instead of halting
definitively the process of neointimal hyperplasia. Further follow-up
is warranted to evaluate the long-term efficacy of DES.
Tissue growth outside the stent 
(Vessel remodeling)
Polymer based sirolimus-eluting stents (Cypher) and polymer
based paclitaxel-eluting stents (Taxus) are used in daily practice,
and several types of drugs and durable or erodable polymers have
been tested in clinical trials.1,3,13,14 After BMS implantation, expan-
sive vessel remodeling (i.e. increasing plaque outside the stent) was
reported.15 In the TAXUS II trial, the increased plaque outside the
stent 6 months after BMS implantation had regressed completely at
2 years (Table 2).16 Thus, it is likely that mechanical injury and bio-
logical reaction against the stainless steel stent that may have
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induced the inflammation, had subsided by 2 years. After sirolimus
and everolimus-eluting stents implantation, increasing plaque area
outside the stent was insignificant in both the First In Man
(sirolimus)17 and SPIRIT FIRST (everolimus) trials18, whereas a sig-
nificantly increasing plaque area behind the stent was observed with
paclitaxel-eluting stents in the TAXUS II15 and PISCES trials19, and
tissue growth exceeded the vessel reaction observed with BMS in
both trials. The EPC capture stents induce the rapid establishment
of a functional endothelial layer early in the healing response and the
mean plaque volume outside the stent was similar immediately post
procedure and at 6-month follow-up, demonstrating that overall
expansive remodeling did not occur with this device.20
The vessel reaction outside the stent differs from the reaction
observed inside the stent, and the different drugs, polymers, and
pharmacokinetics result in various effects on tissue growth not only in
the intrastent neointima but also on vessel remodeling outside the
stent. Interestingly, the timing of regression of the plaque outside the
stent was also different. For sirolimus-eluting stents, significant
expansive plaque outside the stent was not observed during follow-up
and shrinkage of plaque outside the stent occurred at 4 years.17 For
paclitaxel-eluting stents, complete regression of expansive plaque
outside the stent was observed at 2 years in the slow release group in
TAXUS II trial, and partial regression was observed at 1 year in the
PISCES and at 2 years in the moderate release group in the TAXUS II
trial.12,16 The exact reason for these variant vascular responses is
unknown. The tissue growth outside the stent may be more complex
and heterogeneous, compared to tissue growth inside the stent. The
tissue growth inside the stent consists of smooth muscle cell and a
Table 1. Tissue growth inside the stent (Neointimal volume)
4 or 6 months 1 year 2 years 4 years p-value*
BMS (N=77)16, mm3 28.7±33.2 – 23.9±25.1 – 0.017
– 16.7%
Limus family Sirolimus (N=23)17, mm3 2.1±1.7 3.8±3.3 7.0±6.7 8.4±5.8 <0.0001**
81.0% 233.3% 300.0%
ABT-578 (N=86)21 6.1±7.4 14.2±11.8 – – N.A.
132.8%
Everolimus (N=16)18, mm3 9.1±12.2 13.0± 9.0 – – 0.14
42.2%
Paclitaxel TAXUS SR (N=43)16, mm3 9.4±12.1 – 13.6±11.3 – 0.018
44.7%
TAXUS MR (N=41)16, mm3 10.7±15.8 – 16.9±17.3 – 0.013
57.9%
Conor (30 day/10 ug) (N=30)12, mm3 11.2±11.6 17.7±10.3 – – 0.0004
58.0%
Conor (30 day/30 ug) (N=15)12, mm3 9.4±11.9 13.8±17.1 – – 0.29
46.8%
Below percentage line shows relative difference, compared to 4 or 6 months
* Paired t -test. ** Repeat variance of analysis (ANOVA)
Table 2. Plaque volume outside the stent (Vessel remodeling)
Post stenting 4 or 6 months 1 year 2 years 4 years p-value*
BMS (N=77)16, mm3 122.6±32.6 130.6±29.3 – 116.6±28.4 – 0.01
6.5% –4.9%
Limus family Sirolimus(N=23)17, mm3 155.5±42.8 160.4±60.4 153.5±61.6 156.8±57.7 138.4±42.2 0.53
3.2% –1.3% 0.8% –11.0%
Everolimus(N=16)18, mm3 151.8±67.1 159. 5± 64.0 152.8± 56.8 – – 0.1370
5.1% –4.2%
Paclitaxel TAXUS SR(N=43)16, mm3 121.9±40.2 135.8±44.0 – 114.8±30.7 – 0.002
11.4% –5.8%
TAXUS MR(N=41)16, mm3 113.8±30.5 140.7±41.6 – 127.3±37.4 – 0.0007
22.8% 11.9%
Conor (30 day/10 ug) (N=30)12, mm3 135.1±37.1 160.1±46.3 153.0±55.7 – – 0.0001
18.5% 13.2%
Conor (30 day / 30 ug) (N=15)12, mm3136.6±29.6 154.1±33.0 144.5±26.9 – – 0.002
12.8% 5.5%
CD34 antibody coating
EPC capture coating (N=16)20, mm3 163.0±56.6 165.0±62.9 – – – 0.37
1.2%
Below percentage line shows relative difference, compared to 4 or 6 months
*Paired t –test, comparison between post stenting and 4 or 6 month follow–up
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proteoglycan rich matrix, whereas the tissue growth outside the stent
consists of several components; 1) cell proliferations and intracellular
matrix, 2) oedema caused by mechanical injury and chemical injury
due to drug, polymer and stent, 3) growth or regression of existing
atherosclerotic plaque. Studies involving larger sample sizes and
more detailed analyses with novel in vivo techniques of tissue charac-
terisation may be necessary to assess and better understand the
process of vessel remodeling after DES implantation.
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‘‘Full metal jacket’’ (stented length _>64 mm) using
drug-eluting stents for de novo coronary artery lesions
Jiro Aoki, MD, Andrew T.L. Ong, MBBS, FRACP, Gaston A. Rodriguez Granillo, MD,
Euge`ne P. McFadden, MD, FRCPI, Carlos A.G. van Mieghem, MD, Marco Valgimigli, MD,
Keiichi Tsuchida, MD, Georgios Sianos, MD, PhD, Evelyn Regar, MD, PhD, Peter P.T. de Jaegere, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pim J. de Feyter, MD, PhD, Ron T. van Domburg, PhD, and
Patrick W. Serruys, MD, PhD Rotterdam, The Netherlands
Background Stented segment length was a predictive factor for restenosis in the bare metal stent era. The
objective of the study was to evaluate the medium-term clinical outcome and the potential for adverse effects when
very long segments (ie, z64 mm of stented length) are treated by drug-eluting stent (DES) implantation, an approach
colloquially referred to as a ’’full metal jacket.’’
Methods Since April 2002, we have used DES as the default stent for all percutaneous coronary interventions.
From our prospective institutional database we identified 122 consecutive patients, with de novo coronary lesions, in
whom a coronary artery was treated with at least 64 mm of overlapping DES: 81 patients were treated with
sirolimus-eluting stents and 41 with paclitaxel-eluting stents.
Results The mean number of stents per lesion was 3.3 F 1.1, and the median stented length was 79 mm (range
64-168 mm). Periprocedural Q-wave myocardial infarction (MI) occurred in 2 patients (1.6%) and subacute stent
thrombosis in 1 patient (0.8%). During 1-year follow-up, 5 patients (4.1%), including 3 patients treated for acute MI with
cardiogenic shock, died and 10 patients (8.2%) had nonfatal MI (creatine kinase–MB N3 times). The 1-year target
vessel revascularization rate was 7.5% and the overall incidence of major adverse cardiac events was 18%.
Outcomes in sirolimus-eluting stents and paclitaxel-eluting stents groups did not differ statistically.
Conclusions The use of DES for the treatment of diffuse lesions was associated with a low rate of repeat
revascularization, irrespective of stent type. No safety concerns were raised at medium-term follow-up. (Am Heart J
2005;150:994-9.)
In the bare metal stent era, the length of a stented
segment was an independent predictor of in-stent
restenosis.1-3 Recent randomized trials, in low-risk
patient/lesion cohorts, showed that drug-eluting stents
(DES) reduce the need for repeat intervention com-
pared with bare metal stents.4-7 Drug-eluting stents are
rapidly replacing bare metal stents and there has been
a tendency toward longer stented segment lengths,
given the full lesion coverage from a proximal to a
distal bangiographically normalQ segment to avoid stent
gaps and the incomplete coverage of lesions which
have been associated with restenosis after DES im-
plantation.5,8 However, the clinical effect of very long
and overlapping DES implantation in the so-called full
metal jacket approach and the potential effects of
increased metal and local drug exposures are un-
known. In this report, we investigate the clinical
outcome after very long sirolimus-eluting stent (SES)
and paclitaxel-eluting stent (PES) implantations in a
consecutive group of 122 patients (124 lesions) who
were treated with at least 64 mm of DES without any
gap in the same vessel.
Methods
Patient selection and procedure
Since April 2002, we have adopted a policy of universal
DES implantation for all percutaneous coronary interventions
requiring stents at our center, irrespective of clinical
presentation or lesion morphology. Sirolimus-eluting stents
were exclusively used until March 2003. Since March 2003,
PES has been exclusively used. In total, 122 consecutive
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patients were treated with at least 64 mm of DES without any
gap in the same vessel for diffuse coronary lesions, chronic
total occlusion, or extensive dissections; this represents 7% of
our patients treated exclusively with DES in the same period.
The longest available individual stent length was 33 mm in
SES and 32 mm in PES. We defined a full metal jacket as
64 mm of continuous stent, calculated as the total of the
2 longest PES lengths.
All interventions were performed using standard techniques.
Written informed consent was obtained from all patients as
part of the prospective consecutive database. Periprocedural
use of glycoprotein IIb/IIIa and intravascular ultrasound (IVUS)
was at the discretion of the operator. All patients received a
loading dose of 300-mg clopidogrel followed by a daily dosage
of 75 mg for 6 months, in addition to life-long aspirin therapy.
End point definition and clinical follow-up
Patients were followed up prospectively and major
adverse cardiac events (MACEs) were evaluated. Major
adverse cardiac event was defined as death, nonfatal
myocardial infarction (MI), or target vessel revascularization
(TVR). Myocardial infarction was defined as a creatine
kinase–MB (CK-MB) level that was N3 times the upper limit
of normal, based on the recommendations in the American
College of Cardiology/American Heart Association guide-
lines.9 For patients who presented with an acute coronary
syndrome and elevated baseline enzyme, a diagnosis of
periprocedural MI required a fall and rise of CK-MB of 50%
above the previous level.10 Target vessel revascularization
was defined as a reintervention in the treated vessel. Stent
thrombosis was angiographically documented as a complete
occlusion or a flow-limiting thrombus of a successfully
stented segment. Information regarding repeat interventions
was prospectively collected by means of an electronic
database. Survival status was assessed by written inquiries to
the Civil Registry. Questionnaires to assess clinical status
were sent to all living patients. The patient, referring
physician, and peripheral hospitals were directly approached
whenever necessary for additional information. Follow-up
angiography was planned only in patients who were
enrolled during the first 6 months (n = 38).
Statistical analysis
Continuous variables were expressed as mean F SD.
Discrete variables were presented as percentages. Continuous
variables were compared with Student t test or Wilcoxon
ranked scores when applicable. The Fisher exact test was used
for categorical variables. The cumulative incidence of adverse
events was calculated according to the Kaplan-Meier method
and differences were assessed using the log-rank test. All
statistical tests were 2-tailed, and P b .05 was considered
statistically significant. Patient, lesion, and procedural charac-
teristics associated with 1-year MACE on univariate analysis
(P value for selection b.2) were tested for their multivariate
predictive value (tested values were cardiogenic shock, female
sex, multivessel disease, bifurcation stenting, and use of IIb/IIIa
inhibitors). The final model was built by backward stepwise
variable selection with entry and exit criteria set at the P = .05
and P = .1 levels, respectively.
Results
Patient characteristics
Of the 122 consecutive patients, 81 patients (82
lesions) were treated with SES (SES group) and 41
patients (42 lesions) were treated with PES (PES group).
Patient characteristics are reported in Table I; 19% had
diabetes and 39% underwent the index procedure for an
acute coronary syndrome. There were no statistical
differences between groups, apart from a higher
proportion of men in the PES group. Figure 1 presents
the distribution of stented length in this study.
Procedural characteristics
Lesion and procedural characteristics are presented in
Table II. The mean number of stents implanted per
lesion was 3.3 F 1.1 (range 2-7 stents), and the median
Table I. Patient characteristics
All
(n = 122)
SES
(n = 81)
PES
(n = 41)
Age (y) 63 F 11 62 F 12 63 F 11
Male (%) 75 69 88T
Hypertension (%) 42 43 39
Hyperlipidemia (%) 67 62 76
Current smoking (%) 25 26 24
Diabetes mellitus (%) 19 20 17
Prior MI (%) 44 43 46
Prior CABG (%) 5 5 5
Prior PCI (%) 19 17 22
Multivessel disease (%) 70 70 68
Unstable angina (%) 26 31 17
AMI (%) 11 11 12
AMI with shock (%) 3 2 5
CABG, Coronary artery bypass graft surgery; PCI, percutaneous coronary
intervention; AMI, acute MI.
TP b .05 for the comparison between SES and PES groups.
Figure 1
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total stented length was 79 mm (range 64-168 mm).
Glycoprotein IIb/IIIa inhibitors were used in 37% of
patients. In the PES group, the mean stent diameter was
larger (3.0F 0.3 vs 2.7F 0.2 mm, P b .001), with longer
median stented length (77 vs 84 mm, P = .03),
compared with the SES group.
Clinical outcome
Complete clinical follow-up information was avail-
able for all patients. Table III shows 30-day clinical
outcomes as estimated by the Kaplan-Meier method.
A periprocedural MI occurred in 5 patients (4.0%).
Each CK-MB level was 191, 141, 82, 338, and
159 U/L (normal upper limit of CK-MB is 23 U/L in
our institute). Among these patients, 2 patients (1.6%)
had Q-wave MI. The causes of periprocedural MI were
side-branch occlusion (1 patient), distal embolism
(1 patient), distal dissection (1 patient), and dissec-
tion of other treated lesion (2 patients). Subacute
stent thrombosis occurred in 1 patient (0.8%) in the
SES group.
One-year clinical outcomes, estimated by the Kaplan-
Meier method, are presented in Table III. Five patients
(4.1%) died during the first year, 2 received SES, and
3 received PES. In the SES group, 1 patient who received
SES for acute MI with cardiogenic shock died the next
day from cardiogenic shock and the other died of a
pulmonary embolism 275 days after the procedure. In
the PES group, 1 patient who presented with acute MI
Table III. Thirty days and 1 year clinical outcomes cumulative
events rate estimated by Kaplan-Meier
All
(n = 122)
SES
(n = 81)
PES
(n = 41) PT
30 d
Death (%) 1.6 1.2 2.4 .63
MI (%) 5.8 6.2 4.9 .77
TVR (%) 1.7 2.5 0 –
Death, MI (%) 7.4 7.4 7.3 .97
MACE (%) 8.2 8.6 7.3 .79
1 year
Death (%) 4.1 2.5 7.3 .20
MI (%) 10.0 11.2 7.4 .53
TVR (%) 7.5 7.5 7.6 .96
Death, MI (%) 12.3 12.3 12.2 .98
MACE (%) 18.0 18.5 17.1 .87
TVR, target vessel revascularization; MACE, major adverse cardiac events.
TComparison between SES and PES groups (log rank).
Table IV. Paired quantitative angiographic analysis
(mandatory angiographic follow-up group)
SES (n = 38) Pre Post Follow-up
RD (mm) 2.56 F 0.53 2.68 F 0.44 2.76 F 0.37
MLD (mm) 0.43 F 0.58 2.24 F 0.38 2.13 F 0.58
DS (%) 81.9 F 24.6 16.2 F 9.4 23.4 F 19.5
Late loss (mm) 0.12 F 0.58
Binary restenosis
rate (%)
5.3
RD, reference diameter; MLD, minimal lumen diameter; DS, diameter stenosis.
Table II. Lesion and procedural characteristics
All (n = 124) SES (n = 82) PES (n = 42)
Treated vessel
LAD (%) 25 29 17
LCX (%) 12 16 5
RCA (%) 63 55 79*
Lesion type
B1 (%) 1 1 0
B2 (%) 2 2 0
C (%) 98 96 100
CTO (%) 40 38 43
Total occluded length (mm F SD) 23.2 F 10.9 22.9 F 11.2 23.7 F 10.6
Stent number/vessel 3.3 F 1.1 3.1 F 1.0 3.7 F 1.1*
Mean stent diameter (mm) 2.9 F 0.3 2.7 F 0.2 3.0 F 0.3*
Median stent length/vessel (mm) (range) 79 (64-168) 77 (64-140) 84 (64-168)*
Bifurcation stenting (%) 13 15 10
Use of IIb/IIIa inhibitor (%) 37 38 36
Pre-RD (mm) 2.61 F 0.55 2.55 F 0.52 2.74 F 0.60
MLD (mm) 0.44 F 0.52 0.46 F 0.52 0.40 F 0.51
DS (%) 82.3 F 20.6 80.8 F 21.6 85.2 F 18.4
Post-RD (mm) 2.73 F 0.49 2.67 F 0.47 2.86 F 0.51*
MLD (mm) 2.26 F 0.46 2.20 F 0.42 2.37 F 0.52*
DS (%) 17.4 F 10.9 17.4 F 10.8 17.2 F 11.4
LAD, Left descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; CTO, chronic total occlusion; RD, reference diameter;MLD, minimal lumen
diameter; DS, diameter stenosis.
TP b .05 comparison between SES and PES groups.
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with cardiogenic shock died 6 days later from ongoing
heart failure. The second patient underwent an unsuc-
cessful percutaneous coronary intervention 55 days after
the initial procedure to treat another lesion, requiring
emergent coronary artery bypass surgery and died 1 day
after surgery. The remaining patient died of congestive
heart failure 244 days after the initial procedure. This
patient had already suffered MIs twice before the index
procedure and had severe left ventricular dysfunction.
The overall TVR rate was 7.5% and the incidence of
MACE was 18.0% at 1 year. There were no statistically
significant differences between the SES and the PES
groups. Multivariate predictors of 1-year MACE were
cardiogenic shock (hazard ratio 8.96, 95% CI 2.11-28.66,
P = .0006) and female sex (hazard ratio 2.71, 95% CI
1.06-6.02, P = .02). Mean late loss was 0.12 F 0.58 mm
in 38 patients who were consecutively enrolled in the
first 6 months of our experience and who, for this
reason, underwent mandatory follow-up angiography
(Table IV).
Figures 2-4 are a representative example of a patient
successfully treated with 3 stents (SES) with a total stent
length of 84 mm.
Discussion
In this study, median stented length was 79 mm (range
64-168 mm). The incidence of subacute stent thrombo-
sis was 0.8% (1 patient) and the TVR rate was 7.5% at
1 year. Of the 6 patients who had in-stent restenosis
within 1 year, 5 (83.3%) patients had focal restenosis
easily treated with repeat coronary stenting (mean stent
length 20.0 F 8.9 mm).
In the bare metal stent era, the stented length is
an important predictor of in-stent restenosis. How-
ever, there are no precious reports regarding full
metal jacket. The results of this present study are
promising when compared with published data on
bare metal stents with long stented lengths or
multiple stenting despite significantly longer lengths
in this study (Table V).11-14 A group of 21 consec-
Figure 2
Baseline angiography showing diffuse right coronary artery disease.
Figure 3
The patient was successfully treated with 3 Cypher stents (total length
was 84 mm).
Figure 4
Follow-up angiography (216 days after the index procedure)
documenting the absence of in-stent restenosis.
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utive patients from our institution, treated with at
least 64 mm of continuous bare metal stents (BMS)
in the same vessel from the immediate period
preceding the introduction of DES, is included as a
comparison (unpublished data). The 1-year TVR rate
in the BMS group was approximately 3 times higher
than the DES population from this study.
Concerns have been raised regarding the clinical
impact of high local drug concentration in the tissue
wall caused by long stented lengths and overlapped
stents (eg, the development of coronary aneurysms).15,16
We did not observe aneurysm formation in patients who
underwent follow-up angiography beyond 6 months.
Nor was there any evidence of systemic complications,
related to the use of multiple DES, in our patient cohort
up to 1 year.
A limitation of treating diffuse coronary disease with
long stented lengths in the bare metal stent era was a
high incidence of periprocedural MI; this was docu-
mented in several stent trials that enrolled patients
with long lesions.11,13,17 In the ADVANCE study, 21.4%
had elevated CK-MB, with 7.1% N5 times elevated in
the bail out stenting group.13 The definition of MI after
percutaneous coronary interventions differed among
studies.18-20 Even in case of not long length stenting,
reports in the literatures indicated that 8.5% had
elevated CK-MB (N5 times17 or N3 times21) after stent
implantation. If an MI is defined as a CK-MB of N5
times the upper limit of normal, the incidence of
periprocedural MI was 3.3% in our study. Based on our
results, DES use does not increase the incidence of
periprocedural MI compared with published bare metal
stent data.
SES and PES were used in this study in consecutive
periods. This study is limited by its single-arm design and
moderate sample size, and follow-up angiography was
performed in one third of patients, precluding reporting
of quantitative angiographic variables and our main
purpose was not to compare the clinical effect of
2 different types of DES. Procedural characteristics were
not similar between both groups (in the PES group, the
mean stent diameter was larger and the median stented
length was longer compared with the SES group).
However, we found that despite extremely long stent
lengths, the incidence of TVR was quite low for both SES
and PES. Percutaneous coronary intervention using DES
therefore seems to be a feasible, effective, and safe
option for the treatment of patients with diffuse
coronary disease.
Conclusion
Stented length of z64 mm with DES for de novo
coronary artery lesions was safe. Drug-eluting stents had
similar clinical results with low TVR rates. The use of
DES for the treatment of diffuse coronary lesions is a
feasible percutaneous alternative.
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Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes
of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With
Diabetes Mellitus (from the RESEARCH and T-SEARCH Registries)
Andrew T. L. Ong, MBBS, Jiro Aoki, MD, Carlos A. G. van Mieghem, MD,
Gaston A. Rodriguez Granillo, MD, Marco Valgimigli, MD, Keiichi Tsuchida, MD,
Karel Sonnenschein, Evelyn Regar, MD, PhD, Willem J. van der Giessen, MD, PhD,
Peter P. T. de Jaegere, MD, PhD, Georgios Sianos, MD, PhD,
Eugene P. McFadden, MBChB, MD, Pim J. de Feyter, MD, PhD,
Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD*
This study evaluated and compared the efficacy of sirolimus-eluting stents (n � 145
patients) with that of paclitaxel-eluting stents (n � 148 patients) in 293 consecutive
unselected patients who had diabetes mellitus. Baseline clinical characteristics and
presentations were similar: mean age of 64 years, 50% presented with unstable angina
or myocardial infarction, and 66% had multivessel disease. Angiographic and pro-
cedural characteristics differed, with more complex lesions and more vein grafts
managed in the paclitaxel-eluting stent group. Overall mean stented length was 46 �
32 mm. There were no differences in unadjusted outcomes by stent type (1-year major
adverse cardiac event rates of 20.4% for sirolimus-eluting stents vs 15.6% for pacli-
taxel-eluting stents, p � 0.12) or when adjusted for multivariate predictors (adjusted
hazard ratio 0.68, 95% confidence interval 0.37 to 1.24, p � 0.21). Independent
predictors of outcome in patients who had diabetes mellitus were stenting of the left
main artery, stenting of the left anterior descending artery, creatinine clearance, and
female gender. Patients who required insulin had a significantly higher, crude major
adverse cardiac event rate at 1 year compared with those who used oral agents, but
this rate became nonsignificant when adjusted for independent predictors of
outcome. © 2005 Elsevier Inc. All rights reserved. (Am J Cardiol 2005;96:358–362)
The Rapamycin-Eluting Stent Evaluated At Rotterdam Car-
diology Hospital (RESEARCH) and Taxus-Stent Evaluated
At Rotterdam Cardiology Hospital (T-SEARCH) registries
are identical sequential prospective registries that were spe-
cifically set up to evaluate the universal utilization of siroli-
mus- and paclitaxel-eluting stents (SESs and PESs, respec-
tively) in an unrestricted population.1,2 The present study
evaluated short- (1 month) and long-term (12 months) effica-
cies of SESs and PESs in patients with diabetes mellitus (DM).
• • •
We performed a prospective cohort study to investigate the
outcomes of drug-eluting stent implantation in patients who
had DM. Since April 2002, our institution has adopted a
policy of universal drug-eluting stent implantation for all
patients who undergo percutaneous coronary intervention
that requires stenting. All patients are prospectively entered
into a dedicated database. The initial results of this approach
have been published elsewhere.1,2 Until February 2003,
SESs (Cypher, Cordis, a Johnson & Johnson Company,
Miami Lakes, Florida) were exclusively used; subsequently,
PESs (Taxus, Boston Scientific Corp., Natick, Massachu-
setts) became the default stent.
Follow-up was complete for 98% of patients. Survival
status was obtained from municipal civil registries at 1, 6,
and 12 months. All repeat interventions (surgical and per-
cutaneous) and rehospitalizations were prospectively col-
lected during follow-up. Questionnaires concerning anginal
status and medication use were sent to all living patients at
6 and 12 months. Referring physicians and institutions were
contacted for additional information, if required. Written
informed consent was obtained from every patient.
From April 2002 to December 2003, 293 unselected
consecutive patients who had DM and de novo coronary
artery disease were treated exclusively with drug-eluting
stents; 145 patients received SESs and 148 received PESs. The
2 groups were sequential and are part of the RESEARCH and
T-SEARCH prospective registries, respectively. Patients
who have DM constitute 18% of the patient population
treated percutaneously at our institution and were defined by
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Manuscript received December 28, 2004; revised manuscript received and
accepted March 25, 2005.
This study was supported by the Erasmus MC, Rotterdam, The
Netherlands, and by unrestricted institutional grants from Boston Scientific
Corp., Natick, Massachusetts, and Cordis, a Johnson & Johnson Company,
Miami Lakes, Florida.
* Corresponding author. Tel.: 31-10-463-5260; fax: 31-10-436-9154.
E-mail address: p.w.j.c.serruys@erasmusmc.nl (P.W. Serruys).
0002-9149/05/$ – see front matter © 2005 Elsevier Inc. All rights reserved. www.AJConline.org
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therapy; those on oral medications were classified as requir-
ing noninsulin and those on insulin therapy as requiring
insulin.
All interventions were performed according to current
standard procedures using routine high-pressure balloon in-
flations, with the final interventional strategy (including
direct stenting, postdilatation, use of periprocedural glyco-
protein IIb/IIIa inhibitors, and use of intravascular ultra-
sound) at the operator’s discretion.3 Angiographic success
was defined as a residual stenosis �30% by visual analysis
in the presence of Thrombolysis In Myocardial Infarction
grade 3 flow. All patients were advised to maintain lifelong
use of aspirin (�80 mg/day). All patients were pretreated
with 300 mg of clopidogrel. Postprocedurally, patients who
received PESs were prescribed �6 months of clopidogrel
(75 mg/day),4 and those who received SESs were prescribed
clopidogrel for �3 or 6 months depending on the complex-
ity of the procedure.1
The primary outcome was the occurrence of major ad-
verse cardiac events, defined as a composite of all-cause
death, nonfatal myocardial infarction, or target vessel re-
vascularization. Myocardial infarction was diagnosed by an
increase in creatine kinase-MB fraction of �3 times the
upper limit of normal.5 In patients who underwent coronary
artery bypass surgery during follow-up, periprocedural
myocardial infarction was diagnosed by an increase in cre-
atine kinase-MB level of 5 times the upper limit of normal.6
For patients who presented with an acute myocardial infarc-
tion, a diagnosis of repeat myocardial infarction in the acute
phase required a decrease and then increase in creatine
kinase-MB of 50% above the previous level.7 Target lesion
revascularization was defined as a repeat intervention (sur-
gical or percutaneous) to control a luminal stenosis within
the stent or in the 5-mm distal or proximal segments adja-
cent to the stent. Target vessel revascularization was defined
as a reintervention that was influenced by any lesion in the
same epicardial vessel. Angiographic stent thrombosis was
defined as an angiographically documented complete occlu-
sion (Thrombolysis In Myocardial Infarction grade 0 or 1
flow) or a flow-limiting thrombus (Thrombolysis In Myo-
cardial Infarction grade 1 or 2 flow) in a previously suc-
cessfully stented artery in the first 30 days. Suspected stent
thrombosis was defined as unexplained sudden death or
nonfatal myocardial infarction that was unrelated to a
periprocedural complication without repeat angiography.
Two independent cardiologists (AO and JA) reviewed all
major adverse cardiac events.
Continuous variables are presented as mean � SD and
were compared with Student’s unpaired t test. Categorical
variables are presented as counts and percentages and were
compared by Fisher’s exact test. All statistical tests were
2-tailed. Cox’s proportional hazards analysis was performed
to identify independent predictors of major adverse cardiac
events using significant univariate variables and clinically
important variables listed in Tables 1 and 2 (tested variables
were age, gender, insulin requirement, creatinine clearance,
Table 1
Baseline clinical characteristics
Variable SES Group PES Group p Value
(n � 145) (n � 148)
Men 66% 67% 0.8
Age (yrs) 62.6� 10.2 64.6� 10.3 0.08
Non–insulin-requiring DM 73% 77% 0.4
Insulin-requiring DM 27% 23% 0.4
Hypertension 68% 70% 0.7
Hypercholesterolemia* 66% 85% �0.001
Current smoking 23% 20% 0.7
Previous myocardial infarction 37% 42% 0.5
Previous coronary angioplasty 23% 21% 0.8
Previous coronary bypass
grafting
10% 14% 0.5
Single-vessel coronary disease 34% 31% 0.7
Multivessel coronary disease 66% 69% 0.7
Clinical presentation 0.4
Stable angina pectoris 49% 56%
Unstable angina pectoris 38% 34%
Acute myocardial infarction 13% 10%
Hemoglobin-A1c (%) 7.3� 1.3 7.6� 1.5 0.09
Creatinine clearance (ml/min) 87.6� 33.0 80.8� 33.4 0.10
Body mass index (kg/m2) 28.4 � 4.1 27.9� 3.8 0.3
Values are means � SD or percentages.
* Defined as a fasting cholesterol level �5.5mmol/L or use of lipid-
lowering therapy.
Table 2
Angiographic and procedural characteristics
Variable SES Group PES Group p Value
(n � 145) (n � 148)
Treated coronary vessel*
Left anterior descending artery 60% 48% 0.05
Left circumflex artery 40% 34% 0.3
Right artery 32% 42% 0.11
Left main artery 8% 8% 1.0
Bypass graft 3% 10% 0.02
Lesion type†
A 17% 8% 0.02
B1 37% 24% 0.02
B2 45% 47% 0.7
C 47% 56% 0.13
No. of coronary vessels treated 0.5
1 61% 64%
2 35% 28%
3 4% 8%
Multivessel treatment 39% 36% 0.6
Bifurcation stenting 19% 14% 0.4
No. of stented vessels 1.4� 0.6 1.4 � 0.7 0.9
No. of implanted stents 2.4� 1.5 2.3 � 1.4 0.6
Total stented length per patient
(mm)
45.3 � 32.1 48.5 � 33.8 0.4
Nominal stent diameter �2.5 mm 40% 47% 0.2
Chronic total occlusion (�3 mos) 14% 12% 0.6
Glycoprotein IIb/IIIa inhibitor use 18% 28% 0.04
Angiographic success of all
lesions
94% 97% 0.4
Values are means � SD or percentages.
* Expressed as percentage of patients with vessel type treated. Total
exceeds 100%.
† Expressed as percentage of patients with lesion type. Total exceeds
100%.
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presenting symptoms, lesion type, multivessel disease, bi-
furcation stenting, stenting of the left main artery, stenting
of the left anterior descending artery, stent type, number of
stents, total stent length, and minimum stent diameter).
Stent type and requirement for insulin were forced into the
model, whereas other variables were entered in a forward
stepwise method (entry and removal criteria of 0.05 and
0.10, respectively). The cumulative incidence of adverse
events was estimated according to the Kaplan-Meier method.
Baseline clinical characteristics were similar for the 2
groups with the exception of hypercholesterolemia (Table 1).
Sixty-six percent were men and 25% required insulin. Mul-
tivessel coronary disease was present in 66% of patients,
and 50% presented with an acute coronary syndrome (un-
stable angina or acute myocardial infarction). Mean hemo-
globin A1c levels were 7.6 � 1.5% in the PES group and
7.3 � 1.3% in the SES group. More patients in the PES
group were classified as having hypercholesterolemia (de-
fined as a fasting serum cholesterol level �5.5mmol/L or
use of lipid-lowering therapy at the time of the procedure)
due to the more widespread use of lipid-lowering agents in
the latter period.
Significant differences were noted in terms of angio-
graphic and procedural characteristics (Table 2). In the PES
group, more patients received treatment in a bypass graft
(10% vs 3% in the SES group, p � 0.02) and fewer patients
received treatment in the left anterior descending artery
(48% vs 60% respectively, p � 0.05). The use of glyco-
protein IIb/IIIa inhibitors was greater in the PES group (28%
vs 18%, p � 0.04). More complex lesions were treated in the
PES group, with fewer type A or B1 lesions treated (p� 0.02).
Multivessel treatment was performed in 40% of patients. Total
stented length was similar in the 2 groups (48.5 � 33.8 mm in
the PES group and 45.3 � 32.1 mm in the SES group, p �
0.4), as was the number of stents implanted (2.3 � 1.3 vs 2.4
� 1.5 stents, respectively, p � 0.6).
In the first month after stent implantation, there were 10
deaths that were equally divided between groups (Table 3).
Three deaths were clinically suspected to be due to stent
thrombosis (Table 3). There were 8 myocardial infarctions,
5 in the SES group and 3 in the PES group. Of the 6 target
lesion revascularizations, 4 were for stent thrombosis and 2
were the result of a procedural complication that required
urgent coronary surgery. In total, 4 patients (2.8%) in the
SES group and 3 (2.0%) in the PES group had suspected or
Figure 1. Event curves at 1 year for cumulative risks of (A) death, (B) death
or myocardial infarction, and (C) death, myocardial infarction, or target
vessel revascularization.
Table 3
Major adverse cardiac events in the first month after stent implantation
Patients With Events at 0–1
month
SES Group PES Group p Value*
(n � 143) (n � 148)
Death 5 (3.4%) 5 (3.4%) 1.0
Nonfatal myocardial infarction 5 (4.1%) 3 (2.0%) 0.3
Target lesion revascularization 5 (3.4%) 1 (0.7%) 0.1
Target vessel revascularization† 5 (3.4%) 3 (2.0%) 0.5
Any event 14 (9.7%) 9 (6.1%) 0.3
Angiographically proved stent
thrombosis
3 (2.1%) 1 (0.7%) 0.4
Suspected stent thrombosis 1 (0.7%) 2 (1.4%) 1.0
Total stent thrombosis 4 (2.8%) 3 (2.0%) 0.7
* By Fisher’s exact test.
† Includes target lesion revascularization.
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proved stent thrombosis (p � 0.7). A major adverse cardiac
event occurred in 9.7% of patients in the SES group and
6.1% of patients in the PES group within the first 30 days.
At 1 year, there were no differences in the incidence of
death between groups (SES 7.7%, PES 7.2%, p � 0.9;
Figure 1). The incidence of death or myocardial infarction
was also similar (SES 14.1%, PES 10.0%, p � 0.3). The
composite end point of death, myocardial infarction, or
target vessel revascularization was also nonsignificantly dif-
ferent (SES 20.4%, PES 15.6%, p � 0.12), with a trend
favoring PES. Incidences of target lesion revascularization
were 8.8% in the SES group and 5.7% in the PES group
(p � 0.08; Figure 2
When patients were classified by insulin requirement,
patients who required insulin (n � 72) developed more
events compared with those who did not require insulin
(n � 221, crude major adverse cardiac events 27.4% vs
14.6%, respectively, p� 0.008; Figure 3). Hemoglobin A1c
levels were higher in the insulin-requiring DM group than in
the non–insulin-requiring DM group, although not signifi-
cantly (7.6% vs 7.2%, p � 0.4).
Stenting of the left anterior descending artery, stenting of
the left main coronary artery, and female gender were in-
dependently associated with worse outcomes, whereas bet-
ter renal function (defined as milliliter-per-minute incre-
Figure 2. One-year cumulative risks of (A) target lesion revascularization
and (B) target vessel revascularization.
Table 4
Multivariate predictors of major adverse cardiac events at one year
(Cox’s proportional hazards model)
Variable Adjusted HR 95% CI p Value
Stenting of left anterior
descending artery
2.79 1.44–5.39 0.002
Stenting of left main artery 2.78 1.24–6.25 0.013
Creatinine clearance (/ml/min
increment)
0.99 0.98–1.00 0.03
Women 1.90 1.02–3.53 0.04
Use of PES 0.68 0.37–1.24 0.21
Use of insulin 1.48 0.80–2.74 0.22
CI � confidence interval; HR � hazard ratio.
Figure 3. Cumulative risks of (A) death and (B) major adverse cardiac
events stratified by diabetic type. IRDM � insulin-requiring DM; NIRDM �
non–insulin-requiring DM.
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ment in creatinine clearance) was associated with improved
outcomes (Table 4). Insulin requirement, significant in uni-
variate analysis, became nonsignificant in the multivariate
model (adjusted hazard ratio 1.48, 95% confidence interval
0.80 to 2.74, p � 0.22), and no significant differences were
noted with stent type (adjusted hazard ratio 0.68, 95%
confidence interval 0.37 to 1.24, p � 0.21).
• • •
The major finding of this study is that unrestricted use of
PESs in a universal drug-eluting stent environment is asso-
ciated with a nonsignificantly lower incidence of major
adverse cardiac events at 1 year compared with SESs (ad-
justed hazard ratio 0.68, 95% confidence interval 0.37 to
1.24, p � 0.21). Patients with DM and who required insulin
had a significantly higher crude incidence of major adverse
cardiac events compared with those who did not require
insulin in a combined drug-eluting population; this signifi-
cance became nonsignificant after adjustment for multivar-
iate predictors.
Mortality rate at 1 year between groups in our study was
similar (7.7% in SES group and 7.2% in PES group, p �
0.9). It is difficult to compare between studies; however, as
a guide, this result lies between that reported in the stent arm
of the randomized Arterial Revascularization Therapy
Study (6.3%)8 and a multivessel report from the database of
the Cardiovascular Research Foundation (14% to 15%),9
with the caveat that baseline demographics were different.
For a population that had DM, the use of glycoprotein
IIb/IIIa inhibitors in this study was very low; more frequent
use may have improved mortality rates.10
This study has described the experience of a single-
center registry of drug-eluting stents in a moderate number
of patients. Routine angiographic follow-up was not per-
formed, thus precluding an assessment of restenotic rates.
The low use of glycoprotein IIb/IIIa inhibitors is a limitation
but was a reflection of the “real-world” practice of the
operators. The results of this study should be viewed as an
exploratory analysis that reported outcomes after the unre-
stricted use of drug-eluting stents in the real world in pa-
tients who had DM.
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Chronic total occlusion of the left main coronary artery (LMCA) is rare. Recently, percutaneous coronary in-
tervention has been increasingly applied to unprotected LMCA lesions. We describe a patient with chronic to-
tal occlusion of the LMCA who was successfully treated with bifurcation stenting with sirolimus-eluting stents.
(J Interven Cardiol 2005;18:65–69)
Introduction
Chronic total occlusion of the left main coronary
artery (LMCA) is an unusual manifestation of coro-
nary atherosclerotic disease in clinical practice.1–4 The
rarity of this lesion may be accounted for by the rela-
tively high incidence of death in these patients. Coro-
nary artery bypass graft surgery (CABG) has been the
standard of care for LMCA disease, though recently,
percutaneous coronary intervention (PCI) has been in-
creasingly applied to unprotected LMCA lesions.5–12
However, the development of restenosis remains a ma-
jor limitation of late outcomes after PCI, with the oc-
currence of restenosis particularly associated with haz-
ardous clinicalmanifestations. Sirolimus-eluting stents
(SES) have been shown to dramatically reduce the
restenosis rate in selected patients with relatively sim-
ple lesions.13–15 We report a patient with chronic total
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occlusion of the LMCA who was successfully treated
percutaneously with SES implantation.
Case Report
A 35-year-old male presented with an acute anterior
myocardial infarction that was managed medically. He
subsequently complained of on-going chest pain (CCS
class II–III angina16) and underwent coronary angiog-
raphy 9 months later. His resting 12-ECG revealed
evidence of a previousQ-wave anteroseptalmyocardial
infarction, and echocardiography demonstrated hy-
pokinesis of the anteroseptal wall without left ventricle
aneurysm. He was referred for coronary angiography,
which showed a total occlusion of the LMCA (Fig. 1);
the left anterior descending coronary artery (LAD)
and left circumflex coronary artery (LCX) were retro-
gradely filled via Rentrop grade III collaterals17 from
the RCA, which was itself not significantly stenosed
(Fig. 2). The patient rejected coronary artery bypass
grafting, but consented to undergo attempted revascu-
larization with percutaneous coronary intervention.
A 6F introducer sheath was inserted in the right
femoral artery. In addition, a 5F introducer sheath was
inserted in the left femoral artery to enable simultane-
ous right and left coronary injections. In the absence
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subsequently complained of on-going chest pain (CCS
class II–III angina16) and underwent coronary angiog-
raphy 9 months later. His resting 12-ECG revealed
evidence of a previousQ-wave anteroseptalmyocardial
infarction, and echocardiography demonstrated hy-
pokinesis of the anteroseptal wall without left ventricle
aneurysm. He was referred for coronary angiography,
which showed a total occlusion of the LMCA (Fig. 1);
the left anterior descending coronary artery (LAD)
and left circumflex coronary artery (LCX) were retro-
gradely filled via Rentrop grade III collaterals17 from
the RCA, which was itself not significantly stenosed
(Fig. 2). The patient rejected coronary artery bypass
grafting, but consented to undergo attempted revascu-
larization with percutaneous coronary intervention.
A 6F introducer sheath was inserted in the right
femoral artery. In addition, a 5F introducer sheath was
inserted in the left femoral artery to enable simultane-
ous right and left coronary injections. In the absence
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Figure 1. Left coronary artery angiogram, revealing total occlusion
of the left main stem artery.
of antegrade flow through the occlusion, such a dual
injection technique allows visualization of the distal
vessels (LAD and LCX) via the collateral filling from
the RCA, thereby facilitating correct positioning of
the wire. A 6F XB 3.5 guiding catheter (Cordis) was
placed in the left main coronary segment, and success-
Figure 2. Right coronary angiogram demonstrating grade III retro-
grade collaterals arising from the right coronary artery to both the
left anterior descending and the left circumflex arteries.
Figure 3. Left coronary angiogram showing the dissection of the
left main stem artery to the mid-circumflex artery.
ful recanalization was achieved with a 0.0014�� Shi-
nobi wire (Cordis), which was advanced into the dis-
tal LAD. A second 0.0014�� Shinobi wire was taken,
and passage into the LCX was attempted. Unfortu-
nately, this was complicated by catheter/wire-induced
dissection from the LMCA to the mid-LCX (Fig. 3),
and the wire was withdrawn. The LAD/distal LMCA
was stabilized through stent implantation with a 3.0 ×
23 mm SES (Cypher, Cordis), which was then post-
dilated with a 3.5 mm balloon (U-pass, Cordis) giving
a good result (Fig. 4). After several attempts, a 0.0014��
Shinobi wire was eventually successfully crossed, via
the SES struts, into the true lumen of the LCX. Af-
ter sequential predilatation using a 2.0 mm balloon
(Stomer, Medtronic), both the lesion and the mid-LCX
dissection (Fig. 5) were treated with implantation of a
2.5 × 33 mm SES deployed from LCX ostium. The
final angiogram showed good result with TIMI III flow
in both the LAD and the LCX (Fig. 6).18
The patient made an unremarkable recovery andwas
allowed to go home. There were no major adverse
cardiac events during the in-hospital period, and at
9-month clinical follow-up he remained well with no
recurrence of angina.
Discussion
Chronic total occlusion (CTO) of the LMCA is
rare. In patients who are investigated in the catheter
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Figure 4. Left coronary angiogram following stent deploymentwith
a 3.0 × 23 mm sirolimus-eluting stent in the left main stem/left
anterior descending artery.
laboratory, its prevalencevaries from0.04% to0.4%.1–4
CABG has been considered to be the treatment of
choice in LMCA disease, especially for chronic total
occlusion of the LMCA. There are a few published re-
Figure 5. Left coronary angiogram showing that a wire has success-
fully crossed through the stent struts and into the true lumen of the
distal left circumflex artery. The region of dissection can clearly be
seen in the proximal and mid parts of the vessel (contrast staining).
Figure 6. The final angiogram following additional stent implanta-
tion with a 2.5 × 33 mm sirolimus-eluting stent up to the ostium of
the circumflex artery, showing a good result in both the left anterior
descending and the left circumflex arteries.
ports showing that the results of CABG for this group
of CTO`s are beneficial compared to medical ther-
apy.1,2 However, there are no studies comparing PCI
with CABG for such patients. The advent of improved
PCI equipment including stents and atherectomy de-
vices has been shown to be safe and effective in selected
patients with unprotected elective LMCA stenosis,5–12
and recently Trehan et al. have reported a single case
of successful percutaneous stenting of a CTO of an
unprotected LMCA.19 There are two major problems
associated with PCI for chronic total occlusion of the
LMCA. The first relates to the initial procedural diffi-
culty of crossing the occlusion with a wire; published
procedural success rates for CTO`s are generally in the
range of 40–81%.20,21 The second relates to resteno-
sis; both bifurcation lesions and CTO`s are subject to
a higher rate of restenosis compared with simpler le-
sions.22–25 Importantly, the occurrence of restenosis in
the LMCAmay be associated with a significant rate of
mortality. In particular, PCI for bifurcation lesions of
the distal LMCA, whereby both the LAD and the LCX
arteries are stented, is both technically demanding and
at high risk of restenosis.26–28 Drug eluting, stents have
been shown to dramatically reduce the restenosis rate
in elective patients with simple de novo lesions.13–15
The development and more widespread application of
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drug-eluting stents hold the promise of a significant
reduction in restenosis and the need for repeat revas-
cularization. Arampatzis et al. have reported the ef-
fectiveness of SES for the treatment of LMCA. A to-
tal of 31 consecutive patients were treated solely with
SESs either electively, for acute myocardial infarction,
or due to procedural complication-related LMCA dis-
section. In this study, the rate of out-of-hospital clinical
events was extremely low, with zero percent mortal-
ity and 4% target vessel revascularization.29 In addi-
tion, low subsequent binary restenosis rates following
SES implantationhavebeendocumentedboth inCTO’s
(9.1% at 6 months) and bifurcation lesions (22.7% at
6 months).30,31 The technique of bifurcation stenting
(T, culotte, kissing, or crush stenting) with drug-eluting
stents is still controversial.30 Those techniques result-
ing in overlapping stent struts lead to an increase in
the local concentration of drug, which may induce en-
dothelial function impairment and thus be associated
with an increased rate of stent thrombosis. In the current
report, we present a patient who underwent successful
recanalization of an LMCA CTO without the need for
a cardiac support device, and underwent bifurcation
stenting, with SESs. There were no major adverse car-
diac events either in-hospital or over the subsequent 9
months. Further data are needed to fully evaluate the
use of this strategy in such an unusual patient pop-
ulation; however, SES-supported angioplasty may be
a reasonable alternative to CABG in the treatment of
LMCA chronic total occlusion.
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EDITOR’S RESPONSE
In the current case presentation, Dr. Aoki offers a
glimpse at one of the still untapped frontiers in in-
terventional cardiology. Percutaneous management of
left main coronary lesions has remained undesirable
because of the immediate technical difficulties and
the subsequent risk of potentially fatal restenosis. The
present case was particularly difficult because the left
main was chronically occluded into both the left an-
terior descending and the left circumflex coronary ar-
teries. The double catheter approachwith simultaneous
injection into the right coronary artery and the left main
greatly facilitated distal guidewire placement. Achiev-
ing distal guidewire access was the greatest technical
challenge of this particular case. Once distal access
was attained, angiographic success was all but assured.
While I believe that the angiographic results should
have been confirmed with intravascular ultrasound to
ensure adequate stent apposition within this critical
area, this case represents a therapeutic victory over ex-
treme lesion complexity with excellent angiographic
and clinical results. Such cases should only be per-
formed in high-volumecenterswith highly experienced
coronary interventionalists.
However, the acute results in left main coronary
stenting are only part of the battle. The largest hurdle in
the management of these lesions is avoiding restenosis
and its risk for death. The use of drug-eluting stents
in the left main coronary artery may offer a solution.
Arampatzis et al. studied the use of sirolimus-coated
stents in 16 consecutive patients undergoing elective
leftmain stenting in a single center.1 Half of the patients
had lesions involving the left anterior descending/left
circumflex bifurcation. Nine patients had unprotected
left main stenoses. There were no deaths reported dur-
ing 1 year of follow-up. Peri-procedural non-Q-wave
myocardial infarction occurred in one patient. Of the
12 patients who underwent angiographic follow-up at
6 months, only one demonstrated restenosis requiring
repeat percutaneous intervention. No other major ad-
verse coronary events occurred in the entire cohort
during the year following left main intervention. Al-
though the patient in the current case presentation did
not undergo angiographic follow-up, he remained clin-
ically stable and free of angina for 9 months. This case,
therefore, succeeded in illustrating the potential of the
left main coronary stenting in the drug-eluting stent
era. I agree with the authors that this is an area of
interventional cardiology that requires immediate in-
vestigation to fully understand its applications and its
limitations.
STEVEN B.H. TIMMIS M.D.
Division of Cardiology
William Beaumont Hospital
Royal Oak, MI 48073
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Short- and Long-Term Clinical Outcome After Drug-Eluting
Stent Implantation for the Percutaneous Treatment of Left
Main Coronary Artery Disease
Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At
Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH)
Marco Valgimigli, MD; Carlos A.G. van Mieghem, MD; Andrew T.L. Ong, MBBS, FRACP;
Jiro Aoki, MD; Gaston A. Rodriguez Granillo, MD; Eugene P. McFadden, MD, FRCPI;
Arie Pieter Kappetein, MD, PhD; Pim J. de Feyter, MD, PhD; Pieter C. Smits, MD, PhD;
Evelyn Regar, MD, PhD; Willem J. Van der Giessen, MD, PhD; George Sianos, MD, PhD;
Peter de Jaegere, MD, PhD; Ron T. Van Domburg, PhD; Patrick W. Serruys, MD, PhD
Background—The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular
events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown.
Methods and Results—From April 2001 to December 2003, 181 patients underwent percutaneous coronary intervention
for LM stenosis at our institution. The first cohort consisted of 86 patients (19 protected LM) treated with bare metal
stents (pre-DES group); the second cohort comprised 95 patients (15 protected LM) treated exclusively with DES. The
2 cohorts were well balanced for all baseline characteristics. At a median follow-up of 503 days (range, 331 to 873 days),
the cumulative incidence of major adverse cardiovascular events was lower in the DES cohort than in patients in the
pre-DES group (24% versus 45%, respectively; hazard ratio [HR], 0.52 [95% CI, 0.31 to 0.88]; P�0.01). Total mortality
did not differ between cohorts; however, there were significantly lower rates of both myocardial infarction (4% versus
12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P�0.006) and target vessel revascularization (6% versus 23%,
respectively; HR, 0.26 [95% CI, 0.10 to 0.65]; P�0.004) in the DES group. On multivariate analysis, use of DES,
Parsonnet classification, troponin elevation at entry, distal LM location, and reference vessel diameter were independent
predictors of major adverse cardiovascular events.
Conclusions—When percutaneous coronary intervention is undertaken at LM lesions, routine DES implantation, which
reduces the cumulative incidence of myocardial infarction and the need for target vessel revascularization compared
with bare metal stents, should currently be the preferred strategy. (Circulation. 2005;111:1383-1389.)
Key Words: stents � angioplasty � arteries
Despite the recognition that coronary revascularization,in selected patients with multivessel disease, can
presently be accomplished by either a surgical or a
percutaneous approach with no significant difference in
long-term mortality,1,2 coronary artery bypass grafting
(CABG) is still considered the treatment of choice in
patients with left main (LM) disease.3 Several trials have
reported on the safety and feasibility of stent implantation
to treat LM stenosis.4,5 However, particularly in this subset
of patients, restenosis remains a major, and potentially
fatal, complication, precluding more widespread use of
percutaneous coronary intervention (PCI).4,6 In the first
observational report of patients treated with a sirolimus-
eluting stent (SES) for LM disease, a low rate of binary
restenosis and a favorable clinical outcome were reported.7
However, the benefit of drug-eluting stents (DES) on the
short- and long-term incidence of major adverse cardio-
vascular events in this setting, compared with bare metal
stents (BMS), remains largely unknown.
The purpose of the present study was to investigate, in this
subset of patients undergoing revascularization in a tertiary
referral center, the differential impact of DES as opposed to
conventional BMS on the occurrence of short- and long-term
major cardiovascular events.
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Methods
Study Design and Patient Population
Since April 16, 2002, SES (Cypher, Johnson & Johnson, Cordis unit)
have been used as a default strategy for every PCI at our institution
as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital (RESEARCH) registry. From the first quarter of
2003, paclitaxel-eluting stents (PES) (Taxus, Boston Scientific
Corporation) became commercially available, replacing SES as the
strategy of choice in every PCI because of cost-effectiveness
considerations, as part of the Taxus Stent Evaluated At Rotterdam
Cardiology Hospital (T-SEARCH) registry. As a policy, all elective
patients presenting with significant (�50% by visual estimation) LM
disease, referred to our institution for coronary revascularization, are
evaluated by both interventional cardiologists and cardiac surgeons,
and the decision to opt for PCI or surgery is reached by consensus on
the basis of a comprehensive evaluation of the following items:
suitable anatomy and lesion characteristics for stenting and size and
quality of vessels distal to the disease and of arterial and/or venous
conduits for grafting. Finally, patient and/or referring physician
preferences for a percutaneous approach, with both aware of the
procedural risks and contraindications to surgery on the basis of the
presence of comorbidity as evaluated by a cardiac surgeon, are also
considered.
From April 16, 2002, to December 31, 2003, a total of 95
consecutive patients were treated exclusively with �1 DES in the
LM as part of an elective or nonelective revascularization procedure
and constitute the DES group of the present report. Fifty-two patients
in the first cohort (of whom procedural details and medium-term
follow-up were previously reported for 317), received SES exclu-
sively (available, at that time, in diameters from 2.25 to 3.00 mm),
whereas in the following group of 43 patients, PES (available in
diameters from 2.25 to 3.5 mm) were implanted. A control group for
comparison was composed of 86 consecutive patients who received
conventional BMS (available in diameters from 2.5 to 5.00 mm) for
LM treatment in the period immediately before the introduction of
SES. The following BMS were used: BX Sonic or BX Velocity in
35% (Cordis, Johnson & Johnson Company), R-Stent in 29% (Orbus
Medical Technologies), Multi-Link Penta in 28% (Guidant Corp),
Multi-Link Tetra in 8% (Guidant Corp), and other stents in 4%.
Therefore, the total study population comprised all 181 consecutive
patients who underwent percutaneous LM treatment from April 2001
to December 2003 with either BMS or DES in the 2 study phases,
respectively. To stratify the study population into high– and low–
surgical risk groups, the Parsonnet surgical risk score was calculated
for each patient.8 A score �15 was used to identify patients at high
risk, as previously suggested.6,9 Protected LM segment was defined
as the presence of at least 1 patent arterial or venous conduit to at
least 1 left coronary segment. Nonelective treatment was defined as
a procedure performed on referral before the beginning of the next
working day.10
This protocol was approved by the hospital ethics committee and
is in accordance with the Declaration of Helsinki. Written informed
consent was obtained from every patient.
Procedures and Postintervention Medications
All interventions were performed according to current standard
guidelines, and the final interventional strategy, including the use of
glycoprotein IIb/IIIa inhibitors, was left entirely to the discretion of
the operator, except for the stent utilization. Angiographic success
was defined as residual stenosis �30% by visual analysis in the
presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow
grade. All patients were advised to maintain the use of aspirin
lifelong. One-month clopidogrel treatment (75 mg/d) was recom-
mended for patients treated in the pre-DES phase. For patients
treated with either SES or PES, clopidogrel was prescribed for 6
months.
End Point Definitions and Clinical Follow-Up
The primary outcome was the occurrence of major adverse cardiac
events, defined as (1) death, (2) nonfatal myocardial infarction (MI),
or (3) target vessel revascularization. Patients with �1 event have
been assigned the highest ranked event, according to the previous
list. All deaths were considered to be of cardiac origin unless a
noncardiac origin was established clinically or at autopsy. MI was
diagnosed by a rise in the creatine kinase level to more than twice the
upper normal limit with an increased creatine kinase-MB fraction.
Target vessel revascularization was defined as a repeated interven-
tion (surgical or percutaneous) to treat a luminal stenosis within the
stent or in the 5-mm distal or proximal segments adjacent to the
stent, including the ostium of the left anterior descending artery
(LAD) and/or circumflex artery. Information about in-hospital out-
comes was obtained from an electronic clinical database for patients
maintained at our institution and by review of hospital records for
those discharged to referring hospitals (patients were referred from a
total of 14 local hospitals). Postdischarge survival status was
obtained from the Municipal Civil Registries. Information on occur-
rence of MI or repeated interventions at follow-up was collected by
consulting our institutional electronic database and by contacting
referring physicians and institutions and all living patients.
Statistical Analysis
Continuous variables are shown as mean�SD and were compared by
Student unpaired t test. Categorical variables are presented as counts
and percentages and were compared with the Fisher exact test.
Survival curves were generated by the Kaplan-Meier method, and
survival among groups was compared with the log-rank test. Cox
proportional hazards models were used to assess risk reduction of
adverse events. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were censored.
Univariate analysis was performed with the consideration of all
variables reported in Tables 1 and 2. Multivariate analyses, with
consideration of all variables with a value of P�0.10, were per-
formed to identify independent predictors of adverse events. Proba-
bility was significant at a level of �0.05. All statistical tests were
2-tailed. Statistical analysis was performed with the use of Statistica
6.1 (Statsoft Inc).
Results
Baseline and Procedural Characteristics
Baseline and procedural characteristics are shown in Table 1
and Table 2. The 2 groups were well matched for all baseline
characteristics, including comorbidities. Overall, the average
left ventricular ejection fraction was slightly �40%, and
approximately half of the patients in both groups were
admitted with acute coronary syndromes. Acute MI was the
indication to the procedure in 19%; 10% of the patients
presented with severe hemodynamic compromise at entry.
The distal LM was involved in two thirds of cases in both
groups, whereas patients treated with DES had significantly
more 3-vessel disease, more bifurcation stenting, a higher
number of stents, and greater total stent length per patients.
The nominal stent diameter, as a result of limited size
availability, was on average smaller in the DES group, which
explains the more common practice of postdilatation in this
group of patients. Procedural success was 99% in patients
receiving DES: in 1 patient who presented with acute MI and
shock, a final TIMI 1 flow grade was obtained, and the patient
died 3 hours after the procedure. The procedural success was
98% in patients treated in the pre-DES phase: in 2 patients
with acute MI and TIMI 0 flow grade in the left coronary
artery, the LM and proximal LAD were stented, and subse-
quently CABG was performed because of residual critical
stenosis in the left circumflex artery.
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Thirty-Day Outcomes
There were no significant differences between the DES and
the pre-DES groups in the incidence of major adverse
cardiovascular events during the first 30 days (Table 3). In the
DES group, all deaths except 3 occurred in patients pres-
enting with ST-segment elevation acute MI and cardiogenic
shock at entry. In all these patients except 4 with severe
peripheral artery disease, an intra-aortic balloon was placed
during PCI. In the elective population, a total of 2 deaths
occurred; both patients presented with unstable angina with
mild troponin elevation and were refused by surgeons be-
cause of old age (84 years), low left ventricular ejection
fraction (�30%), and diabetic chronic renal insufficiency in 1
patient and diffuse 3-vessel disease associated with small-
caliber vessels in the second. In this second patient the right
coronary artery was occluded. The reason for death was
pulmonary infection, which developed 19 days after the
procedure in the first patient, and cardiogenic shock, which
developed during the intervention, resistant to hemodynamic
support (left ventricular assist device) in the other patient. In
the pre-DES group, all 6 deaths occurred in patients with
ST-segment elevation acute MI, of whom 4 were in cardio-
genic shock at entry. No documented thrombotic stent occlu-
sion occurred in the first 30 days or thereafter.
Long-Term Outcome
After a median follow-up of 503 days (range, 331 to 873
days), the cumulative incidence of major adverse cardiovas-
cular events (death, MI, or target vessel revascularization)
was significantly lower in the DES patients than in the
pre-DES patients (24% versus 45%, respectively; hazard ratio
TABLE 1. Baseline Characteristics of the Study Population
Variables
Pre-DES Group
(n�86)
DES Group
(n�95) P
Age, y * 66�10 64�12 0.18
Men, %* 62 66 0.53
Body mass index, kg/m2* 26�4 27�4 0.31
Diabetes, %* 22 30 0.23
Non–insulin-dependent, % 17 20 0.71
Insulin-dependent, % 5 10 0.17
Hypertension, %* 57 53 0.65
Hypercholesterolemia, % 55 56 0.88
Current smoking, % 19 18 0.8
Creatinine, �mol/L* 102�80 95�31 0.36
LVEF, %* 42�13 41�14 0.85
Medical history, %
Protected LM 22 16 0.17
PCI 35 28 0.42
MI 41 38 0.58
Transient ischemic attack/stroke 8 11 0.81
Heart failure* 16 20 0.36
Severe COPD*† 5 8 0.38
Peripheral arterial disease* 24 22 0.86
Carotid artery disease* 6 6 0.98
Clinical presentation, %
Stable angina 50 48 0.8
Unstable angina 33 33 1
Acute MI* 17 20 0.70
Cardiogenic shock at entry* 9 12 0.66
Parsonnet score 16�11 19�12 0.17
LVEF indicates left ventricular ejection fraction; COPD, chronic obstructive
pulmonary disease.
*Parameters included in the Parsonnet classification.
†Resulting in functional disability or hospitalization, requiring chronic
bronchodilator therapy, or forced expiratory volume in 1 second �75% of
predicted.8
TABLE 2. Angiographic and Procedural Characteristics of the
Study Population
Variables
Pre-DES
Group
(n�86)
DES Group
(n�95) P
Lesion location, %
Ostium 18 27 0.20
Body 40 37 0.31
Distal 66 65 0.9
Pure LM disease, % 2 3 1
LM plus 1-vessel disease, % 29 17 0.4
LM plus 2-vessel disease, % 42 21 �0.001
LM plus 3-vessel disease, % 27 59 0.003
Right coronary artery �70%
stenosis, %
27 53 0.02
Right coronary artery occlusion, % 13 19 0.43
No. of implanted stents 1.2�0.5 1.4�0.6 0.01
Nominal stent diameter, mm 3.6�0.5 3.1�0.32 �0.001
Total stent length per patient, mm 20�9 24�13 0.02
Predilatation, % 67 71 0.62
Cutting balloon, % 5 6 0.94
Rotational atherectomy, % 1 3 0.8
Directional atherectomy, % 6 0 0.007
Postdilatation, % 58 80 0.01
Larger balloon inflated, mm 4�0.6 3.9�0.4 0.07
Maximal pressure, atm 17�2 17�3 0.85
Bifurcation stenting, % 10 26 0.02
Culotte* 11 36 0.4
T technique* 88 44 0.35
Crush* 0 12 0.56
Kissing technique* 0 8 0.91
Intravascular ultrasonography, % 23 27 0.36
Glycoprotein IIb/IIIa inhibitors, % 26 28 0.83
Intra-aortic balloon pump, % 16 15 0.88
Left ventricular assist device, % 0 2 0.52
Minimal lumen diameter, mm,
preintervention
1.05�0.59 1.09�0.44 0.58
Minimal lumen diameter, mm,
postintervention
2.97�0.6 2.83�0.49 0.09
Reference vessel diameter, mm,
postintervention
3.37�0.6 3.25�0.5 0.2
*Relative to patients with bifurcation stenting.
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[HR], 0.52 [95% CI, 0.31 to 0.88]; P�0.01) (Figure, A).
Mortality was similar in the DES (14%) and pre-DES cohort
(16%; HR, 0.79 [95% CI, 0.38 to 1.66]; P�0.54) (Figure, B),
whereas there was a significant reduction in both the rate of
MI (4% versus 12%, respectively; HR, 0.22 [95% CI, 0.07 to
0.65]; P�0.006) and composite death/MI (Figure, C) as well
as in the need for target vessel revascularization (6% versus
23%, respectively; HR, 0.26 [95% CI, 0.10 to 0.65];
P�0.004) (Figure, D) in the DES group. Seventy-four per-
cent of the deaths were cardiac, whereas 3 of 13 in the DES
group and 4 of 14 in the pre-DES phase were attributed to
extracardiac reasons. In Table 4, the baseline and procedural
characteristics of those patients in the DES group who
underwent target vessel revascularization during follow-up
are reported. In all cases, the lesion was located in the distal
LM, in 50% of cases diabetes was present, and all except 1
were women. In 3 cases, in-stent restenosis occurred; in 2
patients intimal hyperplasia developed at the distal edge of
the stent, whereas in 1 patient severe ostial side branch
restenosis (circumflex artery) necessitated reintervention. In
all cases, restenosis was focal (�10 mm in length) and was
successfully treated with repeated PCI. In the pre-DES group,
13 cases of pure in-stent restenosis, of which 3 were focal,
were treated with PCI (9 patients) or CABG (4 patients). In 2
patients, diffuse intimal hyperplasia associated with progres-
sion of atherosclerotic disease in other vessels was treated
with CABG, and in 5 patients (3 with ST-segment elevation
acute MI as the indication for LM intervention), staged
reintervention with CABG (in 4 patients) and PCI (in 1
patient) was performed because revascularization remained
incomplete at the time of the index procedure.
One-year adverse events in patients treated with BMS before the introduction of DES (pre-DES group) and in patients treated exclusively with
DES implantation (DES group). Cumulative risk of major adverse cardiovascular events (MACE) (A), death (B), death or MI (C), and target ves-
sel revascularization (TVR) (D) is shown.
TABLE 3. Thirty-Day Outcomes
Variables
Pre-DES Group
(n�86)
DES Group
(n�95) P*
Death, n (%) 6 (7) 10 (11) 0.60
Nonfatal MI, n (%) 8 (9) 4 (4) 0.24
Death or nonfatal MI, n (%) 14 (16) 14 (15) 0.84
Target vessel revascularization, n (%) 2 (2) 0 (0) 0.22
Repeated PCI 1 (1) 0 (0)
CABG 1 (1) 0 (0)
Any event, n (%) 16 (19) 14 (15) 0.56
Stent thrombosis, n (%)† 0 (0) 0 (0) 1
*By Fisher exact test.
†Angiographically documented.
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Predictors of Adverse Events
The Parsonnet score, ranging from 2.5 to 55.5 (mean value,
18�2; interquartile range, 16.5) was 16�11 and 19�12 in
the pre-DES and DES groups, respectively (P�0.17) (Table
1), with a trend toward a higher rate of patients considered at
high surgical risk (58% versus 46%, respectively; P�0.13) in
the DES compared with the pre-DES cohort.
On univariate analysis, Parsonnet classification, use of
intra-aortic balloon pump, presence of shock at entry,
lesion located in the distal LM, nonelective PCI, troponin
elevation at entry, TIMI flow grade before and after PCI,
reference vessel diameter, left ventricular ejection fraction,
and the use of DES were identified as significant predic-
tors of adverse events. On multivariate analysis, Parsonnet
classification, troponin elevation at entry, lesions located
at distal site, reference vessel diameter, and the use of DES
were independent predictors of major adverse cardiovas-
cular events (Table 5).
Discussion
Despite the feasibility and the high procedural success rate of
percutaneous LM intervention, the long-term incidence of
adverse events in the pre-DES “era” was often reported to be
unacceptably high in this subset of patients.4,6 This reflected
the inclusion of high-risk patients, such as those not consid-
ered “good surgical candidates,” as well as the dramatic
impact of treated vessel failure in this specific anatomic
context. In consecutive patients receiving elective BMS for
unprotected LM treatment, the 3-year cumulative incidence
of death was recently reported to be �16%.6 In that series,
28% of the population was at high surgical risk. More than
50% of our study population was at high surgical risk
according to the Parsonnet classification, thus explaining the
relatively high rate of adverse events we observed. In this
setting, when patients treated with DES were compared with
those treated with BMS, a marked benefit with respect to the
rate of major adverse cardiac events, as evidenced by a 47%
relative risk reduction, emerged in the former. This was
mainly due to the difference in the incidence of MI (67%
relative risk reduction) and target vessel revascularization
(65% relative risk reduction), with no effect on mortality. The
higher prevalence of 3-vessel disease and bifurcation stenting
in the DES group makes the observed benefit even more
convincing. The difference in the incidence of events between
TABLE 4. Characteristics of Patients in the DES Group Who Underwent Target
Vessel Revascularization During Follow-Up
Patient No.
1 2 3 4 5 6
Age, y 66 77 36 70 52 56
Gender F F F M F F
Diabetes Yes No No Yes No Yes
Lesion location Distal Distal Distal Distal Distal Distal
Severe calcification Yes No No No No No
Stent type SES SES PES PES PES PES
Stent No. 2 2 1 2 1 2
Total stent length, mm 16 36 20 48 16 36
Bifurcation stenting No Yes No Yes No Yes
Technique � � � Crush � � � Culotte � � � Culotte
Postdilatation Yes Yes Yes Yes Yes Yes
Final kissing No No No Yes No No
Gap between stents No No No No No No
Stent underexpansion Yes No No No No No
Restenosis location In-stent In-stent* RS In-stent DER DER*
Revascularization type PCI PCI PCI PCI PCI PCI
QCA after PCI
Reference vessel diameter, mm 3.74 3.27 3.53 2.65 2.44 2.76
Minimal lumen diameter, mm 2.12 1.06 3.34 2.49 1.94 2.32
Lesion length, mm 13.4 19.7 13.5 21.3 8.9 18.9
QCA at follow-up
Reference vessel diameter, mm 3.87 3.43 3.21 2.32 1.82 2.36
Minimal lumen diameter, mm 1.23 0.57 0.98 0.99 0.6 0.71
Restenosis length, mm 5.8 9.06 3.6 5.48 7.72 9.5
QCA indicates quantitative coronary angiography; In-stent, restenosis located within the stent
margins; RS, restenosis located in the side branch (the ostium of the circumflex artery); and DER,
distal edge restenosis located within the 5-mm segment distal to the stent.
*More than 1 focal site.
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the 2 groups emerged slowly after the procedure, with no
clear advantage at 30 days, possibly reflecting the specific
mechanism of action of DES on intimal hyperplasia.
The overall advantage of DES remained significant after
adjustment for the Parsonnet score, the anatomic site of
obstruction, and troponin status at entry. Therefore, our data
suggest that when percutaneous treatment of LM coronary
artery disease is undertaken, DES should be used as the
default strategy.
The LM bifurcation was frequently involved (�60%) in
our series, and even when the obstruction was more proxi-
mally located and did not directly involve the LAD or left
circumflex artery ostia, its treatment often required the
management of LM bifurcation. To date, the results of SES
implantation to treat bifurcated lesions have been relatively
disappointing, with high rates of restenosis in the side
branch.11 Our present findings are in keeping with these
previous observations, confirming that in the DES era distal
LM location is an independent predictor of adverse events at
follow-up. Furthermore, because the strategy and technical
aspects of bifurcation management were left entirely to the
preference of treating physicians, no clear conclusions can be
drawn in this regard.
Inconsistent findings have been reported thus far with
regard to the effect of DES on long-term cumulative
incidence of MI. In the first randomized clinical trials
comparing SES or PES with BMS, no difference in the
incidence of MI was observed.12,13 Second-generation
randomized trials assessing the benefit of DES in patients
selected to be at intermediate risk for in-stent restenosis or
all-inclusive registries reported trends toward MI reduction
in the DES group, but none of them reached statistical
significance.14,15 Recently, a clear reduction in the cumu-
lative incidence of MI in the DES group was reported in
the SES-SMART trial, in which a selected group of
high-risk patients has been evaluated.16 Similarly, in our
patient population, a reduced incidence of MI was ob-
served in the DES group. Of note, 2 and 1 cases of MI in
the pre-DES phase were related to target vessel revascu-
larization and not related to target vessel revascularization,
respectively. Whether this difference between studies is
the reflection of a type II error in studies enrolling patients
at low or intermediate risk remains unclear, but when the
retrospective nature of our investigation is considered, data
from prospective studies are needed to confirm our
findings.
Limitations of the Study
The present study is a single-center experience from a tertiary
referral center and lacks the clear advantages of a multicenter
randomized study. In keeping with the aim of our investiga-
tion, an “all-comers” population has been enrolled, clearly
resulting in a heterogeneous group of patients. Further stud-
ies, with larger sample sizes, are required to investigate the
differential impact of DES versus BMS in prespecified
subgroups, stratified according to clinical presentation (stable
versus unstable) or protected versus unprotected type of
treatment.
Despite the fact that the study was conducted over a relatively
short period, we cannot exclude the possibility that improve-
ments in technique or differences in drug prescription could have
partially accounted for the difference observed in terms of major
adverse cardiovascular events between groups. However, con-
ducting randomized trials that seek to assess the efficacy of DES
versus BMS in this specific subset of patients seems unlikely,
and our understanding of the benefit of drug-coated stents to
treat this group of patients will probably also rely in the near
future on well-conducted registries that are able to record and
monitor our daily clinical practice.
Conclusions
The use of DES as a default strategy to treat LM disease was
associated with a significant reduction in adverse events. The
effectiveness of DES persisted even after adjustment for
clinical and procedural variables, including the Parsonnet
TABLE 5. Univariate and Multivariate Cox Proportional
Hazards Analysis
Variables P
Hazard Ratio
(95% CI) �2
Univariate analysis
Distal LM disease 0.003 2.7 (4.8–1.53) 13.3
DES use 0.019 0.54 (0.9–0.32) 5.48
Nonelective PCI 0.0047 2.1 (3.5–1.3) 8
Intra-aortic balloon pump
use
0.0002 2.9 (4.9–1.7) 14
LVEF, % 0.00001 0.95 (0.97–0.93) 20
Parsonnet score �0.00001 1.07 (1.09–1.05) 44
Reference vessel diameter 0.00001 0.36 (0.58–0.32) 19
Shock at entry �0.00001 4.48 (7.9–2.5) 21
TIMI flow before PCI 0.03 0.75 (0.96–0.58) 4.3
TIMI flow after PCI 0.03 0.58 (0.85–0.39) 4.7
Troponin T �0.02 �g/L
at entry
0.0002 3.15 (5.26–1.9) 18
Multivariate analysis 1
Distal LM disease 0.0007 2.94 (5.5–1.57) 76
DES use 0.00009 0.33 (0.57–0.19)
LVEF, % 0.09 0.98 (1.001–0.95)
Parsonnet score 0.0009 1.04 (1.07–1.01)
Reference vessel diameter 0.005 0.51 (0.79–0.33)
Troponin T �0.02 �g/L at
entry
0.02 2.3 (4.4–1.2)
Multivariate analysis 2
Distal LM disease 0.00017 3.3 (6.1–1.7) 68
DES use 0.00018 0.35 (0.6–0.20)
LVEF, % 0.00013 0.95 (0.98–0.94)
Reference vessel diameter 0.0011 0.48 (0.74–0.30)
Shock at entry 0.006 3.49 (8.6–1.4)
Troponin T �0.02 �g/L at
entry
0.016 2.27 (4.2–1.17)
Multivariate analysis model 1 was performed with all major adverse
cardiovascular event predictors on univariate analysis; in multivariate analysis
model 2, the Parsonnet score was removed because of colinearity between the
variables included in the model and those used in the calculation of the score,
such as left ventricular ejection fraction (LVEF), use of intra-aortic balloon
pump, and presence of shock.
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surgical risk score. Our findings apply to a selected group of
patients referred for percutaneous LM treatment and suggest
that in this setting routine DES implantation, by reducing the
cumulative incidence of major adverse cardiovascular events,
should be currently regarded as the strategy of choice. Until
new evidence is provided by randomized clinical trials
directly comparing the surgical and percutaneous approaches,
CABG should remain the preferred revascularization treat-
ment in good surgical candidates presenting with LM coro-
nary artery disease.
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CLINICAL RESEARCH Interventional Cardiology
Sirolimus-Eluting Versus Paclitaxel-Eluting
Stent Implantation for the Percutaneous
Treatment of Left Main Coronary Artery Disease
A Combined RESEARCH and T-SEARCH Long-Term Analysis
Marco Valgimigli, MD, Patrizia Malagutti, MD, Jiro Aoki, MD, Héctor M. Garcia-Garcia, MD,
Gaston A. Rodriguez Granillo, MD, Carlos A. G. van Mieghem, MD, Jurgen M. Ligthart, BSC,
Andrew T. L. Ong, MBBS, FRACP, George Sianos, MD, PHD, Evelyn Regar, MD, PHD,
Ron T. Van Domburg, PHD, Pim De Feyter, MD, PHD, Peter de Jaegere, MD, PHD,
Patrick W. Serruys, MD, PHD
Rotterdam, the Netherlands
OBJECTIVES The purpose of this study was to investigate the long-term clinical and angiographic profile
of sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES) in patients undergoing
percutaneous intervention for left main (LM) coronary disease.
BACKGROUND The long-term clinical and angiographic impact of SES as opposed to PES implantation in
this subset of patients is unknown.
METHODS From April 2002 to March 2004, 110 patients underwent percutaneous intervention for LM
stenosis at our institution; 55 patients were treated with SES and 55 with PES. The two
groups were well balanced for all baseline characteristics.
RESULTS At a median follow-up of 660 days (range 428 to 885), the cumulative incidence of major
adverse cardiovascular events was similar (25% in the SES group vs. 29%, in the PES group;
hazard ratio 0.88 [95% confidence interval 0.43 to 1.82]; p � 0.74), reflecting similarities in
both the composite death/myocardial infarction (16% in the SES group and 18% in the PES
group) and target vessel revascularization (9% in the SES group and 11% in the PES group).
Angiographic in-stent late loss (mm), evaluated in 73% of the SES group and in 77% of the
PES group, was 0.32 � 74 in the main and 0.36 � 0.59 in the side branch in the SES group
vs. 0.46 � 0.57 (p � 0.36) and 0.52 � 0.42 (p � 0.41) in the PES group, respectively.
CONCLUSIONS In consecutive patients undergoing percutaneous LM intervention, PES may perform closely
to SES both in terms of angiographic and long-term clinical outcome. (J Am Coll Cardiol
2006;47:507–14) © 2006 by the American College of Cardiology Foundation
Routine drug-eluting stent (DES) implantation, by reducing
the need for target vessel revascularization (TVR) and angio-
graphic restenosis, has been recently proposed as the preferred
strategy in poor surgical candidates undergoing percutane-
ous left main coronary artery (LM) intervention (1–3).
The longest average follow-up available for this treatment
is currently one year, and whether sirolimus-eluting stent
(SES) or paclitaxel-eluting stent (PES) is performing better
in these patients is unknown (1–3).
Similarly, even for more conventional lesions, the differ-
ential safety and efficacy profile of these two DES options is
largely debated (4–8). When taken together, current evi-
dence possibly suggests that in more complex lesion/patient
subsets, SES performs better and more safely than PES
(4–7,9).
The percutaneous management of LM lesions is a chal-
lenging intervention, where bifurcated vessels, extensive
wall calcification, and poor hemodynamic tolerance often
coexist during treatment.
The purpose of the present study was to investigate, in a
high-risk subset of patients undergoing revascularization in
a tertiary referral center, the differential long-term impact of
SES compared with PES in terms of clinical and angio-
graphic outcome. Intravascular ultrasound analysis has also
been carried out at follow-up to quantity neointimal hyper-
plasia volume.
METHODS
Study design and patient population. Since April 16,
2002, SES (Cypher; Johnson & Johnson-Cordis, Warren,
New Jersey) has been used as a default strategy for every PCI
at our institution as part of the Rapamycin-Eluting Stent
Evaluated at Rotterdam Cardiology Hospital (RESEARCH)
registry. From the first quarter of 2003, PES (Taxus; Boston
Scientific Corp., Natick, Massachusetts) became commercially
available, replacing SES as the strategy of choice in every PCI,
From the Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.
This study was supported by the Erasmus Medical Center, Rotterdam, and by
unrestricted institutional grants from Boston Scientific Corporation (Natick, Massa-
chusetts) and Cordis, a Johnson & Johnson company (Warren, New Jersey).
Manuscript received June 7, 2005; revised manuscript received August 24, 2005,
accepted September 8, 2005.
Journal of the American College of Cardiology Vol. 47, No. 3, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2005.09.040
Chapter  11
102
as part of the Taxus-Stent Evaluated at Rotterdam Cardiology
Hospital (T-SEARCH) registry. As a policy, all elective
patients presenting with significant (�50% by visual estima-
tion) LM disease, referred to our institution for coronary
revascularization, are evaluated both by interventional cardiol-
ogists and by cardiac surgeons, and the decision to opt for PCI
or surgery is reached by consensus as previously described (1).
From April 16, 2002, to March 6, 2004, a total of 110
consecutive patients were treated exclusively with one or
more DES in the LM as part of an elective or nonelective
revascularization procedure and constitute the patient pop-
ulation of the present report. Fifty-five patients first received
exclusively SES, available at that time in diameters from
2.25 to 3.00 mm, and then 55 patients received PES,
available in diameters from 2.25 to 3.5 mm. To ensure
comparability between the two study groups, the Parsonnet
surgical risk score, based on both clinical presentation profile
and comorbidities, and the William Beaumont Hospital
simplified scoring system were calculated for each patient
(10,11). Nonelective treatment was defined as a procedure
carried out on referral before the beginning of the next
working day (12).
The protocol was approved by the hospital ethics com-
mittee and is in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from every
patient.
Procedures and postintervention medications. All inter-
ventions were performed according to current standard
guidelines, and, except for the stent utilization, the final
interventional strategy was left entirely to the discretion of
the operator. Angiographic success was defined as residual
stenosis �30% by visual analysis in the presence of Throm-
bolysis In Myocardial Infarction (TIMI) flow grade 3. All
patients were advised to maintain aspirin lifelong, and
clopidogrel was prescribed for 6 months in both groups.
End point definitions and clinical follow-up. The occur-
rence of major adverse cardiac events, defined as death,
nonfatal myocardial infarction, or target vessel revascular-
ization, was recorded. Patients with more than one event
were assigned the highest ranked event, according to the
previous list. End point definitions were previously reported
(1). In order to make the clinical follow-up of the two
sequential cohorts of patients comparable, clinical outcome
of the SES cohort was censored at two years.
Quantitative angiographic and intravenous ultrasound
analysis. Quantitative analyses of all angiographic data
were performed with the use of edge-detection techniques
(CAAS II; Pie Medical, Maastricht, the Netherlands). A
value of 0 mm was assigned for the minimal luminal
diameter (MLD) in cases of total occlusion at baseline or
follow-up. Binary restenosis (BR) was defined as stenosis of
�50% of the luminal diameter in the target lesion. Acute
gain was defined as the MLD after the index procedure
minus the MLD at baseline angiography. Late loss (LL)
was defined as the MLD immediately after the index
procedure minus the MLD at angiographic follow-up.
Quantitative angiographic measurements of the target le-
sion were obtained in the in-lesion zone (including the
stented segment as well as the margins 5 mm proximal and
distal to the stent). Intravascular ultrasound (IVUS) analysis
was performed after administration of 200 �g of intracoro-
nary nitroglycerin, with an automated pullback at 0.5 mm/s.
All IVUS procedures were recorded on VHS videotape, and
Table 1. Baseline Characteristics of the Study Population
Variables
SES Group
(n � 55)
PES Group
(n � 55)
p
Value
Age (yrs)* 64 � 12 63 � 12 0.54
Males (%)* 64 58 0.84
Body mass index (kg/m2)* 23 � 4 25 � 5 0.31
Diabetes (%)* 34 24 0.29
Hypertension (%)* 54 53 �0.99
Hypercholesterolemia (%) 58 56 �0.99
Current smokers (%) 16 20 0.8
Creatinine (�mol/l)* 96 � 32 100 � 80 0.68
LV ejection fraction (%)* 44 � 16 44 � 12 0.95
Medical history (%)
Protected left main 18 15 0.80
PCI 31 33 �0.99
Myocardial infarction 38 47 0.44
TIA/stroke 9 11 0.74
Heart failure* 16 16 �0.99
COPD severe*† 4 5 �0.99
Peripheral arterial disease* 22 16 0.63
Carotid artery disease* 9 5 0.71
Clinical presentation (%)
Stable angina 49 45 0.86
Silent ischemia 0 4 0.12
Unstable angina 33 33 �0.99
Acute myocardial infarction* 15 18 0.72
Cardiogenic shock at entry* 9 9 �0.99
Parsonnet score 20 � 13 17 � 11 0.27
William Beaumont Hospital
score‡
7.7 � 4.28 7.36 � 4.7 0.73
*Parameter included in the Parsonnet classification. †Resulting in functional disabil-
ity, hospitalization, requiring chronic bronchodilatator therapy, or FEV1 �75% of
predicted. ‡Based on age �65 years, creatinine elevation, multivessel disease, and
occurrence of myocardial infarction within the previous 14 days.
COPD � chronic obstructive pulmonary disease; LV � left ventricular; PCI �
percutaneous coronary intervention; PES � paclitaxel-eluting stent; SES �
sirolimus-eluting stent; TIA � transient ischemic attack.
Abbreviations and Acronyms
BMS � bare-metal stent
BR � binary restenosis
CX � left circumflex coronary artery
DES � drug-eluting stent
IVUS � intravascular ultrasound
LAD � left anterior descending coronary artery
LL � late loss
LM � left main coronary artery
MACE � major adverse cardiac events
MI � myocardial infarction
MLD � minimal luminal diameter
PES � paclitaxel-eluting stent
RCA � right coronary artery
SES � sirolimus-eluting stent
TVR � target vessel revascularization
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images were digitized for analysis. A computer-based con-
tour detection was performed with Qurad QCU analysis
software (Curad, Wijk Bij Duurstede, the Netherlands) as
previously described (13). Intimal hyperplasia volume was
calculated as stent volume minus luminal volume. Percent-
age intimal hyperplasia was defined as intimal hyperplasia
volume divided by stent volume.
Statistical analysis. The sample size was calculated on the
assumption that average late loss in the SES and PES group
would be around 0.15 mm and 0.35 mm, respectively, based
on previous findings. To detect this effect size with a sigma
value of 0.3, 85% power, and a type I error (alpha) of 0.05,
32 patients per group were required. Continuous variables
are shown as mean � standard deviation (SD) and were
compared using Student unpaired t test. Categorical vari-
ables are presented as counts and percentages and compared
with the Fisher exact test. Survival curves were generated by
the Kaplan-Meier method, and survival among groups was
compared using the log rank test. Cox proportional hazards
models were used to assess risk reduction of adverse events.
Multivariable analysis, considering all variables reported in
Tables 1 and 2 with a p value of less than 0.10, was
performed to adjust for possible confounders and identify
whether the stent received was an independent predictor of
adverse events. Probability was significant at a level of
�0.05. All statistical tests were two-tailed. Statistical anal-
ysis was performed with Statistica 6.1 software (Statsoft,
Tulsa, Oklahoma).
RESULTS
Baseline and procedural characteristics. Baseline and pro-
cedural characteristics are shown in Tables 1 and 2. The two
groups were well matched for all baseline characteristics. In
both cohorts, half of the patients presented with a left
ventricular ejection fraction of 45% or less or with acute
coronary syndrome as indication to treatment, and 9% of
the patients presented with severe hemodynamic compro-
mise at entry. The distal LM was overall involved in
two-thirds of cases. In the SES group, nominal stent
diameter was smaller—reflecting the unavailability of stent
bigger than 3.0 mm during the study period—and cumula-
tive stent length tended to be shorter than in the PES
group. Bifurcation stenting was equally employed in both
groups with a clear preference for T-stenting and for culotte
technique in the SES and PES groups, respectively.
Thirty-one patients (56%) in the SES and 25 (45%) in
the PES group received intervention in one or more non-LM
lesion(s) during index procedure (p � 0.18). Complete
Table 2. Angiographic and Procedural Characteristics of the Study Population
Variables
SES Group
(n � 55)
PES Group
(n � 55) p Value
Lesion location (%)*
Ostium 27 22 0.51
Body 29 24 0.54
Distal 64 76 0.28
Pure left main disease (%) 5 5 �0.99
LM plus 1-vessel disease (%) 18 18 �0.99
LM plus 2-vessel disease (%) 20 24 0.82
LM plus 3-vessel disease (%) 57 53 0.87
Right coronary artery �70% stenosis (%) 69 64 0.88
Right coronary artery occlusion (%) 24 20 0.82
Number of implanted stents 1.43 � 0.53 1.50 � 0.6 0.49
Nominal stent diameter (mm) 3.00 � 0.25 3.29 � 0.28 �0.001
Total stent length per patient (mm) 23 � 11 27 � 13 0.07
Predilation (%) 71 60 0.15
Cutting balloon (%) 7 7 �0.99
Rotational atherectomy (%) 2 4 �0.99
Directional atherectomy (%) 0 0 �0.99
Postdilatation (%) 82 72 0.15
Bigger balloon inflated (mm) 3.75 � 0.48 3.70 � 0.5 0.48
Maximal pressure (atm) 18 � 5 19 � 3 0.55
Bifurcation stenting (%) 29 33 0.84
Culotte 0 20 0.009
T-technique 20 5 0.05
Crush 7 4 0.67
Kissing technique 2 4 �0.99
Intravascular ultrasonography (%) 33 27 0.53
IIb/IIIa inhibitors (%) 33 27 0.68
Intra-aortic balloon pump (%) 20 18 �0.99
Left ventricle assist device (%) 5 0 0.24
Temporary pacing during procedure (%) 7 9 �0.99
*Location of disease was not mutually exclusive among LM segments.
LM � left main coronary artery; other abbreviations as in Table 1.
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revascularization was achieved in 27 (49%) patients in the
SES and 36 (65%) in the PES group (p � 0.17).
Overall procedural success was 98%. In one patient
receiving SES, presenting with acute MI and shock, a final
TIMI flow grade 1 was obtained. An abrupt irreversible
occlusion of the circumflex occurred in one PES patient
after deployment of a stent in the left main and proximal left
anterior descending coronary artery (LAD).
Thirty-day outcomes. There were no significant differ-
ences between the SES and PES groups in the incidence of
major adverse cardiac events (MACE) (death, target vessel
revascularization, or myocardial infarction [MI]) during the
first 30 days (Table 3). Eight deaths occurred in 10 patients
presenting with ST-segment elevation acute myocardial
infarction and cardiogenic shock at entry. One elective
patient, undergoing LM treatment under left ventricular
assist device due to end-stage heart disease, died 2 days after
for cardiogenic shock, while the second elective patients
died for non-cardiovascular reasons after 19 days. No
documented thrombotic stent occlusion occurred in the first
30 days or thereafter.
Long-term clinical outcome. After a median follow-up of
660 days (range 428 to 885 days), the cumulative incidence
Figure 1. Adverse events in patients treated with sirolimus-eluting stent
(SES group) and in patients treated exclusively with paclitaxel-eluting stent
implantation (PES group). (A) Cumulative risk of major adverse events
(MACE); (B) death or myocardial infarction (MI); and (C) target vessel
revascularization (TVR). CI � confidence interval.
Table 3. 30-Day and Long-Term Outcomes
Variables
SES
Group
PES
Group
p
Value*
30-day outcome
Whole population (n � 55) (n � 55)
Death, n (%) 7 (13) 3 (5) 0.32
Nonfatal MI, n (%) 2 (4) 2 (4) �0.99
Death or nonfatal MI, n (%) 9 (16) 5 (9) 0.40
TVR, n (%) 1 (2) 0 (0) �0.99
Any event, n (%) 10 (18) 5 (9) 0.27
Stent thrombosis, n (%)† 0 (0) 0 (0)
Elective population (n � 43) (n � 43)
Death, n (%) 2 (5) 0 (0) 0.49
Nonfatal MI, n (%) 2 (5) 2 (5) �0.99
Death or nonfatal MI, n (%) 4 (9) 2 (5) 0.68
TVR, n (%) 1 (2) 0 (0) �0.99
Any event, n (%) 5 (12) 2 (5) 0.44
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Long-term outcome
Whole population (n � 55) (n � 55)
Death, n (%) 6 (11) 7 (13) 0.70
Nonfatal MI, n (%) 2 (4) 4 (7) 0.25
Death or nonfatal MI, n (%) 9 (16) 10 (18) 0.90
TVR, n (%) 5 (9) 6 (11) 0.67
Any event, n (%) 14 (25) 16 (29) 0.74
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
Elective population (n � 43) (n � 43)
Death, n (%) 2 (5) 2 (5) 0.98
Nonfatal MI, n (%) 2 (5) 4 (9) 0.22
Death or nonfatal MI, n (%) 4 (9) 6 (14) 0.51
TVR, n (%) 5 (12) 5 (12) 0.82
Any event, n (%) 9 (21) 11 (25) 0.55
Stent thrombosis, n (%)† 0 (0) 0 (0) �0.99
*By Fischer exact test for 30-day outcome and by log rank test for long-term outcome.
†Angiographically documented.
MI � myocardial infarction; TVR � target vessel revascularization; other
abbreviations as in Table 1.
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of MACE did not significantly differ in the SES compared
to the PES patients (25% vs. 29%, respectively; hazard ratio
[HR] 0.88 [95% confidence interval (CI): 0.43 to 1.82]; p�
0.74) (Fig. 1A). The composite death/MI was 16% in the
SES and 18% in the PES group (HR 0.95 [95% CI: 0.38 to
2.33]; p � 0.90) (Fig. 1B), and cumulative incidence of
TVR was 9% in the SES and 11% in the PES group (HR
0.77 [95% CI: 0.23 to 2.56]; p � 0.66) (Fig. 1C).
In the elective patient population (43 patients in each
group), the cumulative incidence of MACE was similar in
the SES (21%) and PES groups (25%; HR 0.77 [95% CI
0.32 to 1.8]; p� 0.55). The composite of death/MI was 9%
in the SES and 14% in the PES group (HR 0.66 [95% CI
0.19 to 2.3]; p � 0.52), and the need for TVR was 12% in
both groups (HR 0.87 [95% CI 0.24 to 3]; p � 0.8).
The cumulative incidence of MACE was similar in
patients receiving single-vessel stenting (24% in the SES
and 27% in the PES group) and those treated with bifur-
cation stenting (31%, HR 1.38 [95% CI 0.47 to 4]; p �
0.55; and 33%, HR 1.22 [95% CI 0.45 to 3.3]; p � 0.69;
respectively.
After adjustment for nominal stent diameter and total
stent length at multivariable Cox regression analysis, SES
implantation as opposed to PES failed to emerge as an
independent predictor of MACE (HR 0.79 [95% CI 0.5 to
1.5]; p � 0.66). The same remained true after forcing the
Parsonnet score into the model.
Angiographic outcome. Thirty-five patients in the SES
(73% of eligible patients) and 38 patients in the PES group
(77% of those eligible) underwent angiographic follow-up.
Data regarding the quantitative coronary angiography for
main and side branches are presented in Tables 4 and 5,
respectively.
MAIN BRANCH. In the SES and PES groups, the main
treated branch circumflex was LM-LAD in 22 (63%) and
21 (55%) patients, respectively followed by LM-circumflex
in 6 (17%) and 8 (21%), LM alone in 5 (14%) and 6 (16%),
and LM-intermediate branch in 2 (6%) and 3 (8%), respec-
tively. In unprotected patients in the SES and PES groups,
LM-LAD was the main treated branch in 77% and in 63%,
respectively, followed by LM alone in 15% and 17%,
LM-circumflex in 8% and 14%, and LM-intermediate
branch in 0% and 6%, respectively.
Baseline and follow-up angiographic variables did not
differ in the two study groups. No difference was noted in
terms of BR in the two groups as the result of a similar
in-stent and in-lesion LL (Table 4).
SIDE BRANCH. All baseline angiographic variables were well
matched between SES and PES groups in the side branches
receiving stent. At follow-up, both LL and BR were similar
in the two study groups. For those side branches that did not
undergo stenting as part of LM treatment, despite a bigger
reference vessel diameter in the SES than in the PES group,
the pattern of LL was around zero in both groups (Table 5).
COMBINED ANALYSIS. When both main and side branches
were evaluated on a patient basis, in-lesion BR occurred in
7 (20%) and 12 (32%) patients in the SES and PES groups,
respectively (p � 0.44). All cases of nonocclusive restenosis
were focal (length �10 mm).
IVUS analysis. Overall, 46 patients (18 in the SES and 28
in the PES group) underwent IVUS investigation at follow-
up. Their baseline and procedural characteristics did not
differ from those receiving angiographic examination with-
out IVUS (data not shown). In 11 patients in the SES and 16
in the PES group, LM-LAD was evaluated; the study vessel
was LM-CX in 4 SES and 7 PES and LM alone in 3 SES and
5 PES patients. In two patients per group, stent malapposition
was noted. As shown in Table 6 the degree of neointimal
hyperplasia did not differ between the two study groups.
DISCUSSION
Since their introduction to the market, DES use has steadily
increased. Depending on the health care system, they are
Table 4. Quantitative Coronary Angiography Analysis of the
Main Branch
Variables
SES
Group
(n � 35)
PES
Group
(n � 38)
p
Value
Before procedure
RVD (mm) 3.20 � 0.57 3.2 � 0.73 0.82
MLD (mm) 1.26 � 0.74 1.38 � 0.49 0.62
Diameter stenosis (%) 60 � 24 59 � 16 0.85
Lesion length (mm) 9.5 � 3.34 10 � 4.44 0.56
After procedure
In-stent
RVD (mm) 3.10 � 0.5 3.2 � 0.6 0.43
MLD (mm) 2.76 � 0.5 2.81 � 0.5 0.32
Acute luminal gain (mm)* 1.50 � 0.78 1.43 � 0.75 0.66
Diameter stenosis (%) 10.7 � 10 10.8 � 9 0.97
In-lesion
RVD (mm) 2.86 � 0.6 2.77 � 0.66 0.54
MLD (mm) 2.47 � 0.54 2.46 � 0.58 0.61
Acute luminal gain (mm)* 1.21 � 0.84 1.10 � 0.83 0.54
Diameter stenosis (%) 13 � 10 11 � 9 0.45
Follow-up
In-stent
RVD (mm) 3.19 � 0.6 3.01 � 0.6 0.31
MLD (mm) 2.44 � 0.85 2.35 � 0.6 0.60
Diameter stenosis (%) 21.3 � 25 22.8 � 19 0.76
Late loss (mm)† 0.32 � 74 0.46 � 0.57 0.36
Binary restenosis, n (%)‡ 3 (9) 5 (13) 0.71
Reocclusion, n (%)§ 2 (6) 0 (0) 0.24
In-lesion
RVD (mm) 3.00 � 0.66 2.89 � 0.66 0.41
MLD (mm) 2.24 � 0.83 2.2 � 0.63 0.77
Diameter stenosis (%) 22 � 24 22 � 19 0.97
Late loss (mm)† 0.22 � 0.73 0.25 � 0.46 0.86
Binary restenosis, n (%)‡ 3 (9) 4 (11) �0.99
Reocclusion, n (%) 2 (6) 0 (0) 1
*Difference between MLD after procedure and MLD before procedure. †Difference
between MLD at follow-up and MLD after procedure. ‡All non-occlusive restenosis
were focal (length �10mm). §All two restenotic reocclusions occurred in protected
LM lesions.
MLD � minimal lumen diameter; PES � paclitaxel-eluting stent; RVD �
reference vessel diameter; SES � sirolimus-eluting stent.
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now partially or almost completely replacing bare-metal
stents (BMS) during coronary intervention.
Recently, some concerns for the consequences of using
these devices liberally have been raised, which emphasizes
the need to scrutinize those patient/lesion subsets that were
excluded from landmark randomized trials, particularly beyond
conventional eight to nine months’ follow-up (14–17). Yet
in both controlled and observational studies, a potential
differential efficacy and safety profile between SES and PES
has been observed, especially in patient populations consid-
ered to be at higher risk for adverse events. Thus, current
available evidence reinforces the idea that it would be improper
to attribute a class effect to DES and that a high-risk patient
population should be better evaluated to further compare
the safety/efficacy profile of these two stents.
The percutaneous management of LM lesions is a chal-
lenging intervention, where bifurcated vessels, extensive
wall calcification, and poor hemodynamic tolerance often
coexist during treatment as natural extensions of the ana-
tomic characteristics of the lesions (18,19). Moreover,
percutaneous LM intervention, being usually reserved to
poor surgical candidates, is often undertaken in patients
with low ejection fraction or renal dysfunction, which are
known predictors of adverse events even in patients receiv-
ing DES (16).
The main results of our analysis show that, as predicted
by the risk status of the patients, the overall event rate was
higher than that previously reported for non-LM lesions.
However, the safety/efficacy profile of the two DES evalu-
ated was apparently maintained at long-term follow-up,
with PES performing closely to SES in terms of both
clinical and angiographic outcome.
This statement is based on the following findings:
1. The great majority of events occurred in both groups
within one year, considering either the whole (86% in
the SES and 81% in the PES) or the elective population
(78% in the SES and 73% in the PES group). No early
or late angiographically confirmed stent thrombosis has
been observed, with only one sudden death occurring in
an 86-year-old woman affected by a hematological
malignancy seven months after the index procedure.
2. The short- and long-term clinical event rate in the two
study groups was not different, and at multivariable
analysis the stent implanted failed to emerge as an
independent predictor of adverse events.
3. Angiographic and IVUS investigation demonstrated
that late loss and neointimal hyperplasia volume were
similar in the two groups of patients. The angiographic
Table 5. Quantitative Coronary Angiography Analysis in the Side Branches
Stented Branches Nonstented Branches
Variables SES Group PES Group p Value SES Group PES Group p Value
Before procedure n � 12 n � 15 n � 21 n � 23
RVD (mm) 2.63 � 0.67 2.70 � 0.61 0.69 2.44 � 0.72 2.00 � 0.55 0.02
MLD (mm) 1.16 � 0.52 1.27 � 0.77 0.69 1.68 � 72 1.47 � 0.67 0.31
Diameter stenosis (%) 56 � 21 54 � 24 0.61 27 � 28 26 � 25 0.96
Lesion length (mm) 10 � 4 11 � 8 0.76 5.7 � 3 4.9 � 2.1 0.30
After procedure
RVD (mm) 2.73 � 0.79 2.85.0 � 0.57 0.65 2.26 � 0.7 2.00 � 0.6 0.12
MLD in-stent (mm) 1.95 � 0.43 2.32 � 0.45 0.041 — —
MLD in-lesion (mm) 1.9 � 0.38 2 � 0.55 0.46 1.7 � 0.58 1.48 � 0.69 0.27
ALG in-stent (mm) 0.79 � 0.57 1 � 0.6 0.62 — —
ALG in-lesion (mm) 0.72 � 0.55 0.75 � 0.76 0.89 0.01 � 0.66 0.009 � 0.5 0.97
Diameter stenosis (%) 25 � 18 18 � 11 0.17 23 � 25 20 � 23 0.66
Follow-up
RVD (mm) 2.70 � 0.54 2.56 � 0.60 0.40 2.30 � 0.69 2.00 � 0.55 0.20
MLD in-stent (mm) 1.6 � 0.45 1.8 � 0.49 0.35 — —
MLD in-lesion (mm) 1.54 � 0.58 1.62 � 0.65 0.73 1.83 � 0.63 1.40 � 0.77 0.059
Diameter stenosis (%) 39 � 23 29 � 25 0.24 21 � 14 33 � 32 0.13
LL in-stent (mm) 0.36 � 0.59 0.52 � 0.42 0.41 — —
LL in-lesion (mm) 0.33 � 0.42 0.39 � 0.62 0.78 0.13 � 0.44 0.07 � 0.62 0.23
BR in-stent, n (%)* 3 (25) 3 (20) �0.99 — —
BR in-lesion, n (%)* 3 (25) 2 (13) 0.63 1 (5) 6 (26) 0.10
Reocclusion, n (%) 2 (6) 0 (0) 0.24 0 (0) 2 (9) 0.49
*All non-occlusive restenosis were focal (length �10 mm).
ALG � acute luminal gain; BR � binary restenosis; LL � late loss; other abbreviations as in Table 4.
Table 6. Quantitative Intravascular Ultrasound (IVUS) Results
IVUS Variables
SES Group
n � 18
PES Group
n � 28
p
Value
IVUS volumes (mm3)
Luminal 237 � 183 250 � 167 0.80
Vessel 473 � 371 528 � 351 0.63
Stent 256 � 194 267 � 174 0.81
Intimal hyperplasia 19.3 � 26 28 � 60 0.44
Intimal hyperplasia/10 mm* 6.3 � 9 9.6 � 13 0.74
Percentage intimal hyperplasia (%) 7.5 � 8 10 � 14 0.68
*Calculated as intimal hyperplasia volume divided by the length of the region of
interest expressed in mm (24 � 19 in the SES and 29 � 19 in the PES group; p �
0.49), multiplied by 10.
PES � paclitaxel-eluting stent; SES � sirolimus-eluting stent.
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outcome of the nonstented side branches was also
remarkably similar between the two groups.
Among these observations, the last one was unexpected and
deserves special attention.
In all major randomized controlled trials evaluating the
benefit of SES versus BMS, the average in-stent LL for
SES was reported to be constantly equal to or below 0.20,
whereas the same figure for PES, based on PES versus BMS
studies, was around two times higher. The Prospective,
Randomized, Multi-Center, Comparison of the Cypher
Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent
Systems (REALITY) study showed a difference between
these two DES in terms of angiographic end points that was
even bigger, with a mean in-stent LL of 0.9 in SES and 0.31
in the PES group (5). Conversely, in the current investiga-
tion we failed to show any difference between the two stents
in terms of in-stent or in-segment LL or BR, either in the
main branch or in the stented side branches. Interestingly,
this was confirmed by the IVUS analysis. Although the
difference was more striking for SES, the LL in both groups
were actually much higher than the figures expected. The
explanation for this discrepancy can only be speculative for
the moment and it may suggest that angiographic response
to DES is lesion/patient-specific. Data so far available in the
literature are inconclusive in this regard. Park et al. (2)
recently reported an average late loss of 0.05 mm in 102
patients receiving SES for the treatment of unprotected left
main disease, whereas the same figure in 85 LM patients at
higher risk status, treated with either PES or SES, was
cumulatively reported to be 0.58 mm (3). Unfortunately, in
that study no distinction between SES and PES was made
(3).
The lack of availability of SES sizes bigger than 3.0 mm
during the study period, which imposed an aggressive
overdilation strategy to match LM reference diameter,
might have theoretically played a role. However, this tech-
nical issue was at least partially encountered in the series
reported by Park et al. (2) as well.
Alternatively, this difference between studies could pos-
sibly reflect a selection bias, with patients at higher clinical
risk based on previous cardiovascular history and comor-
bidities being more prone to develop a more aggressive
intimal proliferation after DES. To investigate this possi-
bility in an exploratory fashion (this analysis was not
prespecified for the current study), we pooled the LL for
both main branch and all stented side branches as the
outcome variable in a linear regression model. At univariate
analysis including all variables reported in Tables 1 and 2 we
found protected status to be the strongest predictor for high
LL (�� 0.47 [95% CI 0.24 to 0.7]; p� 0.001; adjusted R2�
0.39). Accordingly, we observed that in patients receiving
unprotected LM intervention (n� 59) LL was cumulatively
lower (0.31 � 0.41 vs. 0.63 � 72; p � 0.037) than in
patients receiving protected treatment (n � 14), and, of
note, all occlusive binary restenosis occurred in the protected
group of patients.
Interestingly, none of the variables reported in Tables 1
and 2 differed significantly between patients receiving pro-
tected versus unprotected LM intervention, with the overall
Parsonnet score being 16 � 7.5 in protected versus 18 � 10
in unprotected patients (p � 0.4).
The observed difference in LL between protected versus
unprotected LM intervention might possibly outline a role
for shear stress as potential modulator of vessel response to
DES, as recently suggested by our group (20). This analysis
was exploratory in nature and clearly beyond the scope of
the current investigation. However, it underscores the need
to consider DES performance in the context of the patient
population in which the device was actually tested.
Taken together, our observations suggest that DES may
perform more effectively in good than in poor surgical
candidates, which reinforces the interest in assessing the
value of this treatment as compared with conventional
surgical approach in a properly designed randomized trial.
Study limitations. The present study is a single-center
experience from a tertiary referral center and lacks the clear
advantages of a multicenter randomized study. In particular,
despite the fact that the study was conducted over a
relatively short period, we cannot exclude the possibility that
improvements in technique or differences in drug prescrip-
tion could have partially confounded our main results.
Accordingly, the results of our study are encouraging, but
they cannot be conclusive. Studies with bigger sample sizes
and more prolonged clinical follow-ups are clearly required
to rule out the occurrence of less common device-related
side effects.
Clinical implications of the combined RESEARCH and
T-SEARCH analysis. In the overall results of the unse-
lected RESEARCH versus T-SEARCH comparison, a
shift toward more complex lesions has been noted from SES
to PES cohort (8). This difference was not confirmed in our
current analysis, which focused on LM lesions cumulatively
treated over a longer period of time: more patients in the
SES group received concomitant intervention in non-LM
lesions and fewer reached complete revascularization than in
the PES cohort. However, the stent length was greater in
the PES group. When this finding is combined with the
observed shift from T-stenting in the SES period to culotte
in the PES period as bifurcation technique, it may suggest
that operators have become progressively more familiar with
DES over time and that full lesion coverage with DES had
been more frequently performed in the PES than in the
SES group. The impact of these confounders on our final
result remains incompletely understood.
When taken together, the combined RESEARCH and
T-SEARCH analysis may reinforce the concept that in an
uncontrolled setting such as our clinical practice, the coro-
nary device in itself should probably be regarded among the
principal but clearly not as the only component of the long-
term procedural success in the DES era. Rather, the two
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drug-eluting stents available on the market should always be
put in the context of the characteristics of the treated
patients and the operator’s experience to better forecast their
effect on short- and long-term outcome.
Conclusions. After a median follow-up of two years, no
late serious adverse events, possibly suggesting a time-
dependent change in the therapeutic profile of the investi-
gated devices, were observed.
In a consecutive group of patients undergoing percutane-
ous LM intervention, PES may perform closely to SES in
terms of both clinical and angiographic outcome.
A multinational multicenter randomized study is currently
ongoing to estimate the clinical value of PES-supported LM
intervention with respect to conventional surgical treatment.
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Significant Reduction in Restenosis
After the Use of Sirolimus-Eluting Stents
in the Treatment of Chronic Total Occlusions
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OBJECTIVES The aim of this study was to assess sirolimus-eluting stent (SES) implantation for the
treatment of chronic total coronary occlusions (CTO).
BACKGROUND Long-term results after percutaneous coronary intervention (PCI) in the treatment of CTOs
is hindered by a significant rate of restenosis and reocclusion. In the treatment of relatively
simple nonocclusive lesions, SESs have shown dramatically reduced restenosis rates compared
with bare metal stents (BMS), but whether these results are more widely applicable is
unknown.
METHODS From April 2002, all patients at our institution were treated with SES as the device of choice
during PCI. During the first six months, 563 patients were treated solely with SES, with
treatment of a de novo CTO in 56 (9.9%). This CTO cohort was compared with a similar
group of patients (n � 28) treated in the preceding six-month period with BMS.
RESULTS At one year, the cumulative survival-free of major adverse cardiac events was 96.4% in the
SES group versus 82.8% in the BMS group, p � 0.05. At six-month follow-up, 33 (59%)
patients in the SES group underwent angiography with a binary restenosis rate (�50%
diameter stenosis) of 9.1% and in-stent late loss of 0.13 � 0.46 mm. One patient (3.0%) at
follow-up was found to have reoccluded the target vessel.
CONCLUSIONS The use of SESs in the treatment of chronic total coronary occlusions is associated with a
reduction in the rate of major adverse cardiac events and restenosis compared with
BMS. (J Am Coll Cardiol 2004;43:1954–8) © 2004 by the American College of
Cardiology Foundation
Chronic total occlusions (CTO) are common, and found in
approximately one-third of patients with significant coro-
nary disease who undergo angiography (1,2). Percutaneous
intervention (PCI) of CTOs accounts for 10% to 15% of all
angioplasties; however, after successful recanalization, there
is an increased rate of subsequent restenosis and reocclusion
compared with nonocclusive stenoses (3,4). Although sev-
eral randomized trials demonstrated the efficacy of stent
implantation over balloon-only angioplasty, even with stents
there remains a significant rate of both restenosis (32% to
55%) and reocclusion (8% to 12%) (5–9).
In the treatment of relatively simple lesions, sirolimus-
eluting stents (SES) markedly reduce the restenosis rate,
with continued benefit documented up to two years
follow-up (10,11). Whether these results can be extrapo-
lated to more complex lesions such as CTOs has yet to be
determined. We sought to evaluate the effectiveness of the
SES in a consecutive series of patients with at least one de
novo CTO compared with a similar series treated with bare
metal stents (BMS).
METHODS
Patient population. Commencing in April 2002, all PCI
at our institution was done solely with SESs, irrespective of
clinical presentation or lesion morphology; these patients
comprise the Rapamycin-Eluting Stent Evaluated at Rot-
terdam Cardiology Hospital registry (RESEARCH) regis-
try (further details of the methodology are described else-
where) (12,13). Those deemed at an increased risk of
restenosis (including the CTO population) were considered
for six-month angiographic follow-up. Sirolimus-eluting
stents were available in lengths between 8 mm and 33 mm,
and diameters 2.25 mm to 3.0 mm. In the first six months,
563 patients were treated, including 56 (9.9%) with success-
ful revascularization of at least one CTO. These patients
make up the present study cohort; all received six months
dual antiplatelet therapy with clopidogrel in addition to
aspirin. As predetermined by the RESEARCH protocol,
this study cohort of patients were compared with all those
treated for a CTO in the preceding six months with BMS,
identified from the departments’ dedicated database. Both
groups were treated by the same operators utilizing standard
techniques, the only difference being the type of stent. The
protocol was approved by the local ethics committee and is
in accordance with the principles of Good Clinical Practice
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for Trials of Medicinal Products in the European Commu-
nity and the Declaration of Helsinki. All patients signed a
written informed consent
CTO definition. Chronic occlusion was defined as an
occlusion on angiography with no antegrade filling of the
distal vessel other than via collaterals. All patients included
had a native vessel occlusion estimated to be at least one
month’s duration (9) based on either a history of sudden
chest pain, a previous acute myocardial infarction in the
same target vessel territory, or the time between the diag-
nosis made on coronary angiography and PCI.
Length of occlusion. The length of occlusion was mea-
sured by quantitative coronary angiography either utilizing
antegrade filling via collaterals, or assessment of the retro-
grade collateral filling. This was achieved by catheterizing
both the left and right coronary arteries, and making a
simultaneous injection to delineate the distance between the
site of occlusion and the most proximal part of the vessel
filled retrogradely.
Follow-up. Patients were followed up prospectively and
evaluated for survival-free of major adverse cardiac events
(MACE) using questionnaires and telephone enquiries;
MACE was predefined as: 1) death; 2) nonfatal myocardial
infarction; or 3) repeat target vessel revascularization
(TVR). The diagnosis of acute myocardial infarction re-
quired an elevation of creatine kinase to twice the upper
limit of normal, together with a rise in creatine kinase-MB
fraction. Target vessel revascularization was defined as
either surgical or percutaneous reintervention driven by
significant (�50%) luminal narrowing within the treated
vessel, and was undertaken in the presence of either anginal
symptoms or objective evidence of ischemia.
Angiographic analysis. Quantitative analysis in those SES
patients with follow-up angiography was undertaken in
three coronary segments: in-stent (encompassing the entire
length of stented segment), and the 5-mm proximal and
distal edge segments either side of the in-stent segment.
The target lesion comprised the in-stent plus the proximal
and distal edge segments. Binary restenosis was defined as
�50% diameter stenosis within the target lesion. Late
lumen loss was calculated from the difference in minimal
lumen diameter between postprocedure and follow-up.
Statistical analysis. Discrete variables are presented as
percentages and compared with Fisher exact test. Continu-
ous variables are expressed as mean � SD and compared
with Student t test. Survival-free of adverse events was
calculated according to the Kaplan-Meier method. The
log-rank test was used to compare MACE-free survival
between the two groups. All tests were two-tailed, and a p
value of �0.05 was considered statistically significant.
RESULTS
The baseline patient and lesion characteristics of the two
groups are presented in Tables 1 and 2. One patient in the
BMS group underwent successful recanalization and stent
implantation in two CTOs, thereby making a total of 29
lesions in this group. Mean length of occlusion could be
determined in 45 (80.4%) of the SES group and 17 (58.6%)
of the BMS group. There was no significant difference
between the groups with respect to the postprocedural
quantitative angiography; however, the mean diameter of
stent utilized was greater in the BMS cohort.
There were no in-hospital MACE. Clinical follow-up
data was obtained in 100% of both groups. There were no
deaths in either group; one non–Q-wave acute myocardial
infarction occurred related to subacute stent thrombosis 11
days after SES implantation. This was successfully recana-
lized percutaneously; intravascular ultrasound suggested un-
derexpansion of the SES (2.5 � 33 mm), and the patient
was treated with abciximab and balloon dilation of the
previously implanted stent. At one year, the cumulative
survival-free of MACE was 96.4% in the SES group
compared with 82.8% in the BMS group, p � 0.05 (Fig. 1).
One patient in each group had a reocclusion (1.8% SES
group vs. 3.6% BMS group, p � NS).
At six months, 33 (58.9%) patients in the SES group
underwent follow-up angiography (none in the BMS group)
(Table 3). The binary restenosis rate was 9.1%: one occlu-
sion, one stenosis at the ostium of a side branch after
Table 1. Baseline Patient Demographics
Bare Stents
n � 28
SES
n � 56
p
Value
Mean age (yrs) 59.8 � 11.1 60.2 � 10.0 0.9
Male gender (%) 85.7 71.4 0.2
Current smoker (%) 35.7 26.8 0.5
Diabetes mellitus (%) 7.1 14.3 0.4
Hypertension (%) 39.3 39.3 1.0
Hypercholesterolemia (%) 57.1 55.4 1.0
Previous myocardial
infarction (%)
46.4 55.4 0.6
Previous PCI (%) 21.4 12.5 0.3
Previous CABG (%) 0 0 –
Glycoprotein IIb/IIIa
inhibitor usage (%)
25.0 21.4 1.0
Presence of multivessel
disease (%)
60.7 46.3 0.3
PCI in at least one additional
(nonoccluded) major
epicardial vessel during the
index procedure (%)
28.6 42.6 0.2
CABG� coronary artery bypass grafting; PCI� percutaneous coronary intervention;
SES � sirolimus-eluting stents.
Abbreviations and Acronyms
BMS � bare metal stent
CTO � chronic total occlusion
MACE � major adverse cardiac events
PCI � percutaneous coronary intervention
RESEARCH � Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital registry
SES � sirolimus-eluting stent
TVR � target vessel revascularization
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T-stenting, and the third at the distal outflow of the SES
(this is the same patient with the subacute thrombosis, and
restenosis occurred at the site of balloon dilation during the
second procedure). The patient with occlusion had under-
gone bifurcation T-stenting after successful recanalization
of a heavily calcified left anterior descending artery. At
follow-up, the artery had reoccluded, and there was new
akinesis of the left ventricular anterior wall. This patient
with occlusion was managed with medical therapy; the other
two patients with restenosis underwent percutaneous revas-
cularization.
DISCUSSION
Previous studies have demonstrated the importance of
revascularization of CTOs, with improvement in anginal
symptoms, exercise capacity, and left ventricular function
(14–16). In addition, successful recanalization reduces the
subsequent need for bypass surgery and, importantly, long-
term evaluation has shown a 10-year survival advantage of
73.5% after successful PCI compared with 65.1% in those
with unsuccessful PCI (4,17).
To our knowledge, this is the first report regarding the
efficacy of SES in CTOs, a subset of patients previously
excluded from other protocols and, importantly, at increased
risk of developing restenosis after conventional stent im-
plantation (3). Of the patients who underwent follow-up
angiography, both the in-stent and proximal 5-mm seg-
ments analyzed showed an encouraging late loss of 0.13 �
0.46 mm and 0.10 � 0.80 mm, respectively. The distal 5
mm actually showed an overall benefit, with enlargement of
the vessel (late loss, �0.06 � 0.54 mm).
In addition to the angiographic data, the clinical
follow-up is very encouraging. Importantly, there were no
significant differences in baseline demographics between the
SES and BMS groups, and all procedures were carried out
in the same center by the same operators. There was an
episode of subacute thrombosis in the SES group, but there
appears to be an underlying mechanical cause with under-
expansion of the stent documented on intravascular ultra-
sound. The restenosis rate for BMS is known to be inversely
Table 2. Baseline Procedural Characteristics
Bare Stents
n � 29
SES
n � 56 p Value
Target vessel 0.06
LAD (%) 27.6 51.8
LCX (%) 27.6 25.0
RCA (%) 44.8 23.2
Mean length of occlusion (mm, range) 12.7 (2.4–31.8) 11.3 (4.0–32.1) 0.5
Bifurcation stenting (%) 17.9 14.3 1.0
Mean number of stents in the target vessel 1.8 2.0 1.0
Mean nominal diameter of stent in the main
vessel (mm)
3.03 � 0.56 2.75 � 0.26 � 0.001
Mean length of stent in the main vessel (mm) 23.31 � 9.34 23.89 � 9.21 0.7
Mean total length of overlapping stents in the
main vessel (mm, range)
41.8 (18–112) 45.2 (8–117) 0.7
Postprocedure vessel reference diameter (mm) 2.37 � 0.50 2.35 � 0.46 0.9
QCA data
Minimal lumen diameter (mm) 2.18 � 0.49 2.06 � 0.48 0.3
Diameter stenosis (%) 10.4 11.6 0.6
LAD � left anterior descending artery; LCX � circumflex artery; QCA � quantitative coronary angiography; RCA � right
coronary artery; SES � sirolimus-eluting stents.
Table 3. Postprocedural and Six-Month Follow-Up Quantitive
Angiographic Data for the Sirolimus-Eluting Stent (Patient
Number n � 33)
Proximal
5 mm In-Stent
Distal
5 mm
Postprocedure
Mean diameter (mm) 2.82 � 0.66 2.58 � 0.55 2.10 � 0.64
Minimal lumen
diameter (mm)
2.43 � 0.51 2.04 � 0.45 1.75 � 0.53
% Diameter stenosis 14.1 12.9 21.8
Six-month follow-up
Mean diameter (mm) 3.02 � 0.53 2.46 � 0.81 2.12 � 0.83
Minimal lumen
diameter (mm)
2.33 � 0.90 1.91 � 0.68 1.81 � 0.75
% Diameter stenosis 20.1 21.9 18.2
Late lumen loss (mm) 0.10 � 0.80 0.13 � 0.46 �0.06 � 0.54Figure 1. Kaplan-Meier curves for survival-free of death, acute myocardial
infarction, or target vessel revascularization.
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related to the postprocedural minimal lumen diameter and
the number of stents utilized (18). In the current study,
although the mean diameter of stent used was significantly
greater in the BMS cohort (related to a maximum available
SES diameter of 3.0 mm) with free utilization of postdila-
tion, the postprocedural minimal lumen diameter was not
significantly different between the two groups. The majority
of events related to TVR, with, at one year, a significantly
higher rate of survival free of MACE of 96.4% in the SES
group versus 82.8% in the BMS group.
Four major randomized trials have demonstrated the
efficacy of stent implantation over balloon-only angioplasty
in the treatment of CTOs, reducing the six-month reste-
nosis rate from 68% to 74%, to 32% to 55% (5–8).
Compared with this historical data, our study suggests that
the SES confers a marked further advantage with a signif-
icantly lower binary restenosis rate of 9.1% (p � 0.05) (Fig.
2). In addition, we had only one patient (3.0%) with vessel
reocclusion, compared with rates of between 8% to 12% in
the same published trials utilizing BMS. A recent study of
the clinical results of 376 patients discharged from hospital
without an adverse event after successful intervention of a
CTO showed, at one-year follow-up, a MACE rate of
12.2% (19); our results are, therefore, quite remarkable, with
a MACE-free survival rate of 96.4%.
Study limitations. This study evaluated only a small cohort
of patients, and angiographic follow-up was not obtained in
all, so additional patients with silent reocclusion cannot be
excluded. However, those who did not undergo repeat
angiography were all symptomatically well at follow-up. In
addition, despite the discrepancy in follow-up angiography
rates between the two groups, which might have biased the
results towards more revascularization in the SES group, the
MACE rate remained statistically significant with a bene-
ficial effect in favor of the SES. The study was not
randomized, and used a retrospective comparitive popula-
tion; however, the same operators and interventional tech-
niques were utilized.
Conclusions. The use of SESs in the treatment of complex
patients with CTOs is associated with a reduction in the
rate of MACE and restenosis compared with BMS.
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Drug-eluting stent implantation for chronic total 
occlusions: comparison between the Sirolimus- 
and Paclitaxel-eluting stent
Abstract
Aims: Long-term results following percutaneous coronary intervention (PCI) with bare metal stents in the
treatment of chronic total occlusions (CTOs) is hindered by a significant rate of restenosis and re-occlu-
sion. Drug-eluting stents have shown dramatically reduced restenosis rates for the treatment of relatively
simple non-occlusive lesions, though there is only limited data as to the efficacy in CTO’s. We evaluated
the long-term results of the sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) for the treatment
of CTOs. 
Methods and results: From April 2002, all patients at our institution were treated with SES as the device of
choice during PCI. During the first quarter of 2003 the default strategy changed to the use of PES. Drug-
eluting stent implantation was carried out in CTOs (defined as >3 months’ duration) in 9% of de novo PCI
procedures. A total of 76 consecutive patients were treated with SES implantation, followed by a consecu-
tive series of 57 patients treated with PES implantation. These patients were compared with a similar group
of patients (n=26) treated with BMS in the 6-month period preceding April 2002. 
At 400 days, the cumulative survival-free of target vessel revascularization was 80.8% in the BMS group
versus 97.4% and 96.4% in the SES and PES groups respectively (p=0.01).
Conclusions: The use of both the SES and PES in the treatment of chronic total coronary occlusions
reduces the need for target vessel revascularization compared to bare metal stents.
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Introduction
Successful percutaneous therapy of chronic total occlusions (CTOs)
has been shown to improve symptoms of angina and left ventricu-
lar function, and reduce the subsequent need for coronary artery
bypass surgery1-5. In addition, in the long-term, recanalization of a
CTO can reduce mortality compared with those with an unsuccess-
ful attempt at recanalization6. However, the long-term outcome of
percutaneous coronary intervention (PCI) for chronic total coronary
occlusions is subject to an increased risk of restenosis and re-occlu-
sion compared with non-occlusive lesions1,7. The advent of drug-
eluting stents is revolutionising the practice of interventional cardi-
ology. Several randomized trials have demonstrated a dramatic
reduction in restenosis rates compared with bare metal stents when
used for the treatment of relatively simple lesions8-11. In addition,
preliminary data has confirmed the efficacy utilizing the sirolimus-
eluting stent (SES) for the treatment of chronic total occlusions12. In
the present report, we evaluate the use of drug-eluting stent implan-
tation for chronic total occlusions in a consecutive series of patients,
with comparison between the sirolimus- and paclitaxel-eluting
stents.
Methods
The sirolimus-eluting stent (Cypher™, Johnson & Johnson - Cordis
unit) received CE mark approval in April 2002. Since that time, all
patients undergoing percutaneous therapy in our institution have
been treated with drug-eluting stent implantation as the default
strategy. During the first quarter of 2003, our strategy switched from
the sirolimus- to the paclitaxel-eluting stent (Boston Scientific)
enabling a comparison of the two stent types. All consecutive
patients with successful chronic occlusion recanalization were
enrolled. Those patients treated with drug-eluting stent implantation
were compared to all those treated for a CTO in the preceding 
6-months with bare metal stents (BMS), identified from the depart-
ments’ dedicated database. All groups were treated by the same
operators utilizing standard techniques; the only difference being
the type of stent.
During the procedure, heparin was given to maintain an activated
clotting time ≥ 250 seconds. All patients received lifelong aspirin,
and before the procedure were pre-treated with a loading dose of
300mg clopidogrel, additional anti-platelet therapy was given with
clopidogrel for 1 month in the BMS group, and for 6-months in the
drug-eluting stent groups. The use of Glycoprotein IIb/IIIa inhibitor
therapy was at the discretion of the operator and was only given
once wire passage was confirmed as successful. The protocol was
approved by the local ethics committee and is in accordance with
the principles of Good Clinical Practice for Trials of Medicinal
Products in the European Community and the Declaration of
Helsinki. All patients signed a written informed consent
Chronic total occlusion definition
Complete occlusion of a coronary artery on angiography, with no
antegrade filling of the distal vessel other than via collaterals. All
patients included had a native vessel occlusion estimated to be of
at least 3-months’ duration, based on either a history of sudden
chest pain, a previous acute myocardial infarction in the same tar-
get vessel territory, or the time between the diagnosis made on coro-
nary angiography and PCI. 
Length of occlusion
This was measured by quantitative coronary angiography (CAAS II;
Pie Medical Imaging, The Netherlands) either utilizing antegrade fill-
ing via collaterals, or assessment of the retrograde collateral filling
achieved through making a simultaneous injection into both the left
and right coronary arteries to delineate the distance between the site
of occlusion and the most proximal part of the vessel filled retro-
gradely. This length evaluated only the occluded vessel, and did not
therefore include stenosis of the vessel pre- and post- the occlusion.
Follow-up
Patients were prospectively followed-up for clinical events, and eval-
uated for survival-free of major adverse cardiac events (MACE)
using questionnaires and telephone enquiries. MACE was pre-
defined as: 1) death, 2) non-fatal myocardial infarction (AMI), or 3)
repeat target vessel revascularization (TVR). The diagnosis of AMI
required an elevation of creatine kinase to twice the upper limit of
normal, together with a rise in creatine kinase-MB fraction. TVR was
defined as either surgical or percutaneous reintervention driven by
significant (>50%) luminal narrowing within the treated vessel, and
was undertaken in the presence of either anginal symptoms or
objective evidence of ischemia. Follow-up angiography was under-
taken in all patients in the presence of anginal symptoms at clinical
evaluation; in addition those patients treated during the first
6-months of DES implantation were invited. 
Statistical analysis
Discrete variables are presented as percentages and compared with
Pearson’s chi-square test. Continuous variables are expressed as
mean ± standard deviation and compared with one-way ANOVA.
Cumulative survival and MACE-free survival were calculated
according to the Kaplan-Meier method. The log-rank test was used
to compare MACE-free survival between the groups. A p value of
<0.05 was considered as significant. 
Results
There were no significant differences between the groups with
respect to baseline patient characteristics (table 1). Procedural
characteristics are presented in table 2. One patient in both the
BMS and PES groups had stent implantation in 2 chronic occlu-
sions. Occlusion length was able to be measured in 74.1%, 84.2%,
and 72.4%of the BMS, SES, and PES groups respectively (p=0.3).
Both drug-eluting stent cohorts were treated with a higher number
of stents resulting in a longer length of stented segment. 
At one year, there was a single death occurring in hospital, 22 days
after successful RCA recanalization and PES implantation. The
patient had been admitted 1 week previously, with no evidence of
a cardiac problem, and the cause of death was related to an inop-
erable glioblastoma. There were 4 patients who had an acute
myocardial infarction, all having been treated with drug-eluting
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stent implantation. The first had SES implantation for a RCA CTO
together with PCI of the LAD. There was a peri-procedural eleva-
tion of creatine kinase (maximum elevation of 854 IU/l) related to
loss of a sizeable septal branch related to the LAD stent (non-
occluded vessel). The second related to subacute thrombosis
occurring 11 days after SES implantation (a 2.5x33mm and a
3.0x33mm) in a LAD occlusion. IVUS suggested that 2.5mm stent
was under-expanded and the patient was treated with a glycopro-
tein IIb/IIIa inhibitor and balloon dilatation. The third had PES
implantation for a RCA CTO together with treatment of the left main
stem. On day 14, he complained of chest pains and had a maxi-
mum CK elevation of 819. Angiography demonstrated an excellent
result in the RCA, but haziness of the ostium of the left circumflex
artery which was subsequently treated with further PCI (culprit
lesion in other vessel). The fourth patient had SES implantation (a
2.5x33mm and a 3.0x33mm) for a LAD CTO. At 6-months, control
angiography demonstrated no evidence of restenosis, but he was
admitted 4 months later to another hospital with a myocardial
infarction that was managed medically. 
Clinical research
Table 1. Baseline patient demographics 
BMS SES PES p value
n=26 n=76 n=57
Mean age (years) 60.3±11.0 61.1±10.6 58.4±10.4 0.3
Male sex (%) 92.3 65.8 80.7 0.3
Current smoker (%) 30.8 18.4 22.8 0.5
Diabetes mellitus (%) 7.7 14.5 19.3 0.4
Hypertension (%) 42.3 42.1 50.9 0.7
Hypercholesterolemia (%) 57.7 67.1 75.4 0.6
Previous myocardial infarction (%) 46.2 51.3 43.9 0.8
Previous CABG (%) 0 3.9 5.3 0.5
Glycoprotein IIb/IIIa inhibitor usage (%) 23.1 18.4 19.3 0.9
PCI in at least one additional (non-occluded) major 26.9 38.2 47.4 0.4
epicardial vessel during the index procedure (%)
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention
Figure 1. Kaplan-Meier estimates of the cumulative survival-free of
target vessel revascularization following stent implantation in a chron-
ic total occlusion for patients treated with sirolimus-eluting (SES),
paclitaxel-eluting (PES), or bare metal stent (BMS) implantation.
Table 2. Baseline procedural characteristics
BMS SES PES p value
Number of CTO lesions treated n=27 n=76 n=58
Target vessel 0.5
LAD (%) 29.6 46.1 22.4
LCX (%) 25.9 19.7 27.6
RCA (%) 44.4 34.2 50.0
Bifurcation stenting (%) 7.4 13.2 13.8 0.7
Mean length of occlusion (mm) 13.0±7.2 10.3±5.9 11.2±6.6 0.2
Mean number of stents in the target vessel 1.8±0.8 2.2±1.2 2.6±1.3 0.03
Mean nominal diameter of stent in the main vessel (mm) 3.0±0.6 2.8±0.3 2.8±0.4 < 0.001
Mean total lengths of stent in the main vessel (mm) 41.5±23.3 48.8±27.4 58.0±32.8 0.04
Post-procedure QCA data
Reference vessel diameter (mm) 2.34±0.43 2.35±0.51 2.60±0.49 0.008
Minimal lumen diameter (mm) 2.12±0.51 2.04±0.43 2.26±0.42 0.02
Diameter stenosis (%) 11.6 12.9 14.1 0.6
SES: sirolimus-eluting stents, PES: paclitaxel-eluting stents, LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery
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All events in the bare stent group related to the need for target ves-
sel revascularization. At one year, the survival-free of target vessel
revascularization was significantly higher in the SES and PES
groups compared with the BMS group (97.4% and 96.4% versus
80.8% respectively, p=0.01) Figure 1.
Discussion
In the present report we have demonstrated the efficacy of drug-
eluting stent implantation for the percutaneous treatment of chron-
ic total occlusions when compared to bare metal stents. In addition,
we have shown that both the sirolimus- and paclitaxel-eluting stent
are associated with a low rate of target vessel revascularization at
6 months.
There have been several randomized trials that have demonstrated
the efficacy of stent implantation over balloon-only angioplasty for
the percutaneous treatment of CTOs, reducing the 6-month
restenosis rate from 68-74% to 32-55%13-17. Initial randomized
studies of drug-eluting stent implantation, demonstrated efficacy in
reducing restenosis compared to conventional stent implantation,
but excluded patients with CTOs8-11. However, recent preliminary
data from our own group have shown that the efficacy of the SES is
applicable in the treatment of CTOs (defined as >1 months’ dura-
tion), with a one year cumulative survival-free of major adverse car-
diac events of 96.4%12. In the present study, we evaluate a larger
series of consecutive patients treated for a truly chronic total occlu-
sion (>3 months in duration) with drug-eluting stent implantation.
We have shown that both the SES and PES significantly reduce the
need for TVR, with a cumulative survival-free of TVR of 80.8% in the
BMS group versus 97.4% and 96.4% in the SES and PES groups
respectively (p=0.01) Figure 1. 
Importantly, there were no significant differences in baseline demo-
graphics between the groups, and all procedures were carried out
in the same centre by the same operators. Restenosis following
BMS implantation is known to be inversely related to the post-pro-
cedural MLD and the number of stents utilized18. In the current
study, the mean nominal diameter of stent used was significantly
greater in the BMS cohort, related to a maximum available SES and
PES diameter of 3.0mm and 3.5mm respectively. In addition,
despite utilizing a greater number of stents, both the SES and PES
demonstrated efficacy over the BMS. Furthermore, the beneficial
effect of the SES occurred despite a smaller post-procedural MLD.
All major adverse cardiac events in the BMS group related to the
need for TVR, including 1 patient who required coronary artery
bypass surgery. Within the drug-eluting stent groups there were
5 additional non-TVR events. One patient had a subacute thrombo-
sis, but this might have been avoidable with evidence from IVUS
demonstrating a possible underlying mechanism of inadequate
stent expansion. In addition, there is good evidence in a further 3 of
these cases that the event was unrelated to treatment of the occlud-
ed vessel. One patient died of non-cardiac causes, and 2 of the
myocardial infarctions were thought to be related to intervention
carried out in another (non-occluded) vessel. The fifth patient pre-
sented with an AMI in the territory of the target vessel, 4 months
after control angiography demonstrated patent stents. Clopidogrel
medication had been stopped at the time of the follow-up
angiogram, such that the patient was on aspirin therapy alone. The
duration of dual anti-platelet therapy needed to reduce / abolish the
risk of late stent thrombosis in patients treated with DES, particular-
ly for complex disease, is still unclear. Recently, Ong et al. reported
on late (>30 days) stent thrombosis following DES implantation in a
consecutive cohort of >2000 patients, they found a low incidence of
0.35% (95% confidence limits 0.17% to 0.72%)19. Importantly,
there were no episodes in patients continuing on dual anti-platelet
therapy. However, whether there is a true benefit in continuing
clopidogrel in addition to aspirin, over and above the possible dis-
advantages, requires further large scale evaluation.
In patients with significant coronary artery disease, although a CTO
is found in at least one third, the majority are treated with either
medical therapy or are referred for coronary artery bypass surgery,
with percutaneous treatment of CTOs accounting for only 10-15%
PCI procedures20. The major limitation of PCI for CTOs is the inabil-
ity to cross the lesion with a wire, however great advancements have
been made in the manufacture of specialized wires, and there are
additionally, promising novel technologies such as the Intraluminal™
wire and Frontrunner catheter21-23. The current report has demon-
strated the efficacy of drug-eluting stent implantation in CTOs and,
together with improvements in recanalization rates, a strategy of
percutaneous therapy of CTOs will become more widely applicable.
Study limitations
The study was not randomized, and angiographic follow-up data
was not routinely obtained in all patients, so additional events such
as silent re-occlusion cannot be excluded. However, clinical follow-
up was obtained in >99% patients (all but one patient), and assess-
ment of symptomatic status in those that did not require re-inter-
vention, showed that all were symptomatically well at follow-up. The
study was not randomized, and used a retrospective comparative
population; however the same operators and interventional tech-
niques were utilised.
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The percutaneous treatment of coronary bifurcation
stenoses is hampered by an increased rate of subse-
quent restenosis. The present study reports on the
outcomes of a consecutive series of 58 patients with
65 de novo bifurcation stenoses treated with siroli-
mus-eluting stent implantation in both the main vessel
and side branch. At 6 months, the incidence of major
adverse cardiac events was 10.3% (1 death and 5
target lesion revascularizations) with no episodes of
acute myocardial infarction or stent thrombosis. �
2004 by Excerpta Medica, Inc.
(Am J Cardiol 2004;91:115–118)
Percutaneous coronary intervention of bifurcationlesions is associated with lower procedural suc-
cess rates1 and an increased subsequent rate of major
adverse cardiac events (MACEs) and restenosis. Var-
ious techniques and strategies have been applied in an
attempt to improve outcomes, including kissing bal-
loon dilatation and the use of stent implantation in
both branches.2 The use of adjunctive atherectomy
was found to be disadvantageous in the Coronary
Angioplasty Versus Excisional Atherectomy Trial
(CAVEAT-I) trial.3 Although there was an improved
initial angiographic result with less residual stenosis,
this was at the expense of a higher rate of side branch
occlusion and acute myocardial infarction. In the
long-term, results of angioplasty in bifurcations have
been hampered by problems of restenosis, particularly
after stent implantation within the side branch.4,5 Re-
cently, sirolimus-eluting stents (SESs) have demon-
strated dramatically reduced restenosis rates in pa-
tients with relatively simple lesions.6,7 We sought to
investigate the safety and efficacy of SESs in a con-
secutive series of unselected patients with de novo
bifurcation lesions enrolled in the Rapamycin-Eluting
Stent Evaluation At Rotterdam Cardiology Hospital
(RESEARCH) registry.8
• • •
Since April 2002, SES implantation (Cypher, John-
son & Johnson–Cordis, Miami, Florida) has been used
as the default strategy for all patients treated in our
institution, as part of the RESEARCH registry.8
Briefly, this single-center registry aims to evaluate the
efficacy of SES implantation in the “real world” of
interventional cardiology. All consecutive patients
were enrolled, irrespective of clinical presentation and
lesion characteristics, and the incidence of MACEs
was prospectively evaluated during follow-up. At 6
months, a total of 563 consecutive patients were
treated solely with SESs. Of these, 58 patients
(10.3%) with de novo bifurcation lesions were treated
with SES implantation in both the main and side
branches; these patients comprise the present study
population. The patients’ informed written consent
was obtained in accordance with the rules of the
institutional ethics committee, which approved the
study.
All procedures were performed with standard in-
terventional techniques, except with the use of the
SES as the device of choice. The strategy of bifurca-
tion stenting employed and the use of kissing balloon
dilatation after procedure was at the operators’ discre-
tion. One of 4 methods of stenting was used: T-
stenting, culotte stenting, kissing stents, or the “crush”
technique. T-stenting and culotte stenting have been
previously described.5,9 Kissing stents involved simul-
taneous implantation of the stents within both
branches, with the proximal edges alongside each
other, thereby bringing forward the point of diver-
gence. The crush technique involves positioning both
stents, with the proximal part of the side branch stent
lying well within the main vessel, while ensuring that
the edge of the stent in the main vessel is more
proximal than the side branch stent. The side branch
stent is deployed first, and the balloon and wire are
carefully withdrawn. The main vessel stent is then
deployed, thereby crushing the proximal part of the
side branch stent.10 SESs were available in diameters
from 2.25 to 3.00 mm and lengths from 8 to 33 mm.
During the procedure, intravenous heparin was given
to maintain an activated clotting time of �250 sec-
onds. All patients were prescribed lifelong aspirin and
clopidogrel for 6 months. The use of glycoprotein
IIb/IIIa inhibitors was at the discretion of the operator.
Clinical and angiographic follow-up was per-
formed at 6 months. MACEs were predefined as
death, myocardial infarction, or target lesion revascu-
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larization. The diagnosis of myocardial infarction re-
quired an elevation of creatine kinase levels to twice
the upper limit of normal, together with an increase in
the creatine kinase-MB fraction. Target lesion revas-
cularization was defined as either surgical or percuta-
neous reintervention driven by significant (�50%)
luminal diameter narrowing either within the stent or
the 5-mm borders proximal and distal to the stent, and
was undertaken in the presence of either anginal
symptoms or objective evidence of ischemia.
Coronary angiograms were obtained in multiple
views after intracoronary injection of nitrates. For the
main branches, 3 coronary segments were subjected to
quantitative angiography: in-stent, proximal edge, and
distal edge segment. The in-stent analysis encom-
passed the length of all stents used during the proce-
dure. The proximal and distal edge segment included
up to 5 mm from the proximal and distal edge of the
total segment treated with the study stents, respec-
tively. For the side branches, 2 segments were ana-
lyzed: in-stent and distal edge 5-mm segment. Quan-
titative coronary angiographic (QCA) analysis was
performed using the Cardiovascular Angiography
Analysis System II (CAAS II; Pie Medical, Maas-
tricht, The Netherlands). The reference vessel diame-
ter, minimal lumen diameter, and percent diameter
stenosis were measured before and after the procedure
and at follow-up. The late loss was calculated as the
difference between the minimal lumen diameter after
the procedure and that at follow-up. Binary restenosis
was defined as the presence of �50% diameter steno-
sis within the target lesion.
Fifty-eight patients with 65 bifurcation lesions
were included in this study. Baseline patient charac-
teristics are listed in Table 1. The lesion characteris-
tics and stenting technique utilized are presented in
Table 2. At 6 months, the survival-free of MACEs was
89.7%. One patient died after bifurcation stent implan-
tation of the left main stem for an acute myocardial
infarction. This patient was admitted in cardiogenic
shock, and despite the use of abciximab and intra-
aortic balloon pump support, died shortly after the
procedure due to left ventricular failure. There were
no episodes of acute or subacute stent thrombosis, and
no patient had a myocardial infarction. Target lesion
revascularization was undertaken in 5 patients (8.6%)
as outlined in the following.
Of 65 lesions, 6-month angiographic follow-up
was performed in 44 lesions. The binary restenosis
rate was 22.7% (10 of 44 lesions). QCA data are
presented in Table 3. Angiographic restenosis oc-
curred in 4 lesions within the main branch (1 in the
proximal segment; 3 in the in-stent segment), yielding
a restenosis rate of 9.1%. Angiographic restenosis
occurred in 6 of the side branches, all within the
in-stent segment. Of these 6 restenoses, 5 occurred at
the ostium of side branch after the use of T-stenting
(Figure 1). All 4 patients with a restenosis within the
main vessel and 1 patient with a restenosis at the
ostium of a side branch underwent percutaneous target
lesion revascularization with new drug-eluting stent
implantation. Directional coronary atherectomy was
additionally used in 1 patient. The remaining 5 pa-
tients, all with ostial side branch restenoses, were
asymptomatic and treated with medical therapy alone.
TABLE 3 Quantitative Coronary Angiography
Proximal
Segment
In-stent
Segment
Distal
Segment
Main branch (n � 44)
Reference diameter (mm) N/A 2.64 N/A
Minimal lumen diameter (mm)
Preprocedure N/A 0.64 N/A
Postprocedure 2.39 2.19 1.86
6-mo follow-up 2.26 2.07 1.85
Diameter stenosis at 6 mo (%) 28.3 22.9 25.4
Late lumen loss (mm) 0.12 0.12 0.01
Restenosis rate (%) 2.3 6.8 0
Side branch (n � 44)
Reference diameter (mm) 1.99 N/A
Minimal lumen diameter (mm)
Preprocedure 0.61 N/A
Postprocedure 1.80 1.57
6-mo follow-up 1.49 1.47
Diameter stenosis at 6 mo (%) 31.0 21.9
Late lumen loss (mm) 0.31 0.09
Restenosis rate (%) 13.6 0
Values are presented as mean values or relative percentages.
TABLE 1 Baseline Clinical Characteristics (n � 58)
Age (yrs) 63 � 10
Men 42 (72%)
Hypertension 26 (45%)
Hypercholesterolemia 35 (60%)
Diabetes mellitus 16 (28%)
Current smoker 16 (28%)
Previous myocardial infarction 22 (38%)
Previous coronary angioplasty 5 (9%)
Previous coronary artery bypass surgery 3 (5%)
No. of coronary arteries significantly narrowed
1 15 (26%)
2 28 (48%)
3 15 (26%)
Presentation with an acute coronary syndrome 18 (31%)
Values are presented as the numbers (relative percentages) or mean value �
SD.
TABLE 2 Lesion and Procedural Characteristics (number of
lesions � 65)
Coronary artery treated with bifurcation stenting
Left anterior descending/diagonal 39 (60%)
Left circumflex/obtuse marginal 16 (25%)
Right coronary/posterior descending 4 (6%)
Left main stem—left anterior descending/circumflex 6 (9%)
Stenting technique
T-stenting 41 (63%)
Culotte stenting 5 (8%)
Kissing stenting 2 (3%)
Crush stenting 17 (26%)
Kissing balloon dilatation after stenting 20 (31%)
Glycoprotein IIb/IIIa inhibitor use 20 (31%)
Values are presented as the numbers (relative percentages).
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The major findings of this study of bifurcation
stenting include the following. (1) SES implantation
in both the main and side branches is feasible and
associated with a low procedural complication rate
and no episodes of stent thrombosis. (2) The target
lesion revascularization rate of 8.6% is seemingly
diminished compared with historical controls. (3) An-
giographic restenosis rates of the main and side
branches are 9.1% and 13.6%, respectively, with an
overall restenosis rate of 22.7%. (4) Five of the 6
restenoses occurring in the side branch were located at
the ostium after using the T-stenting technique.
Drug-eluting stent deployment in both vessels to
treat bifurcation lesions may raise theoretical concerns
that it could result in a propensity to stent thrombosis.
When we treat bifurcation lesions with SESs using the
culotte, kissing, or crush stenting techniques, there are
some overlapping stent struts, where the higher con-
centration of sirolimus may induce endothelial func-
tion impairment and thus be associated with an in-
creased rate of stent thrombosis. Although these
stenting techniques were applied in 37% of the lesions
treated, no stent thrombosis was reported during fol-
low-up, implying that sirolimus has a wide safety
margin.
Several strategies have been advocated to treat
bifurcation lesions with percutaneous coronary inter-
vention, such as deployment of stents in both vessels,
stenting in 1 branch with balloon angioplasty in the
other, and mechanical debulking. The published re-
ports regarding the subsequent need for target lesion
revascularization utilizing bare stents range from 17%
to 53%5,11,12; thus, the rate of 8.6% in our study is
very favorable. In addition, the rate observed in the
present study may underestimate the true beneficial
treatment effect of SES as explained in the following.
Five of the 6 restenoses in the side branch occurred
at the ostium after T-stenting. When we apply T-
stenting, stent positioning must be extremely accurate
to ensure complete coverage of the side branch os-
tium. This is particularly difficult and/or impossible to
achieve when the angle between the 2 branches is
much �90°. Restenosis at this site may therefore be
mainly a reflection of incomplete coverage. The reste-
nosis rate in the side branch following T-stenting was
16.7% (5 of 30 lesions), whereas that following the
other stent techniques was 7.1% (1 of 14 lesions). The
present study is limited because the choice of strategy
was nonrandomized, and there is no comparison with
alternative strategies, such as the use of stent implan-
tation in the main vessel alone, with balloon-only
angioplasty of the side branch. In addition, the sample
size was relatively small, and any difference between
the different techniques was not statistically signifi-
cant. However, our results suggest that it seems wise
to ensure the complete coverage of the ostium with
SESs using stenting techniques other than T-stenting.
The crush technique is technically easier and quicker
to do than a culotte, but further data with longer
follow-up from a larger population are needed to fully
determine the efficacy of these techniques.
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Outcome of Percutaneous Coronary Intervention
Versus Coronary Bypass Grafting for Patients With Low
Left Ventricular Ejection Fractions, Unstable Angina
Pectoris, and Risk Factors for Adverse Outcomes With
Bypass (the AWESOME Randomized Trial and Registry)
Steven P. Sedlis, MD, Kodangudi B. Ramanathan, MD, Douglass A. Morrison, MD,
Gulshan Sethi, MD, Jerome Sacks, PhD, and William Henderson, PhD, for the
Investigators of the Department of Veterans Affairs Cooperative Study #385, the
Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)
The recently concluded Angina With Extremely Seri-
ous Operative Mortality Evaluation (AWESOME) was
a randomized clinical trial of percutaneous coronary
intervention versus coronary bypass graft surgery
among patients with medically refractory ischemia
who were at high risk for coronary bypass graft
surgery because of >1 risk factors that included se-
verely reduced left ventricular (LV) function, defined
as LV ejection fraction <35%. This study reports the
outcome of patients with LV ejection fraction<35% in
the randomized clinical trial and the physician-di-
rected and patient choice registries of the AWESOME
study. �2004 by Excerpta Medica, Inc.
(Am J Cardiol 2004;94:118–120)
Angina With Extremely Serious Operative Mortal-ity Evaluation (AWESOME) was a nationwide,
prospective, randomized, Department of Veterans Af-
fairs clinical trial designed to compare the long-term
survival with coronary bypass graft surgery (CABG)
versus percutaneous coronary intervention (PCI) for
patients with medically refractory myocardial isch-
emia and increased risk of adverse outcomes with
CABG. Patients were enrolled only if they had �1 of
5 risk factors for adverse outcomes with CABG (prior
CABG; myocardial infarction within 7 days; left ven-
tricular ejection fraction [LVEF] �35%; age �70
years; or intra-aortic balloon required to stabilize).
Eligible patients who were deemed by their physicians
and by study investigators to be suitable for CABG
and PCI were asked to participate in the randomized
trial. Eligible patients who were acceptable for either
CABG or PCI but who refused randomization were
entered into a prospective patient choice registry. El-
igible patients who were unacceptable for either
CABG or PCI were entered into a physician-directed
registry. The study protocol and the 3-year survival
and quality of life of patients enrolled in the random-
ized study and registry have been previously report-
ed.1–3 EF was reported by the investigator at each site
and estimated from contrast ventriculography or echo-
cardiography or calculated by radionuclide ventricu-
lography. Patients with EFs �35% were a prespeci-
fied subgroup for analysis.
• • •
Differences in baseline variable frequencies were
tested by chi-square tests for proportions. Long-term
survival was measured by Kaplan-Meier survival es-
timates, which were plotted. The statistical signifi-
cance of global differences between survival curves
was judged by a log-rank test.
There were 2,431 patients enrolled in the AWE-
SOME study between 1995 and 2000, including 446
patients with EFs �35% (94 randomized and 352
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Treatment of de novo bifurcation lesions: 
comparison of Sirolimus- and Paclitaxel-eluting stents 
Abstract
Objective: Both the sirolimus-(SES) and paclitaxel-eluting (PES) stents have been shown to reduce resteno-
sis rates when used in relatively simple lesions. This study aimed to evaluate the results of a consecutive
series of patients treated with drug-eluting stent implantation for de novo bifurcation lesions, and compared
outcomes with respect to stenting strategy and stent type.
Patients: From April 2002 to September 2003, all patients at our institution were treated with drug-eluting
stent implantation. A consecutive series of 144 patients were treated for 167 de novo bifurcation lesions
with SES, followed by 104 patients treated with PES for 113 lesions.
Results: Clinical follow-up at 6 months was obtained in 99% patients with survival-free of major adverse
cardiac events (MACE) of 93.7% for SES versus 85.8% for PES, p=0.05. By multivariate analysis, factors
predictive for MACE were age, diabetes mellitus, previous CABG, multivessel disease, treatment for acute
myocardial infarction, and treatment with PES. Survival-free of target lesion revascularization (TLR) was
95.7% for SES versus 86.8% for PES, p=0.01, with stent type being the only independent predictor.
Technique of stenting was not a predictor of either MACE or TLR.
Conclusions: MACE rates for both the SES and PES are low compared with historical data of bare metal
stents. The most effective techniques for bifurcation stenting remain undefined. Our data suggests a high-
er need for TLR for the PES compared with the SES, however further randomized studies are needed to
fully evaluate both stenting strategy, and any difference between the stents.
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bifurcation lesions,
Sirolimus, Paclitaxel.
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Introduction
The outcome of percutaneous therapy (PCI) of bifurcation lesions
with bare metal stents is hindered by an increased rate of procedural
complications1, and a high rate of restenosis particularly when both
the main vessel and side branch are stented2,3,4,5,6. The advent of
drug-eluting stents is revolutionising the practice of interventional
cardiology by demonstrating a reduction in the subsequent rate of
restenosis. There is evidence of efficacy in randomized trials for
both the sirolimus- (SES) and paclitaxel-eluting (PES) stents for the
treatment of relatively simple lesions7,8. In addition, the sirolimus-
eluting stent for the treatment of bifurcation lesions has demonstrat-
ed a low rate of adverse cardiac events compared with historical
data utilizing bare metal stents9,10. However, the most effective tech-
nique of stenting for bifurcation lesions with drug-eluting stents is
currently unknown. In the present report we evaluate the rate of
major adverse cardiac events following PCI for bifurcation lesions
treated with either SESs or PESs in a consecutive series of patients.
In addition, outcomes were assessed with respect to the baseline
bifurcation anatomy and type of stenting strategy employed. 
Methods
Bifurcation classification: All lesions were classified on baseline
angiography according to the Duke classification (figure 1). 
Procedure: The sirolimus-eluting stent (Cypher™, Johnson &
Johnson - Cordis unit) received CE mark approval in April 2002.
Since that time, all patients undergoing percutaneous therapy in our
institution have been treated with drug-eluting stent implantation as
the default strategy. During the first quarter of 2003, our strategy
switched from the sirolimus- to the paclitaxel-eluting stent (Boston
Scientific) enabling a comparison of the two stent types. All consec-
utive patients were enrolled irrespective of clinical presentation and
lesion characteristics, and the incidence of major adverse cardiac
events (MACE) was prospectively evaluated during the follow-up.
All procedures were performed with standard interventional tech-
niques. The strategy of bifurcation stenting employed, and the use
of kissing balloon dilatation post-procedure were at the operators’
discretion. One of 6 methods of stenting was used: stenting of the
main vessel with balloon-only angioplasty of the side branch; type A
T-stenting (stenting first of the side branch, followed by stenting of
the main vessel); type B T-stenting (stenting of the main vessel fol-
lowed by stenting of the side branch because of a sub-optimal
result)2; the ‘crush’ technique11; culotte stenting12; or kissing stents
(simultaneous implantation in the main vessel and side branch with
the proximal edges of the stents side by side). SESs were available
in diameters from 2.25 mm to 3.00 mm and lengths from 8 mm to
33 mm. PESs were available in diameters from 2.25 mm to 3.5 mm
and lengths from 8mm to 32mm. During the procedure, intra-
venous heparin was given to maintain an activated clotting time
≥250 seconds. Patients were preloaded with 300 mg clopidogrel,
and received life-long aspirin together with 75 mg clopidogrel per
day for 6-months. The use of glycoprotein IIb/IIIa inhibitors was at
the discretion of the operator. The protocol was approved by the
Institutional ethics committee and is in accordance with the princi-
ples of Good Clinical Practice for Trials of Medicinal Products in the
F I G U R E 1 .
Fig. 1: The Duke classification of bifurcation lesions.
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European Community and the Declaration of Helsinki. All patients
signed a written informed consent
Follow-up: Clinical follow-up was obtained using telephone calls and
questionnaires, and evaluated the rate of major adverse cardiac
events (MACE) which were pre-defined as death, acute myocardial
infarction (AMI), or target vessel revascularization (TVR). The diag-
nosis of AMI required an elevation of creatine kinase levels to twice
the upper limit of normal, together with a rise in creatine kinase-MB
fraction. Target lesion revascularization was defined as either surgi-
cal or percutaneous reintervention driven by significant (>50%)
luminal diameter narrowing either within the stent or the 5mm bor-
ders proximal and distal to the stent, and was undertaken in the
presence of either anginal symptoms or objective evidence of
ischemia. Target vessel revascularization was defined as revascular-
ization within the target vessel including encompassing the target
lesion. The definition of stent thrombosis was the presence of intra-
stent thrombosis, with or without stent occlusion, documented on
angiography, and was categorized as acute if occurring within
24 hours or subacute if within 30 days after stent implantation.
Statistical analysis: Discrete variables are presented as percentages
and compared with Fisher exact test. Continuous variables are
expressed as mean ± standard deviation and compared with
Student’s t test. Cumulative survival and MACE-free survival were
calculated according to the Kaplan-Meier method. The log-rank test
was used to compare MACE-free survival between the two groups.
All tests were two-tailed, and a p value of <0.05 was considered as
significant. Logistic regression models were established to investi-
gate independent predictors of MACE (death, AMI, or TVR), and tar-
get lesion revascularization. Variables entered were age, gender,
diabetes mellitus, hypertension, hypercholesterolemia, smoking,
multivessel disease, prior AMI, prior CABG, clinical presentation,
use of a glycoprotein IIb/IIIa inhibitor, target vessel, bifurcation
anatomy, stent type, stenting technique, diameter of stent, total
length of stents, and use of kissing balloon post-dilatation. Odds
ratio with corresponding 95% confidence intervals are reported.
Results
The baseline patient and procedural characteristics for the SES and
PES cohorts are presented in tables 1 and 2 respectively. There
were no significant differences between the 2 groups with respect
to baseline patient characteristics, though there was a trend
towards an increased usage of glycoprotein IIb/IIIa inhibitors in the
PES group (38.5% versus 27.8% in the SES group, p=0.07). There
was no significant difference in the number of stents used, howev-
er, the mean nominal diameter of stent used in the main vessel was
greater with the PES (2.93 ± 0.34mm versus 2.85 ± 0.23 for the
SES, p=0.007). For those patients treated with stent implantation in
the side branch, though there was no significant difference in the
number of stents used, the total length of stented segment in the
side branch was longer for the PES-treated patients (18.8 ±
10.5mm versus 14.1 ± 7.6mm, p=0.0001). The choice of stenting
strategy during the 2 treatment periods is presented in figure 2.
The total number of lesions treated with each stenting technique
was single stent utilization in 55 (19.6%), type A T-stenting in
47 (16.8%), type B T-stenting in 46 (16.4%), crush stenting in 
88 (31.4%), culotte stenting in 24 (8.6%), and kissing stents in
20 (7.1%). There was no difference with respect to the use of kiss-
ing balloon post-dilatation between the SES and PES cohorts.
Clinical follow-up was obtained in 99.2% patients. Angiographically
documented stent thrombosis occurred in 2 patients treated with
SES (1.4%) and 3 patients treated with PES (2.9%), p=0.4 (Table 3).
All episodes of stent thrombosis were subacute (within 30 days fol-
lowing stent implantation), and were treated percutaneously, all
patients survived. The cumulative incidence of major adverse car-
diac events at 6-months for the SES and PES groups are presented
in Table 4, and the survival-free of MACE at 6-months is illustrated
in figure 3. The independent predictors for MACE and TLR by mul-
tivariate analysis are shown in Table 5. The only factor found to be
predictive for TLR was stent type. Neither the baseline bifurcation
anatomy, nor the type of stenting strategy utilized, were predictive of
events.
At 6-months, survival-free of TLR was 95.7% for SES versus 86.8%
for PES, p=0.01 (figure 4). TLR was for subacute thrombosis in
5 patients (see above), was for restenosis of the main vessel in
4 lesions treated with SES (2.4%) and 6 lesions treated with PES
(5.3%), for restenosis of the side branch in 3 lesions treated with
SES (1.8%) and 3 treated with PES (2.7%), and for restenosis of
both branches in 2 lesions treated with SES (1.2%) and 2 treated
with PES (1.8%). 
Discussion
In the present report we have demonstrated low rates of major
adverse cardiac events at 6-months for both the sirolimus- and
paclitaxel-eluting stents when used for the treatment of de novo
bifurcation lesions. Independent predictors for MACE were age, dia-
betes mellitus, multivessel disease, previous CABG, treatment in the
setting of acute myocardial infarction, and therapy with PES. Target
lesion revascularization (TLR) at 6-months was higher in the PES
group than the SES group, with a survival-free of TLR of 86.8% ver-
sus 95.7% respectively, p=0.01. By multivariate analysis, the use of
PES was the only factor predictive for TLR.
The most effective strategy for the treatment of bifurcation lesions
with drug-eluting stents is currently unknown. In the present study,
the choice of stenting strategy was at the operators’ discretion.
Previous data from our group following bifurcation stenting with the
SES, demonstrated an overall restenosis rate of 23%9. The majority
of restenoses of the side branch occurred at the ostium following
T-stenting. Indeed, the restenosis rate in the side branch following
T-stenting was 16.7% whilst that following other stenting techniques
was 7.1%. We hypothesised that these restenoses might relate to
inadequate / incomplete coverage of the ostium of the side branch
thereby reducing the efficacy of the drug-eluting stent. This led to a
shift away from a strategy of T-stenting, towards methods which
ensure complete coverage - the crush and culotte techniques of
stenting (figure 2). One potential disadvantage of these strategies
however, is that they lead to an area of double or triple layer of stent
struts raising theoretical concerns that the increased dosage of drug
at this site might induce endothelial dysfunction and potentiate the
risk of thrombosis. Despite the change in stenting technique in the
present study, the choice of strategy was not an independent pre-
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Table 1. Baseline patient demographics 
SES PES p value
n=144 n=104
Mean age (years) 62.4 ± 10.5 60.3 ± 11.8 0.1
Male sex (%) 74.3 73.1 1
Current smoker (%) 27.1 27.9 1
Diabetes mellitus (%) 18.8 17.3 1
Hypertension (%) 43.1 46.2 0.7
Hypercholesterolemia (%) 56.9 62.5 0.3
Previous myocardial infarction (%) 35.4 38.5 0.2
Previous CABG (%) 4.9 3.8 0.9
Clinical presentation 0.4
Stable angina (%) 65.3 67.3
Unstable angina (%) 21.5 17.3
Acute ST-elevation myocardial infarction (%) 13.2 16.3
Glycoprotein IIb/IIIa inhibitor usage (%) 27.8 38.5 0.07
PCI in at least one additional major epicardial vessel 
during the index procedure (%) 40.3 39.4 1
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention.
Table 2. Baseline procedural characteristics
SES PES p value
Total number of bifurcation lesions treated 167 113
Target vessel 0.3
LAD / diagonal (%) 61.1 56.6
LCX / obtuse marginal (%) 19.2 17.7
RCA bifurcation (%) 9.6 8.0
LMS (%) 10.2 17.7
Bifurcation classification 0.4
A (%) 4.8 3.5
B (%) 7.2 5.3
C (%) 8.4 6.2
D (%) 17.5 20.4
E (%) 8.4 3.5
F (%) 44.0 50.4
Total occlusion (TIMI 0 flow) (%) 9.6 10.6
Pre-dilatation of main vessel (%) 59.3 54.0 0.4
Pre-dilatation of the side branch (%) 42.5 31.9 0.07
Pre-dilatation with kissing balloons (%) 15.0 13.3 0.9
Mean number of stents in the main vessel 1.56 ± 0.84 1.48 ± 0.67 0.4
Mean nominal diameter of stent in the main vessel (mm) 2.85 ± 0.23 2.93 ± 0.34 0.007
Mean total lengths of stent in the main vessel (mm) 30.4 ± 17.7 30.3 ± 17.8 1.0
Mean number of stents in side branch 1.11 ± 0.36 1.13 ± 0.39 0.8
Mean nominal diameter of stent in the side branch (mm) 2.53 ± 0.29 2.60 ± 0.35 0.06
Mean total lengths of stent in the side branch (mm) 14.1 ± 7.6 18.8 ± 10.5 0.0001
Nominal diameter of balloon in side branch for POBA 2.28 ± 0.44 2.19 ± 0.49 0.5
Post-dilatation with kissing balloons (%) 47.3 45.1 0.9
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, LAD: left anterior descending artery, LCX: circumflex artery, RCA: right coronary artery,
LMS: left main stem, POBA: plain old balloon angioplasty.
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Table 4. Cumulative incidence of major adverse cardiac events at
6-months for the Sirolimus- and Paclitaxel-eluting stents 
SES PES p value 
n=144 n=104 (log rank)
Death (%) 1.4 3.2 0.4
Death or AMI (%) 4.9 7.1 0.5
Death, AMI, or TLR (%) 6.3 13.2 0.08
Death, AMI, or TVR (%) 6.3 14.2 0.05
SES: Sirolimus-eluting stents, PES: Paclitaxel-eluting stents, 
AMI: acute myocardial infarction, TLR: target lesion revascularization,
TVR: target vessel revascularization.
Table 5. Independent predictors of major adverse cardiac events
and target lesion revascularization at 6 months
Odds ratio 95% confidence 
intervals
MACE
Age 1.02 1.01 to 1.05
Prior CABG 2.75 1.1 to 7.2
Diabetes mellitus 2.15 1.2 to 4.0
Multivessel disease 1.36 1.0 to 1.9
Presentation with acute 
myocardial infarction 2.35 1.1 to 5.0
Therapy with Sirolimus-eluting stent 0.71 0.4 to 1.0
TLR
Therapy with Sirolimus-eluting stent 0.45 0.19 to 0.95
MACE: major adverse cardiac event; CABG: coronory artery bypass graft
surgery; TLR: target lesion revascularization
F I G U R E 4 .
Fig. 4: Kaplan-Meier curves for survival-free of target lesion revascu-
larization (TLR) for the Sirolimus-eluting (SES) and Paclitaxel-eluting
stent (PES).
F I G U R E 2 .
Fig. 2: The type of stenting strategy employed for the Sirolimus-
eluting (SES) and Paclitaxel-eluting stent (PES).
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Fig. 3: Kaplan-Meier curves for survival-free of major adverse cardiac
events (MACE) for the Sirolimus-eluting (SES) and Paclitaxel-eluting
stent (PES).
Table 3. Demographic of the 5 patients angiographically documented stent thrombosis 
Age, Stent Target Time to Diabetes Use of Clinical Stenting Kissing
sex type vessel thrombosis, mellitus GP IIb/IIIa presentation strategy balloon
days inhibitor at index post-dilatation
74yr F SES LAD 1 N N SA Crush Y
57yr M SES LAD 18 Y Y AMI Type B “T” N
66yr M PES LCx 7 N N UA Crush N
46yr F PES LAD 6 N N AMI Crush N
51yr F PES LCx 4 N Y AMI Type B “T” Y
SES: Sirolimus-eluting stent; PES: Paclitaxel-eluting stent; LAD: left anterior descending; LCx: left circumflex; SA: stable angina; AMI: acute myocar-
dial infarction; UA: unstable angina.
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dictor for either MACE or the need for TLR. The current study is lim-
ited by the lack of angiographic follow up, so cannot fully evaluate
restenosis which, particularly when occurring in the side branch,
may be clinically silent. 
Currently, there is only one published randomized evaluation of
drug-eluting stents for bifurcation lesions10. This randomized
85 patients to a single SES with balloon-angioplasty of the side
branch, versus implantation of 2 SESs. The overall rate of resteno-
sis at 6 months was 26% (19% in the single stent group versus
28% in the double stent group, p=NS). However, the study was lim-
ited by the high crossover rate with 51% of the patients in the sin-
gle stent group crossing to the double stent group because of a sub-
optimal result in the side branch. In addition, the approach to stent-
ing technique was not uniform. However, both this randomized
study, and the registry data from our group demonstrate an
improvement in the restenosis rates compared with historical data
of bare metal stenting. 
Restenosis following bare stent implantation is related to the length
of stent, and inversely related to the diameter13. The majority of
TLRs were for restenosis within the main vessel stent, yet the nom-
inal stent diameter was actually bigger for the PES. This probably
related to a larger available diameter of PES (3.5mm versus 3.0mm
for the SES), and throughout the study, post-dilatation was carried
out whenever necessary. The mean total length of stent used in the
side branch of the PES group was significantly longer than the SES
group. However, neither stent diameter nor length was an inde-
pendent predictor for subsequent MACE or need for TLR. 
Previous data of bare metal stent implantation in bifurcation
lesions, demonstrate rates of target lesion revascularization of
between 16% and 38%2,3,4,5,6. Compared with this historical data,
in the current study, TLR was certainly lower for the SES (survival-
free of TLR of 95.7% at 6 months). However, multivariate analysis
demonstrated a significantly higher need for TLR following stenting
with the PES compared with the SES, with the majority of TLRs in
the main vessel. This might reflect a difference in the efficacy of
the 2 drugs, at least at the current dosages, or relate to differences
in stent design14. The SES is a closed-design stent whereby each
cell is bound on all sides with the junction of each strut pair joined
to another strut pair junction. The PES however, is an open-cell
design meaning that some of the junction nodes are unattached
within the stent structure. A previous of 54 patients undergoing
elective stenting showed that platelet activation was lower in those
receiving a closed versus open-cell designed stent15. In the pres-
ent study, though not significantly different between the 2 groups,
subacute thrombosis did occur in a higher percentage of the PES
patients (2.9% versus 1.4%, p=0.4). The same authors15 exam-
ined stent implantation in the pig model and found that more tis-
sue prolapse occurred following implantation of a stent with an
open cell design. Both the SES and PES have been evaluated in
large randomized studies and compared with their respective bare
stents (Bx Velocity™ and Express™)16,17. Though the inclusion cri-
teria in these studies were not absolutely identical, both studies
were very similar and included patients with stable or unstable
angina and single de novo lesions; bifurcation lesions were exclud-
ed. Both the mean lesion length, and reference vessel diameter
were similar. Evaluation of the angiographic follow-up of those
treated with bare stents, showed a mean in-stent lumen loss of
1.00 ± 0.70mm in SIRIUS (Bx Velocity™), and 0.92 ± 0.58mm in
TAXUS-IV (Express™). The higher late lumen loss in the Bx
Velocity™ stent conflicts with the suggestion that the lower TLR
rate with SES in the present study might relate to the difference in
stent design. Both the SES and PES are covered by polymer coat-
ings to facilitate drug-elution. Previous evaluation of other polymers
has suggested that these can in themselves promote varying
degrees of an inflammatory response and restenosis18. In the same
randomized studies, evaluation of the drug-eluting stent cohorts
showed a mean in-stent late loss of 0.17 ± 0.45mm in SIRIUS, and
0.39 ± 0.50mm in TAXUS-IV, perhaps suggesting the SES is more
efficacious at inhibiting the development of neointimal hyperplasia
than the PES. 
Interpretation of the results of the present study with respect to stent
type is limited by the lack of randomization. The REALITY study is a
multicenter evaluation of more than 1300 patients with multivessel
disease, randomized to either SES or PES implantation. Initial results
were recently presented at the American College of Cardiology meet-
ing in 200519. There was no significant difference with respect to the
overall rates of MACE between the stent types (9.2% for SES versus
10.6% for PES, p=0.41). However, in keeping with the difference in
the degree of platelet activation related to stent design15, the rate of
stent thrombosis was higher for the PES group (1.8% versus 0.4%,
p=0.0196). Furthermore, all angiographic parameters with respect
to efficacy of suppression of neointimal growth were better following
SES implantation. The in-stent late loss was 0.09 ± 0.43mm for the
SES, versus 0.31 ± 0.44mm for the PES, p<0.001. Such a difference
may potentially be clinically relevant when treating complex lesions
such as bifurcations, particularly when vessels with a small diameter
are stented. Patients with bifurcation lesions were not excluded from
this study, and a more detailed analysis of subgroups such as those
treated for a bifurcation lesion is awaited.
The most effective strategy for percutaneous therapy of bifurcation
lesions with drug-eluting stents needs to be carefully evaluated in
future studies. Interpretation of future randomized studies should
take into account baseline anatomical differences of bifurcation
lesions as the best strategy for a true bifurcation lesion (involving
both the main vessel and side branch) may not necessarily be the
same as that for lesions affecting only one of the branches. In addi-
tion, restenosis particularly at the side branch may not always lead
to a recurrence in symptoms and follow-up angiography should be
carried out to fully evaluate the results. 
Study limitations
The major limitations of this study are that it is a single centre reg-
istry and is non-randomized, with the choice of stenting strategy left
entirely at the operators’ discretion. In addition, routine angiograph-
ic follow-up data was not obtained, and additional restenoses giving
rise to minimal / no symptoms, particularly at the ostium of the side
branch, cannot be excluded. However, clinical follow-up data was
available for >99% providing an accurate reflection of the rate of
clinically important adverse events following therapy of bifurcation
lesions in a consecutive series of patients without exclusion.
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Conclusions
The use of both the sirolimus- and paclitaxel-eluting stents for the
treatment of de novo bifurcation lesions appears feasible and safe,
both demonstrating low rates of major adverse cardiac events at
6-months. The increased rate of target lesion revascularization fol-
lowing PES implantation needs to be further evaluated in a random-
ized fashion, and at present, the most appropriate technique for
bifurcation stenting with drug-eluting stents remains unclear.
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OBJECTIVES We sought to determine the real-world incidence of angiographically confirmed and possible
stent thrombosis (ST) in an unrestricted population during the first 30 days after bare-metal
stent (BMS), sirolimus-eluting stent (SES), and paclitaxel-eluting stent (PES) implantation.
BACKGROUND Current data on ST in drug-eluting stents (DES) have come from randomized trials with
strict entry criteria, which limits their generalizability to daily practice.
METHODS The study population comprised three sequential cohorts of 506 consecutive patients with
BMS, 1,017 consecutive patients with SES, and 989 consecutive patients treated with PES.
RESULTS In the first 30 days after stent implantation, 6 BMS (1.2%, 95% confidence interval [CI] 0.5%
to 2.6%; p � 0.9), 10 SES (1.0%, 95% CI 0.5% to 1.8%), and 10 PES (1.0%, 95% CI 0.6%
to 1.9%) patients developed angiographically proven ST. Multiple potential risk factors were
identified in most patients with ST. Bifurcation stenting in the setting of acute myocardial
infarction was an independent risk factor for angiographic ST in the entire population (odds
ratio [OR] 12.9, 95% CI 4.7 to 35.8, p� 0.001). In patients with DES who had angiographic
ST, 30-day mortality was 15%, whereas another 60% suffered a nonfatal myocardial
infarction; no further deaths occurred during six months of follow-up. Including possible
cases, 7 BMS (1.4%, 95% CI 0.7% to 2.8%), 15 SES (1.5%, 95% CI 0.9% to 2.4%), and 16
PES (1.6%, 95% CI 1.0% to 2.6%) patients had ST.
CONCLUSIONS The unrestricted use of SES or PES is associated with ST rates in the range expected for
BMS. Stent thrombosis was associated with a high morbidity and mortality. Bifurcation
stenting, when performed in patients with acute myocardial infarction, was associated with an
increased risk of ST. (J Am Coll Cardiol 2005;45:947–53) © 2005 by the American
College of Cardiology Foundation
Drug-eluting stents (DES) reduce clinical events related to
restenosis. Concerns have been raised regarding the inci-
dence of stent thrombosis (ST) with the unrestricted use of
these stents. Data from the bare-metal stent (BMS) era
report a high morbidity and mortality with ST (1,2).
Evidence for ST in DES has come from randomized
controlled trials with strict entry criteria for the treatment of
single lesions, limiting conclusions that are applicable to the
real-world setting (3–6). Other information has come from
electronic registries with inherent biases that preclude gen-
eralization of the findings. A single-center registry recently
reported its results with sirolimus-eluting stents (SES) (7).
The aim of this present study is to describe the incidence of
ST (both angiographically proven and including possible
cases) in three consecutive populations while analyzing the
unrestricted use of a control BMS group, SES, and
paclitaxel-eluting stents (PES).
METHODS
Study design and patient population. Since April 2002,
SES (Cypher; Cordis Corp., Miami Lakes, Florida, a
Johnson & Johnson Company) have been the stents of
choice for all percutaneous coronary interventions irrespec-
tive of their clinical presentation or clinical outcome (8). In
the first quarter of 2003, PES (Taxus; Boston Scientific
Corp., Natick, Massachusetts) replaced SES as the default
stent.
This present study comprises three sequential cohorts: a
control group of the last 506 consecutive patients treated
with BMS before April 2002; 1,017 consecutive patients
with SES treated between April 2002 and February 2003;
and 989 consecutive patients with PES treated between
February 2003 and December 2003.
Procedure and antiplatelet management. All interven-
tions were performed according to current standard guide-
lines, and the final interventional strategy including peripro-
cedural glycoprotein IIb/IIIa and intravascular ultrasound
use, was left to the discretion of the operator. Patients were
pretreated with aspirin and a loading dose of 300 mg of
clopidogrel. After their procedure, all patients were pre-
scribed a lifelong aspirin regimen. Clopidogrel was pre-
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scribed for at least one month in the BMS group, for at least
three months in the SES group (8), and for at least six
months in the PES group.
Follow-up. As part of the national health system, our
institution as a tertiary referral center is the only interven-
tional facility within our catchment area. The survival status
of our patients at one and six months after discharge was
obtained from the Municipal Civil Registries. Details of all
repeat interventions (surgical and percutaneous) were col-
lected prospectively during follow-up. Referring physicians
and institutions were contacted whenever necessary for
additional information. This protocol was approved by the
Hospital Ethics Committee, and written, informed consent
was obtained from every patient.
Definitions. Stent thrombosis was considered to have oc-
curred when confirmed angiographically: either Thrombol-
ysis In Myocardial Infarction (TIMI) flow grade 0 or 1 or
the presence of flow-limiting thrombus (TIMI flow grade 1
or 2) occurring in an acute (within 24 h of stent implanta-
tion) or subacute (between 1 and 30 days) time period after
stent implantation (9). In addition, a clinical definition of
“possible stent thrombosis” was used for patients who
within the first 30 days experienced sudden death, who
suffered a fatal out-of-hospital cardiac arrest, or who suf-
fered a myocardial infarction (MI) that was not clearly
attributable to another coronary lesion and who did not
undergo repeat angiography. All deaths and MIs were
reviewed independently by two interventional cardiologists
(A.O., E.Mc.F) for “possible stent thrombosis.”
Statistical analysis. Categorical variables were compared
using the Fisher exact test and continuous variables with the
Student t test or one-way analysis of variance where appro-
priate. Univariate and forward stepwise (entry criteria of
0.05 and exit criteria of 0.10) multivariate logistic regression
analysis were performed to identify characteristics or vari-
ables independently associated with stent thrombosis. From
the univariate analysis, the following baseline, clinical,
angiographic and procedural variables were entered into the
multivariate model: bifurcation stenting, diabetes, smallest
stent diameter, multilesion stenting, and acute myocardial
infarction (AMI) as the indication. All probability values are
Table 1. Baseline and Procedural Characteristics
BMS
(n � 506)
SES
(n � 1,017)
PES
(n � 989) p Value
Baseline characteristics
Age, yrs, mean � SD 61.0 � 11.4 61.9 � 11.3 61.7 � 11.4 0.3
Male, % 73 70 74 0.1
Diabetes, % 16 18 17 0.6
Hypercholesterolemia, % 52 55 60 �0.01
Current smoker, % 35 28 28 �0.01
Hypertension, % 40 41 41 0.9
Previous MI, % 43 32 35 �0.01
Previous PCI, % 22 25 26 0.2
Previous CABG, % 11 9 8 0.2
Multivessel disease, % 54 57 56 0.4
Indication for index procedure �0.01
Stable angina, % 42 43 41
Unstable angina, % 35 36 30
Acute MI, % 20 19 26
Silent ischemia, % 3 2 3
Number of vessels treated, mean � SD 1.4 � 0.6 1.4 � 0.6 1.4 � 0.6 0.8
LAD, n 281 594 540
LCx, n 164 332 333
RCA, n 194 398 384
Others, n 29 75 90
Total stent length, mm (mean � SD) 31.9 � 22.1 42.5 � 29.6 44.2 � 29.4 �0.01
Stents implanted, mm (mean � SD) 1.9 � 1.1 2.3 � 1.5 2.2 � 1.4 �0.01
At least one �2.5 mm stent implanted (%) 23 38 38 �0.01
Bifurcations stented, % 5 18 17 �0.01
Glycoprotein IIb/IIIa use (%) 37 21 28 �0.01
BMS � bare metal stent; CABG � coronary artery bypass grafting; LAD � left anterior descending; LCx � left circumflex;
MI� myocardial infarction; PCI� percutaneous coronary intervention; PES� paclitaxel-eluting stent; RCA� right coronary
artery; SES � sirolimus-eluting stent.
Abbreviations and Acronyms
AMI � acute myocardial infarction
BMS � bare-metal stents
CI � confidence interval
DES � drug-eluting stents
MI � myocardial infarction
OR � odds ratio
PES � paclitaxel-eluting stents
SES � sirolimus-eluting stents
ST � stent thrombosis
TIMI� Thrombolysis In Myocardial Infarction
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two-sided, and statistical significance was set at the 0.05
level. A cumulative event graph consisting of patients with
angiographic stent thrombosis was generated plotting the
proportion of patients with stent thrombosis (Y-axis)
against time (X-axis) stratified by stent type. Incidences of
stent thrombosis are reported as a percentage with associ-
ated 95% confidence intervals (CIs).
RESULTS
Baseline and procedural characteristics. The patients in
our cohort were at high risk, with unstable angina or AMI
being the indication in more than one-half of the cases
(Table 1). Multivessel disease was present in more than
one-half of the population. One-third of the population had
a previous AMI, whereas one-quarter had previous coronary
interventions. Glycoprotein IIb/IIIa use was lower in the
SES and PES groups compared with the BMS group.
Clinical outcome. Angiographic ST was documented in
26 of 2,512 patients (Table 2). Six cases occurred in the
BMS group (1.2%, 95% CI 0.5% to 2.6%), 10 cases
occurred in the SES group (1.0%, 95% CI 0.5% to 1.8%),
and 10 cases occurred in the PES group (1.0%, 95% CI
0.6% to 1.9%). The first two SES patients with ST have
been reported previously (10). Most stent thromboses oc-
curred in the first 11 days, regardless of stent type, with a
mean time to event of 5.8 � 5.4 days (Fig. 1).
In the BMS population, there were two acute stent
thromboses and four subacute stent thromboses. Among the
six patients, ST presented as AMI in five patients. None
died during the six months of follow-up (Table 2). In the
combined group of SES and PES (2,006 patients), there
were 2 cases of acute ST and 18 cases of subacute ST (Fig.
1). A detailed description of these patients is given in Table
3. Analysis via intravascular ultrasonography was performed
in four patients. In most patients, at least one recognized
risk factor for ST (i.e., long stented length, use of small
stents, use of multiple stents, and residual dissection after
stent implantation) was present. Importantly, 2 of the 20
patients had not taken clopidogrel.
Mortality and morbidity. Overall, 20 of 26 patients (77%)
re-presented with an AMI, whereas the other 6 re-
presented with angina pectoris (Table 2). Of these 26
patients, 3 (Patients #12, #18, and #20 from Table 3—all in
the DES population) died at days 11, 5, and 3, respectively.
Two patients died during reintervention from intractable
ventricular fibrillation, whereas the third underwent emer-
gency surgery after a suboptimal reintervention and could
not be weaned from bypass. The incidence of death at 30
days was 12%, whereas another 65% suffered a nonfatal MI.
Among the survivors of ST, there were no further deaths in
the six months after reintervention.
Possible ST. Thirty-day survival data was complete for
98% of patients (Table 4). There were 12 patients who were
judged with “possible stent thrombosis,” of which 9 died
and 3 had nonfatal MIs. Of the nine deaths, four were
out-of-hospital sudden deaths, three occurred in hospital
with ventricular tachycardia as the initiating preterminal
rhythm, and two had ST-segment elevation and died before
they could undergo reangiography. Among those with MIs,
one patient developed a postprocedural enzyme leak, and
another developed ventricular fibrillation requiring multiple
cardioversions the day after the procedure. Repeat coronary
angiography six months later demonstrated occluded stents
in both of these patients; whereas a third underwent
coronary angiography 14 days after stent implantation
because of an increase in cardiac enzyme levels, which
demonstrated an in-stent filling defect which was treated
Figure 1. Cumulative incidence of angiographic stent thrombosis stratified
by groups against time. Vertical line � day 11 on horizontal axis. BMS �
bare-metal stents; PES � paclitaxel-eluting stents; SES � sirolimus-
eluting stents.
Table 2. Outcome Following Angiographic Stent Thrombosis
BMS SES PES p Value
Angiographic stent thrombosis, n (%) 6 (1.2%) 10 (1.0%) 10 (1.0%) 0.9
Clinical presentation
Acute MI, n 5 7 8
Angina, n 1 3 2
Maximum total CK, mean � SD 4,983 � 2,570 1,268 � 476 3,361 � 1,404 �0.01
Maximum CK-MB, mean � SD 397 � 186 171 � 80 322 � 166 �0.01
Outcome
30-day mortality, n 0 0 3
6-month mortality, n 0 0 3
CK � creatine kinase; other abbreviations as in Table 1.
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with abciximab, and subsequently underwent repeat percu-
taneous coronary intervention two weeks later. Including
the suspected cases, the combined incidence of angiographic
and possible ST was 1.4% (95% CI 0.7% to 2.8%) in the
BMS control group, 1.5% (95% CI 0.9% to 2.4%) in the
SES group, and 1.6% (95% CI 1.0% to 2.6%) in the PES
group. In the combined total of 38 documented and possible
ST, there were 12 deaths (32%) and 20 nonfatal MIs (53%)
in the first 30 days.
Multivariate analysis. By univariate analysis, bifurcation
stenting was the only significant factor (p � 0.01). Multi-
variate analysis was performed with the following covariates
based on their significance on univariate analysis as well as
their potential clinical impact: diabetes (p � 0.07), smallest
stent diameter (p � 0.13), multilesion stenting (p � 0.17),
AMI as the indication (p � 0.3), and bifurcation stenting.
By multivariate analysis, bifurcation stenting was the only
independent predictor of ST (odds ratio [OR] 3.0, 95% CI
1.3 to 6.8, p � 0.01). When the interaction of bifurcation
stenting by AMI was entered as a covariate, it was highly
significant (OR 12.9, 95% CI 4.7 to 35.8, p � 0.001), and
bifurcation stenting as a covariate was no longer significant.
DISCUSSION
The main findings in this study can be summarized as
follows: 1) the incidence of angiographic ST in an un-
selected, complex DES population was low (�1.0%), within
the same range as the corresponding BMS population and
concordant with previously published results from the BMS
Table 3. Detailed Description of Drug-Eluting Stent Patients With Angiographic Stent Thrombosis
Patient 1 2 3 4 5 6 7 8 9 10
Type of DES SES SES SES SES SES SES SES SES SES SES
Time to Thrombosis (days) 0.125 11 7 10 1.08 6 3 7 17 3
Baseline characteristics
Age (yrs) 72 61 86 57 75 55 53 58 58 74
Gender F F F M F F M M M M
Diabetes � � � � � � � � � �
Current smoker � � � � � � � � � �
Previous MI � � � � � � � � � �
Previous intervention � � � � � � � � � �
Index procedure
Indication for procedure UAP AP UAP AMI, ST AP AP, ISR UAP post-AMI AP AMI UAP post-AMI
Glycoprotein IIb/IIIa use � � � Y � � � Y Y �
Angiographic features of index procedure
Culprit vessel LAD LAD LAD LAD LAD/DIAG LAD/DIAG RCA LAD DIAG LAD
Lesion type (AHA) B1 C C C B2 C B2 B2 B2 B2
Bifurcation technique (where
performed)
� � � � crush t-stent � � t-stent �
Final kissing balloons in bifurcation
stenting
� � � � Y N N
Minimum stent diameter (mm) 2.25 2.5 3 3 3 2.5 3 2.75 3 2.75
Total stent length (mm) 26 66 41 26 36 41 41 18 31 36
Total stents implanted 2 2 3 2 2 2 2 1 2 2
Reintervention
Clinical presentation AMI AP AMI AP AMI AMI AMI AP AMI AMI
Additional stent implanted Y � Y Y � � Y � �
IVUS findings (where performed) RD UD � RD � � � � UD
Site of thrombosis in bifurcation lesions � � � � MB�SB SB � � SB �
Incomplete oral anti-platelet therapy � � � � � � � � Y �
Successful procedural outcome Y Y Y Y Y Y Y Y Y Y
AMI� acute myocardial infarction; AP� angina pectoris; DIAG� diagonal branch; IM� intermediate branch; LAD� left anterior descending artery; LCx� left circumflex
artery; MB � mainbranch; N � no; OMCx � obtuse marginal branch; RCA � right coronary artery; RD � residual dissection; SB � sidebranch; ST � stent thrombosis; UAP
� unstable angina pectoris; UD � underdeployment; Y � yes; other abbreviations as in Table 1.
Table 4. Incidence of Stent Thrombosis Classified by Definition
Stent Type
Number of
Patients
Angiographically Proven
Stent Thrombosis
n (% [95% CI])
Possible Stent
Thrombosis
n (% [95% CI])
All Stent Thrombosis
n (% [95% CI])
BMS 506 6 1 7
(1.2% [0.5%–2.6%]) (0.2% [0.0%–1.1%]) (1.4% [0.7%–2.8%])
SES 1,017 10 5 15
(1.0% [0.5%–1.8%]) (0.5% [0.2%–1.1%]) (1.5% [0.9%–2.4%])
PES 989 10 6 16
(1.0% [0.6%–1.9%]) (0.6% [0.3%–1.3%]) (1.6% [1.0%–2.6%])
CI � confidence interval; other abbreviations as in Table 1.
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era; 2) the inclusion of possible ST increases the overall
incidence of ST to �1.5%; 3) angiographically proven ST
was associated with a high mortality and morbidity; 4)
patients who developed ST often had multiple high-risk
features, regardless of stent type; and 5) the association of
bifurcation stenting for AMI was a highly significant
independent risk factor for ST.
The availability of DES as the default stent at our
institution has allowed us to analyze this new technology in
an unrestricted population (8), a population that would
have comprised any BMS population in the pre-DES
era. Therefore, this availability allows us to analyze inci-
dences in an “all-comers” population because patients were
enrolled irrespective of clinical presentation or outcome. In
this population sample, angiographic ST rates in the first 30
days for both DES, i.e., SES and PES, occurred within the
range as that reported in the BMS era (1,2,11,12).
The angiographic definition used is the most accurate for
diagnosis but may underestimate the true incidence of ST
because some patients who have a presumed ST may die
before receiving medical attention. Conversely, the use of
major adverse cardiac events (i.e., death and MI in addition
to the angiographic findings) to define ST overestimates the
true incidence because not all patients who die suddenly or
suffer a MI do so because of ST (13). This consideration is
important in our heterogeneous unrestricted population
with multivessel disease, previous MI, and previous revas-
cularization. Furthermore, not all patients who die will
Table 3 Continued
11 12 13 14 15 16 17 18 19 20 Mean � SD, %
PES PES PES PES PES PES PES PES PES PES
0.04 4 7 6 3 4 24 5 5 3 6.3 � 5.7
59 50 67 47 61 52 60 54 65 31 59.7 � 11.9
M M M F M F M M M M 13 M:7 F
� � � � � � � � � � 30%
� � � � � � � � � � 30%
� � � � � � � � � � 45%
� � � � � � � � � � 25%
AMI AMI AP AMI AP AMI AP AMI AP AP
� � � Y � � � Y Y � 30%
RCA LAD OMCX LAD/DIAG LCx LCx/OMCx LCx LAD/Diag LAD/IM/LCx LAD
B2 B2 C C B2 C C C C B2
� � crush crush � t-stent � crush culotte crush � 40%
� � N N � N � N Y �
3 3.5 2.5 2.5 2.5 2.25 2.25 2.75 2.25 3 2.7 � 0.3
28 24 32 36 20 44 32 36 140 84 41.2 � 27.8
1 1 2 2 1 2 2 2 8 4 2.2 � 1.5
AMI AMI AMI AMI AMI UAP UAP AMI AMI AMI AMI � 75%
� � Y � Y � Y � � � Yes � 35%
� � � � � � � � � �
� � SB SB � SB MB�SB SB MB�SB �
� � � � Y � � � � � 10%
Y Died Y Y Y Y Y Y Died Died Death � 15%
Table 5. Clinical Trials on Drug-Eluting Stents
Trial Name
Number of Patients
in Drug-Eluting Arm
Total Stent
Length mm
(Mean � SD)
Incidence of Stent
Thrombosis in the
First 30 Days (%)
SIRIUS (3) 533 23.0 � 8.6 0.2*
E-SIRIUS (6) 157 21.5 � 6.7 1.1*
C-SIRIUS (5) 50 23.8 � 8.4 2.0*
TAXUS-IV (4) 662 21.9 � 8.1 0.3†
SES group 1,017 42.5 � 29.6 ‡1.0–1.5§
PES group 989 44.2 � 29.4 ‡1.0–1.6§
*Definition of stent thrombosis was not stated. †Stent thrombosis defined as angiographically proven, or cardiac death or
myocardial infarction in the first 30 days. ‡Stent thrombosis defined as angiographically proven. §Stent thrombosis defined as
angiographically proven, or adjudicated death or myocardial infarction in the first 30 days.
Abbreviations as in Table 1.
951JACC Vol. 45, No. 6, 2005 Ong et al.
March 15, 2005:947–53 Stent Thrombosis in Drug-Eluting Stents
Chapter  16
150
undergo autopsy studies to determine the cause of death. To
attenuate this overestimation and to provide an accurate
figure, we have adjudicated all deaths and noncatheterized,
nonfatal MIs within the first 30 days in the three groups and
included them with the angiographically proven patients to
provide an overall incidence for each group.
The incidences of ST for both groups of DES are within
the range reported in the larger randomized clinical trials of
DES (3–6) despite longer total stent length, multivessel
treatment, and a heterogeneous population (Table 5). This
incidence complements information already available from
the randomized trials regarding the safety of these new
devices.
Angiographic ST was associated with a high mortality
and morbidity in our study. Within the DES population, 15
patients (75%) experienced a MI as their diagnosis at the
second presentation, and 3 (15%) died during the reinter-
vention procedure. The inclusion of possible ST patients
increased the mortality to 32%. Given the small number of
events, the fact that no deaths occurred in the BMS group
was most likely due to chance. These results are in concor-
dance with the results of a large BMS registry (2).
Previous studies have demonstrated that residual dissec-
tion (1,11), long stents (1), small final lumen diameter (1),
and use of multiple stents (2) are risk factors for the
development of ST. In our series, multiple risk factors were
identified in most patients who developed ST. Patients with
ST had more multiple lesions treated, smaller minimum
stent diameters, and longer stent lengths compared with
those without ST; however, these factors were not signifi-
cant on univariate analysis. What did emerge and which has
not been previously reported is that patients undergoing
bifurcation stenting had a higher incidence of ST compared
with those without bifurcation stenting. A recent study on
bifurcations reported a 3.5% incidence of ST, which is
higher than the overall incidence in this population (14).
Although stent implantation for AMI was not significant
on univariate analysis, the interaction of AMI and bifurca-
tion stenting when entered as a covariate for ST on
multivariate analysis emerged as a highly significant inde-
pendent predictor, and bifurcation stenting as a covariate
was no longer significant. This result confirms a clinical
suspicion in our department regarding the increased risk of
ST in patients treated with bifurcation stenting in the
setting of AMI.
Mechanical reasons that predispose to ST can be modi-
fied by interventional technique. Optimizing stent place-
ment including, if necessary, intravascular ultrasound-
guided postdilation, kissing balloon postdilation with
bifurcation stenting, and careful inspection for residual
dissection after stent implantation, may further reduce the
incidence of ST.
Pharmacologic reasons for ST, i.e., inadequate antiplate-
let therapy, are patient-specific factors. Recent research
literature has focused on “resistance” to either aspirin (15) or
to clopidogrel (16). Currently, most laboratories do not
routinely test for antiplatelet resistance. In our series, two
patients who had not taken their prescribed clopidogrel after
the procedure developed ST.
This report covers ST occurring in the first 30 days after
stent implantation only, during which all patients received
dual antiplatelet therapy. The duration of clopidogrel ther-
apy differed among the three groups; in part, it reflects
uncertainty with regards to re-endothelialization after DES
implantation. Late ST has been reported to occur with
BMS (17) and with DES (18), including a reported fatality
(19) after clopidogrel discontinuation. At this stage, the
incidence of late ST in the DES era is unknown, and further
studies are required to clarify this potential late complica-
tion.
Comment on sample size and statistical comparisons.
Because ST occurs at a low incidence (�1.0 to 1.5%), a
small sample size may underestimate or overestimate the
true incidence. In a previously published report from our
institution, we reported an angiographic incidence of 0.4%
in 508 patients (8). In the present study we extended the
population to incorporate the entire period of DES used to
date at our institution (n � 2,006) to allow a more accurate
analysis of the true incidence of ST in the DES population.
Despite having 2,512 patients, the low and small/negligible
absolute difference in incidence precludes formal statistical
comparisons of ST rates among the three groups because it
lacks sufficient statistical power. To achieve adequate power
would require sample sizes in the order of �100,000
patients. To date, this study is the largest series of patients
reported on in the DES era.
Study limitations. These single-center registry data com-
plement available randomized data, as they reflect the results
of unrestricted DES use.
Conclusions. Despite having a more complex cohort with
high-risk inclusion criteria, longer stent lengths, and more
complex procedural features, the incidence of ST with DES
are in the same range as the BMS population observed in
our present study. They also are in agreement with previ-
ously reported data by others from the BMS era and with
those results reported on in the earlier randomized DES
trials. Furthermore, the two groups of DES, i.e., SES and
PES, share an incidence of �1.0% to 1.5%. Stent throm-
bosis is associated with a high morbidity and mortality.
As extensively documented in previous reports with BMS,
mechanical reasons were observed to be frequent associations
for ST with DES. In this study, bifurcation stenting in the
setting of AMI was a highly significant independent predictor
for angiographic ST.
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Endothelial Progenitor Cell Capture by
Stents Coated With Antibody Against CD34
The HEALING-FIM (Healthy Endothelial Accelerated
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Rotterdam, the Netherlands; Fort Lauderdale, Florida; and Toronto, Canada
OBJECTIVES This study was designed to evaluate whether rapid endothelialization of stainless steel stents
with a functional endothelium prevents stent thrombosis and reduces the restenotic process.
BACKGROUND A “pro-healing” approach for prevention of post-stenting restenosis is theoretically favored
over the use of cytotoxic or cytostatic local pharmacologic therapies. It is believed that the
central role of the vascular endothelium is to maintain quiescence of the underlying media and
adventitia.
METHODS Sixteen patients with de novo coronary artery disease were successfully treated with
implantation of endothelial progenitor cell (EPC) capture stents.
RESULTS Complete procedural and angiographic success was achieved in all 16 patients. The
nine-month composite major adverse cardiac and cerebrovascular events (MACCE) rate was
6.3% as a result of a symptom-driven target vessel revascularization in a single patient. There
were no other MACCE despite only one month of clopidogrel treatment. At six-month
follow-up, mean angiographic late luminal loss was 0.63 � 0.52 mm, and percent stent
volume obstruction by intravascular ultrasound analysis was 27.2 � 20.9%.
CONCLUSIONS This first human clinical investigation of this technology demonstrates that the EPC capture
coronary stent is safe and feasible for the treatment of de novo coronary artery disease. Further
developments in this technology are warranted to evaluate the efficacy of this device for the
treatment of coronary artery disease. (J Am Coll Cardiol 2005;45:1574–9) © 2005 by the
American College of Cardiology Foundation
The emergence of drug-eluting stents has dramatically
reduced the incidence of in-stent restenosis (1,2). This
therapy interferes with the natural healing response by
preventing or significantly delaying the formation of a
functional endothelial lining over the stent (3).
Recently, the existence of circulating endothelial progen-
itor cells (EPCs) has been identified as a key factor for
re-endothelialization (4). The early establishment of a
functional endothelial layer after vascular injury has been
shown to assist in the prevention of neointimal proliferation
and thrombus formation (5,6). The EPC capture stents
have been developed using immobilized antibodies targeted
at EPC surface antigens. The HEALING-FIM (Healthy
Endothelial Accelerated Lining Inhibits Neointimal
Growth-First In Man) registry is the first clinical investi-
gation using this technology.
METHODS
Patient selection. The HEALING-FIM registry is a
single-center, prospective, non-randomized registry trial.
Patients were eligible if they were between ages 18 and 85
years and had a diagnosis of stable or unstable angina or
silent ischemia. Additional eligibility criteria were the pres-
ence of a single primary target lesion in a native coronary
artery that was 2.5 to 3.5 mm in diameter that could be
covered by a single trial stent (13 mm or 18 mm length), a
stenosis of 51% to 99% of the luminal diameter as estimated
visually, and a flow rate of grade 1 or higher according to the
classification of the Thrombolysis In Myocardial Infarction
(TIMI) trial. Patients were not eligible for enrollment if
they had an evolving myocardial infarction; stenosis of the
left main coronary artery; a lesion located at an ostial
location; a calcified lesion that could not be completely
dilated before stenting; angiographically visible thrombus
within the target lesion; a left ventricular ejection fraction of
�30%; or an intolerance of aspirin, clopidogrel, ticlopidine,
heparin, stainless steel, or contrast material. The trial was
reviewed and approved by the ethics review committee, and
written informed consent was obtained from all patients.
Study device: EPC capture stent. The EPC antibody
surface consists of a covalently coupled polysaccharide
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intermediate coating with murine monoclonal anti-human
CD34 antibodies, attached to a stainless steel stent (R stent,
OrbusNeich, Fort Lauderdale, Florida) (Fig. 1). This anti-
body specifically targets CD34� cells (endothelial pro-
genitor cells are CD34 positive) in the vascular circula-
tion. This device was supplied in aqueous sodium azide
solution as a preservative to maintain bioactivity and
required hand crimping by the operator onto a percuta-
neous transluminal coronary angioplasty balloon catheter
before implantation.
Study procedures. Lesions were treated according to local
standard interventional techniques. Specifically, the decision
to predilate or direct stent was at the investigator’s discre-
tion, and post-dilation was performed as required to ensure
that the residual stenosis was �20% by visual assessment,
with a TIMI flow grade rate 3. In case of a dissection or
incomplete coverage of the lesion, implantation of addi-
tional EPC capture R stents was permitted.
Intravenous boluses of heparin were administered to
maintain an activated clotting time �300 s during the
implantation. Treatment with aspirin, at a dose of at least 80
mg/day, was initiated at least 12 h before the procedure and
continued for one month. In addition, a loading dose of 300
mg of clopidogrel was administered before the procedure,
followed by 75 mg daily for 28 days. Glycoprotein IIb/IIIa
inhibitors were used at the operator’s discretion. Angio-
graphic success was defined as the successful implantation of
the study device, with a stenosis of �20% of the vessel
diameter with TIMI flow grade 3.
Follow-up. All patients were scheduled for a clinical
follow-up at one, six, and nine months following the
implantation procedure to assess the anginal status and
the occurrence of major adverse cardiac and cerebrovas-
cular events (MACCE). An electrocardiogram was ob-
tained at each visit, and an angiographic and intravascular
ultrasound (IVUS) study was performed at a mean of 185
� 14 days.
Quantitative angiographic and IVUS analysis. Coronary
angiograms were obtained in multiple views after an intra-
coronary injection of nitrates. Offline quantitative analyses
of preprocedural, postprocedural, and six-month follow-up
angiographic data were performed. Restenosis was defined
as a reduction of 50% or more of the luminal diameter. Late
luminal loss was defined as the difference between the
minimal luminal diameter after procedure and at six
months. The target lesion was defined as the stented
Abbreviations and Acronyms
EPC � endothelial progenitor cell
HAMA � human antimurine antibody
HEALING-FIM � Healthy Endothelial Accelerated
Lining Inhibits Neointimal
Growth-First In Man
IVUS � intravascular ultrasound
MACCE � major adverse cardiac and
cerebrovascular events
MI � myocardial infarction
SMC � smooth muscle cell
TIMI � Thrombolysis In Myocardial
Infarction
Figure 1. Endothelial progenitor cell (EPC) capture coating technology.
1575JACC Vol. 45, No. 10, 2005 Aoki et al.
May 17, 2005:1574–9 First Human Experience of EPC Capture Stent
color figures on page 224
163
First human experience of EPC capture stent 
segment plus the 5-mm segments proximal and distal to the
stented segment.
Intravascular ultrasound was performed with an auto-
mated pullback at 0.5 mm/s to examine the target lesion at
postprocedure and six-month follow-up. Lumen, stent, and
external elastic membrane contours were detected with the
use of CUARD QCU analysis software (CUARD BV,
Wijk Bij Duurstede, the Netherlands), applying a three-
dimensional reconstruction as described elsewhere (7).
Study end points. The primary safety end point of this
study was the absence of stent thrombosis up to six months.
The second end point was a composite of MACCE, defined
as cardiac death, stroke, Q-wave or non–Q-wave myocardial
infarction (MI), and target vessel revascularization. Stroke
was defined as a focal neurologic deficit resulting from a
vascular cause involving the central nervous system. Q-wave
MI was defined as development of new abnormal Q waves
not present on the patient’s baseline. Non–Q-wave MI was
defined as a creatine kinase of more than twice the upper
limit of normal with an abnormal level of the MB isoen-
zyme of creatine kinase. The efficacy end point was late
luminal loss as determined by quantitative coronary angiog-
raphy and % stent volume obstruction by IVUS at six
months. Stent thrombosis was angiographically docu-
mented as a complete occlusion (TIMI flow grade 0 or 1) or
a flow-limiting thrombus (TIMI flow grade 1 or 2) of a
previously successfully treated artery.
Detection of human antimurine antibody (HAMA).
Human antimurine antibody testing was not added to the
study until several patients had already returned for follow-
up. Testing with baseline data was conducted on 4 of 16
patients. The HAMA was determined by a commercially
available enzyme-linked immunosorbent assay kit (ME-
DAC, Hamburg, Germany) (8). A positive assay was
defined as �10 ng/ml. Significant levels of HAMA were
defined as �150 ng/ml.
Histology. One specimen was retrieved by directional
atherectomy (Flexi-cut, Guidant Europe SA, Diegem, Bel-
gium), fixed in 4% buffered formaldehyde with metal stent
fragments removed and embedded in paraffin.
Sections were stained with hematoxylin eosin and an
elastin stain (Resorcin Fuchsin) for general assessment of the
tissue. Cellular characterization was performed with immu-
nocytochemistry, using antibodies against smooth muscle
(specific alpha-actin), leukocytes (CD45), macrophages
(mac 387), proliferation cells (Mib 1), and EPC (CD34).
All antibodies except anti-CD34 were obtained from
DAKO (DakoCytomation, Produktionsvej, Denmark).
Statistical analysis. Because of the size of the patient
population in this nonrandomized registry, no formal sta-
tistical analysis was conducted to determine the efficacy of
the device. Continuous variables are expressed as mean �
SD. Comparisons between postprocedure and six-month
follow-up values were performed with a two-tailed paired t
test. A p value�0.05 was considered statistically significant.
RESULTS
Baseline characteristics and procedural outcome. Over-
all, 16 patients were enrolled in the HEALING-FIM
registry between May and November 2003. Table 1 presents
the baseline characteristics and procedural outcomes for this
patient population. A second overlapping stent was im-
planted in two patients to treat a dissection following
implantation of the first stent.
Clinical outcome. Table 2 provides an overview of the
MACCE at one and nine months. There was no subacute
thrombosis or MACCE in the first month after implanta-
tion. During the first nine months, MACCE occurred in a
patient with insulin-dependent diabetes with diabetic ne-
phropathy. This patient (#12) was admitted with a non–
ST-segment elevation MI (maximum creatinine kinase level
was 524 U/l) at six months after the index procedure and
underwent recatheterization that demonstrated focal in-
stent restenosis with TIMI flow grade 3 and no visible
contrast detect, which could have been caused by stent
thrombosis. No MACCE was reported in other patients.
Six-month angiographic and IVUS results in stented
segment. Scheduled coronary angiography at six months
was performed in 15 patients (93.8%). The patient who
refused angiography was asymptomatic. At six months,
mean late luminal loss was 0.63 mm on quantitative
Table 1. Baseline Characteristics and Procedural Outcomes,
Patients (n � 16)
Men 11 (69%)
Age (yrs) 68 � 10
Diabetes 5 (31%)
Hypertension 12 (75%)
Hypercholesterolemia 12 (75%)
Family history 6 (38%)
Current smoking 4 (25%)
Unstable angina 8 (50%)
Target coronary artery
LAD 8 (50%)
RCA 5 (31%)
LCX 3 (19%)
Lesion type
A 8 (50%)
B1 6 (38%)
B2 2 (13%)
C 0 (0%)
Angiographic features
Lesion length (mm) 10.6 � 4.0
Reference vessel diameter (mm) 2.63 � 0.30
Minimal luminal diameter (mm) 0.95 � 0.33
Diameter stenosis (%) 63.7 � 11.9
Procedural outcomes
Mean stent diameter (mm) 3.3 � 0.3
Mean stent length (mm) 18.4 � 6.4
Overlapping stenting 2 (13%)
Post dilation 8 (50%)
Direct stenting 2 (13%)
Use of glycoprotein IIb/IIIa inhibitor 3 (19%)
Angiographic success 16 (100%)
LAD � left anterior descending; LCX � left circumflex; RCA � right coronary
artery.
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coronary angiography and percent stent volume obstruction
was 27.2% on IVUS (Table 3). Binary restenosis occurred in
two patients (13.3%). Restenosis was focal in one patient
and diffuse in the other. In the case of the patient with
diffuse restenosis (case #4), the patient had no symptoms
and a percent diameter stenosis was 58% at six months. This
patient did not undergo repeat revascularization. Focal
restenosis occurred in an insulin-dependent patient (case
#12). This patient was subsequently treated with directional
coronary atherectomy and implantation of a paclitaxel-
eluting stent. Intravascular ultrasound analysis revealed
incomplete stent apposition in one patient (6.3%), which
had resolved at six months. Furthermore, no late-acquired
incomplete stent apposition was observed for the entire
patient population.
Histology of the atherectomy specimen. Histologic anal-
ysis showed tissue consisting of a mixture of myxoid and
fibrous material with variable cell density. Some of the
fibrous pieces showed a paucity of cells. The myxoid
fragments consisted of smooth muscle cells (SMCs) within
variable amounts of proteoglycan (Figs. 2A to 2C). Some
thrombus remnants were seen and assessed to be several
days old (Figs. 2D and 2E, no SMCs, only some nuclei),
presumably related to the small MI. The atherectomy
specimens included metal stent fragments. That indicates
that the plaques behind the stent struts were included in the
specimens. There were large areas of calcification in both
the fibrous and myxoid tissue (Fig. 2F), presumably old
plaque, as these were also observed with IVUS. Immuno-
cytochemistry (Figs. 2C and 2E) shows that most cells were
SMC-alpha-actin positive. Mib-1 (proliferation), Mac387
(macrophages), and CD34 were negative. There were only a
few CD45-positive cells (leukocytes).
HAMA test results. The HAMA testing was conducted
on a subset of the population (last four consecutive patients).
A positive assay due to the treatment with the study device
was not observed in these patients.
DISCUSSION
This study is the first clinical experience with implantation
of a bioengineered stent. The results of the HEALING-
FIM registry show that the EPC capture stent is safe and
feasible: with no stent thrombosis (30 days or 6 months),
and MACCE occurred in only one patient (6.3%), despite
only 30 days of clopidogrel therapy.
This clinical registry was preceded by several experimen-
tal studies. In an in vivo study, at 1 h after deployment the
EPC capture stent showed a �90% cell coverage, while the
bare stainless steel stents were almost completely devoid of
cells. Histologic analysis at 31 days showed that percent area
luminal stenosis was significantly reduced with the EPC
capture stents compared with stainless steel stents (15.49 �
4.54% vs. 23.96 � 7.70%, p � 0.01) (9).
These preclinical and preliminary clinical results have to
be interpreted carefully, considering the recent emergence of
new technologies such as drug-eluting stents. Drug-eluting
stents inhibit the inflammatory and proliferative process of
the normal healing response, including the formation of a
confluent endothelial layer on the stent (3). The EPC
capture stents induce the rapid establishment of a functional
endothelial layer early in the healing response. In this
registry, the atherectomy specimen indicated a well-healed
artery with minimal inflammation.
Of note, the neointimal hyperplasia in the EPC capture
coating stents was not significantly reduced when compared
with the usual late loss seen after conventional bare metal
stent implantation. It has been argued that EPC capture
coating covers only the stent struts, and theoretically no
Table 2. Clinical Outcomes at 1 Month and 9 Months
Death
Within 1 month 0%
9 months 0%
Stroke
Within 1 month 0%
9 months 0%
Q-wave MI
Within 1 month 0%
9 months 0%
Non–Q-wave MI
Within 1 month 0%
9 months 6.3% (1/16)
TVR
Within 1 month 0%
9 months 6.3% (1/16)
MACCE
Within 1 month 0%
9 months 6.3% (1/16)
Stent thrombosis
Within 1 month 0%
9 months 0%
MACCE � major adverse cardiac and cerebrovascular events; MI � myocardial
infarction; TVR � target vessel revascularization.
Table 3. Serial Quantitative Analysis of the Stented Segment by
QCA and IVUS (n � 15)
Post
6-Month
Follow-Up
p
Value
QCA
RVD (mm) 2.71 � 0.31 2.69 � 0.32 0.738
MLD (mm) 2.47 � 0.29 1.84 � 0.56 0.0004
%DS 8.5 � 3.4 32.1 � 16.7 0.0001
Stent thrombosis (%) 0%
Late loss (mm) 0.63 � 0.52
Loss index 0.45 � 0.39
Binary restenosis 13.3% (2/15)
IVUS
Vessel volume (mm3) 336.5 � 86.7 339.9 � 88.9 0.583
Stent volume (mm3) 173.5 � 44.9 175.0 � 42.6 0.715
Plaque behind stent
volume (mm3)
163.0 � 56.6 165.0 � 62.9 0.371
Neointima volume (mm3) 51.7 � 47.8
% in-stent obstruction 27.2 � 20.9
In-stent malapposition 6.7% (1/15) 0%
DS � diameter stenosis; IVUS � intravascular ultrasound; MLD � mean luminal
diameter; QCA � quantitative coronary angiography; RVD � revascularized vessel
diameter.
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early functional endothelial lining can be expected in the
interstrut space, although the interstrut area in the animal
model (healthy coronary artery undergoing direct stenting)
was covered with functional endothelium within 48 h; this
situation differs substantially from a human pathologic
atherosclerosis vessel after balloon injury. In addition, the
bioactivity of these prototype EPC capture stents used in
HEALING-FIM registry was unstable and was easily
reduced by sterilization with gamma irradiation. It was
subsequently discovered through the use of a bioassay that
gamma irradiation lessened the immunoaffinity of EPC
capture prototype stents used in this trial. Therefore, it is
likely that the reduced bioactivity of EPC capture stents in
the HEALING-FIM registry may not have been enough to
inhibit neointimal hyperplasia after stent implantation.
The technology behind the creation of an EPC affinity
surface is achieved by attaching murine monoclonal antihu-
man CD 34 antibodies to the stent. An immunoreaction
against the murine monoclonal antibody may occur in
patients who have human ant-murine antibody (HAMA).
In addition, production of HAMA may result in the
neutralization of the EPC capture surface. In this registry,
increased HAMA levels were not observed in the four
patients who underwent serial HAMA testing, and no
patients exhibited systemic symptoms of immunoreaction.
This safety issue was in agreement with other trials, evalu-
ating immunologic treatment using murine antibody for
ovarian cancer (10).
Because of the small sample size and single-center en-
Table 4. Evolution of Endothelial Progenitor Cell Capture
Stent: Improvement From HEALING-FIM (H1) to
HEALING II (H2)
Device
H1 - Wet, hand-crimped
H2 - Dry, premounted
Stability
H1 - Wet; supplied in sodium azide preservative; required rinsing
before use
H2 - Dry, formulated to preserve antibody structure & activity
Sterilization
H1 - Gamma irradiation; 15 to 25 kGy
H2 - Gamma irradiation; �15 kGy
Bioactivity
H1 - Significant reduction in activity with sterilization
H2 - Stable with sterilization
Figure 2. Overview (A) and details (left: B, C; mid:D, E; right: F) of the atherectomy specimen obtained six months following stent placement. Histology
shows a mixture of myxoid (B, C) and fibrous material (F) consisting of smooth muscle cells (C, E) within variable amounts of extracellular matrix. Some
fragments contained thrombus remnants (Th) (D, E) and calcifications (Ca) (F). A � elastin stain; B, D, F� hematoxylin eosin; C, E �
immunocytochemistry for smooth muscle cell-specific alpha actin.
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rollment, the present study did not fully evaluate the efficacy
of this device. However, further developments in this
technology, such a providing a dry stent premounted on a
delivery system and maintaining good activity post-
sterilization, are currently being evaluated in the
HEALING-II registry (Table 4). The technology for pre-
serving antibody structure and bioactivity has advanced,
resulting in a higher capture of EPCs (Fig. 3). As a result of
these improvements, further clinical investigation of this
technology is warranted to evaluate the efficacy of this device
for the treatment of coronary artery disease.
Conclusions. The present study demonstrates that the
EPC capture stent is safe and feasible. Further study and
development of this promising technology are needed to
confirm the clinical efficacy of this bio-engineered stent.
Reprint requests and correspondence: Dr. Patrick W. Serruys,
Thoraxcenter, Bd 406, Erasmus Medical Center, Dr. Molewater-
plein 40, 3015 GD Rotterdam, the Netherlands. E-mail: p.w.j.c.
serruys@erasmusmc.nl.
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Figure 3. Endothelial progenitor cell capture stent bioactivity (in vitro).
The cell-binding activity of the HEALING-FIM and HEALING-II
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stents were exposed to a suspension of human CD34� cells (kg-1a cells,
American Type Culture Collection) for 1 h with agitation. Excess cells are
removed and bound cells are tagged with a fluorescent nuclear stain (DAPI,
4=6-diamidino-2-phenylindole). After rinsing, the stents were placed in a
microplate for analysis in a fluorescent plate reader. The number of cells
bound was calculated by interpolation from standard curve on the same
plate.
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Despite the advances in the treatment of patients with
coronary artery disease, sudden cardiac death is still
unacceptably prevalent. Patients with ischemic heart 
disease usually require a combination of therapies (drugs
and coronary intervention) and may continue to experien-
ce symptoms. 
Recently, numerous percutaneous interventional treat-
ments and diagnostic tools have been developed to diag-
nose the vulnerable plaque and to treat the large number
of patients with myocardial ischemia. Ongoing research
on the use of drug eluting stents, catheter based bypass
graft (percutaneous approaches that use the adjacent ve-
nous circulation to bypass an obstructed artery and stent-
based approach for ventricle to coronary artery bypass),
therapeutic angiogenesis and myogenesis, and the cathe-
ter based devices to detect the plaque vulnerability and
composition (lipid-rich atheromatous core, thin fibrous
cap, and expansive vessel remodeling) may result in ad-
ditional diagnostic and therapeutic options for patients
with coronary artery disease. 
Key words: Percutaneous coronary bypass. Angioge-
nesis. Myogenesis. Vulnerable plaque.
INTRODUCTION
In-stent restenosis has long been considered the
main limitation hampering the long-term efficacy of
coronary stenting. However, use of drug eluting stents,
such as sirolimus eluting stents (Cypher) and paclita-
xel eluting stents (TAXUS), are associated with
markedly reduced restenosis rates in several random-
ized trials and registries.1-4 Drug eluting stents are now
used in a majority of intracoronary stenting proce-
dures. Nevertheless, in-stent restenosis still occurrs in
some patients and some specific problems, such as
late thrombosis after discontinuation of antiplatelet
therapy has been reported.5
Recently, other approaches to treat the coronary
artery disease have been introduced. Percutaneous ap-
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Estrategias emergentes en cardiología
intervencionista
A pesar de los avances que se han efectuado en el tra-
tamiento de los pacientes con enfermedad coronaria, los
cuadros de muerte súbita por causa cardíaca tienen toda-
vía una prevalencia inaceptable. Los pacientes con car-
diopatía isquémica requieren habitualmente la combina-
ción de distintas formas de tratamiento (fármacos e
intervención coronaria), a pesar de lo cual pueden seguir
presentando sintomatología. 
Recientemente, se han desarrollado numerosas formas
de tratamiento mediante intervención percutánea y distin-
tas herramientas diagnósticas que permiten la detección
de las placas vulnerables y el tratamiento del elevado nú-
mero de pacientes que presentan isquemia miocárdica.
La investigación actual respecto al uso de endoprótesis
con capacidad de liberación de fármacos, bypass corona-
rio efectuado con catéteres (abordajes percutáneos en
los que se utiliza la circulación venosa adyacente para re-
vascularizar la arteria obstruida, así como el abordaje
mediante endoprótesis para la conexión entre el ventrícu-
lo y la arteria coronaria), los abordajes terapéuticos de
angiogénesis y miogénesis, y las técnicas intracoronarias
para la detección de la vulnerabilidad y la composición de
las placas (placas ateromatosas con abundante core lipí-
dico, cubierta fibrosa fina y remodelado positivo), puede
facilitar opciones diagnósticas y terapéuticas adicionales
en los pacientes con enfermedad coronaria. 
Palabras clave: Bypass coronario percutáneo. Angio-
génesis. Miogénesis. Placas vulnerables.
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tics of TCFA lesions: large lipid core, thin cap (≤65
µm) and positive remodeling. Detection of these
non-obstructive, lipid rich, high-risk plaques may
potentially have an important impact in the preven-
tion of acute myocardial infarction and sudden
death.
CATHETER-BASED CORONARY BYPASS
Percutaneous in Situ Coronary Venous
Arterialization
Catheter based coronary bypass has evolved since
1995.14,15 Percutaneous approaches that use the adja-
cent venous circulation to bypass an obstructed artery
are being tested. In percutaneous in situ coronary ve-
nous arterialization (PICVA), a coronary artery is
connected to the adjacent vein at one site upstream
from the lesion, directing oxygenated blood flow into
the vein (Figure 2). The oxygenated blood then tra-
vels through the venous system in the reverse direc-
tion to perfuse the myocardium. In a percutaneous in
situ coronary artery bypass (PICAB), 2 channels are
created between the coronary artery and the adjacent
vein, one upstream and the other downstream from
the lesion (Figure 3). The blood enters the upstream
channel, flows through the isolated vein to bypass the
lesion, and re-enters the healthy segments of the
artery through the downstream channel. Oesterle et al
reported the initial clinical experience with PICVA.15
PICVA was attempted in eleven patients with severe
angina and no reasonable option for either angioplas-
ty or surgical revascularization. In 6 patients, the
adjacent vein could not be adequately targeted for
successful needle and wire delivery. PICVA was
successfully completed in 5 patients. Two of the 5
cases had catastrophic complications and died within
48 hr of the procedure. Of the remaining 3 cases, all
patients experienced an improvement in their anginal
symptoms. However, 3-month follow-up angiography
revealed a closed PICVA channel in 2 patients. After
this initial clinical experience, the system of devices
is currently undergoing significant modification (the
new imaging strategy and modified connecting and
blocking devices), and a further clinical study is un-
derway.
Stent-Based Approach for Ventricle 
to Coronary Artery Bypass
Alternative approach, also performed via sternoto-
my, is a ventricle to coronary artery bypass (VCAB).
In this procedure, a stent-based device (VSTENT) is
used to create a conduit between the left ventricle and
the left coronary artery, thereby increasing flow in the
coronary artery. The advantage of this approach is that
no grafting is necessary and it can be performed rapid-
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proaches that use the adjacent venous circulation to
bypass an obstructed artery and stent-based approach
for ventricle to coronary artery bypass are being tes-
ted. Therapeutic angiogenesis and myogenesis are also
being tested. Ongoing research on angiogenetic gene
therapies and stem-cell transfer may result in additio-
nal therapeutic options benefiting patients with myo-
cardial ischemia. 
Despite the advances in the treatment of patients
with coronary artery disease, sudden cardiac death is
still prevalent. Sudden cardiac death occurs in half of
all cardiac deaths and plaque rupture is the cause in
more than 70% of such deaths.6,7 In addition, silent
plaque rupture and its consequent wound healing ac-
celerate plaque growth and is a more frequent feature
in arteries with less severe luminal narrowing.8
It has been established that atherosclerotic plaque
composition is a key determinant of the fate of such
lesions.9 Lipid-rich necrotic cores occupying a large
percentage of the plaque are considered highly throm-
bogenic and prone to rupture.9,10 In addition, high le-
vels of free-cholesterol and cholesterol clefts are com-
mon features of ruptured plaques and its most
prevalent predecessor, the thin-cap fibro atheroma
(TCFA) (Figure 1).6,11
A previous study of a large series of sudden death
patients showed the presence of ruptured TCFA as
the underlying cause of 60% of acute thrombi. Fur-
thermore, 70% of those patients presented additional
TCFAs without overlying rupture.12 Several novel in-
vasive imaging techniques have been developed with
the intention to identify one of more features of
TCFA.13 Such techniques target the main characteris-
Figure 1. Thin-cap fibro atheroma (TCFA). TC indicates thin fibrous
cap; NC, Large necrotic lipid core.6
(Reprinted with permission of Lippincott Williams & Wilkins.)
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ly. Only one experimental revascularization procedure
has been reported.16
RETROGRADE PERFUSION
Synchronized retroinfusion with arterial blood to
coronary veins was able to partially reduce myocar-
dial ischemia in patients undergoing percutaneous
coronary angioplasty (PTCA).17 In general, patients
with left main stenosis or left main-equivalent steno-
sis are considered to be at high risk for PTCA. Pohl
et al reported on the 1-year results of a prospective
randomized single center study (Myoprotect I) in 44
patients with symptomatic left main or left main-
equivalent lesions, who were randomly assigned to
the stent group (n=23) or the bypass group (n=21).18
In all patients randomized to percutaneous treatment,
selective pressure-regulated retroperfusion of arterial
blood into the anterior cardiac vein was applied du-
ring ischemia. Twenty-eight-day mortality and 1-year
mortality rate as well as quality of life scores were
Figure 2. Percutaneous in situ coronary venous arterialization (PIC-
VA).15
(Reprinted with permission of John Wiley & Sons Ltd. All Rights Re-
served.)
Figure 3. Percutaneous in situ coronary artery bypass (PICAB).15
(Reprinted with permission of John Wiley & Sons Ltd. All Rights Re-
served.)
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similar in both groups. Though event free survival
was lower and target lesion revascularization rate was
higher in the stent group, retroperfusion-supported
stent implantation was associated with substantially
lower costs and might be considered as an alternative
treatment option in the selected group of high-risk
patients.
THERAPEUTIC ANGIOGENESIS 
AND VASCULOGENESIS
Chronic imbalances of myocardial oxygen supply
and demand produced by a coronary artery stenosis or
occlusion have been shown to increase growth of the
coronary collateral circulation. Angiogenesis and vas-
culogenesis are adaptive responses of the coronary
collateral circulation to myocardial ischemia.
Therapeutic angiogenesis and vasculogenesis,
which involves the administration of angiogenic
growth factors, cytokines or stem cells to stimulate
collateral formation and improve myocardial perfu-
sion, is being tested as an alternative strategy for pa-
tients with medically intractable angina who are not
candidates for mechanical revascularization therapies
(Figure 4). 
Angiogenic Cytokines
Preclinical studies have established a foundation for
rational development of therapeutic angiogenesis.20-23
A variety of growth factors and chemokines convin-
cingly increase the formation of small blood vessels in
experimental models. Most clinical trials to date in-
volve transfer of vascular endothelial growth factor
(VEGF) or fibroblast growth factor (FGF) by several
delivery strategies (Figure 5).24
Protein Transfer
With the advent of recombinant DNA technology,
large quantities of purified proteins can be pro-
duced for therapeutic use (Table 1).25 Advantages
of locally administering purified angiogenic factors
include easy dose titration, repeat administration if
necessary, and rapid metabolism to prevent
toxicity.25 The primary disadvantages have been
either a lack of efficacy in placebo-controlled stu-
dies or a need for administration during coronary
artery bypass graft (CABG). Methods combining
angiogenic proteins with slow-release systems are
in development. 
Exogenous
Administration
EPC Bone
Marrow
Peripheral
Blood
Endothelium
Target
Organs
Proliferation
Differentiation
Mobilization
Circulation
Recruitment
Growth factors
Cytokines
Hormones
Endogenous
Constitutive or
Ischemia-Induced
Vasculogenesis
in Situ EPC
Differentiation and
Proliferation
Antiogenesis
EC Sprouts From
Pre-Existing Blood 
Vessel
Figure 4. Growth factors, cytokines, or hor-
mones released endogeneously in response
to tissue ischemia, or administered exoge-
nously for therapeutic neovascularization, act
to promote endothelia progenitor cell (EPC)
proliferation, differentiation, and mobilization
from bone marrow (via the peripheral circula-
tion) to neovascular foci.19
(Reprinted with permission of Journal of Cli-
nical Investigation.)
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Gene Therapy
Gene therapy is an approach in which the genetic
material directing production of a protein is trans-
ferred in place of the protein itself. A number of ve-
hicles are used for transferring DNA to heart tissue,
including purified DNA, DNA/lipid complexes, ade-
no-associated viruses, or adenovirus.24,25 An advan-
tage of this approach appears to be localized, sus-
tained but not indefinite production of angiogenic
factors.26 Apparent disadvantages are the possibili-
ties of vector toxicity, an immune response to the
gene therapy vector, or inappropriately localized
gene transfer resulting in angiogenesis in a tumour
or the retina. 
The efficacy of gene transfer approaches to thera-
peutic angiogenesis is now being tested in clinical
trials (Table 2).25,27-33 Early uncontrolled open-label
clinical trials generally gave positive results, al-
though the possibility of a placebo effect was not ex-
cluded. Controlled Phase II trials are providing posi-
tive but not definitive results. This is promising, since
the patient population being studied has failed all
other therapies and is likely to be refractory to inter-
vention. However, most of the efficacy measures
studied to date are surrogate endpoints such as exer-
cise tolerance time (ETT), angina, or perfusion.
While these measures are useful in suggesting clini-
cal efficacy, hard clinical endpoints such as mortality,
myocardial infarction (MI) and the need for revascu-
larization should be studied. Long-term follow up
data are also necessary. An important observation is
that the safety results of these trials indicate no major
problems. Potential side-effects such as worsening of
atherosclerosis, retinopathy or cancer, have not been
observed in clinical trials.
Two large Phase III clinical trials (AGENT 3 and 4)
were designed to evaluate further the safety and effica-
cy of Ad5FGF4.31 Both trials were designed as ran-
domized, double blind and placebo controlled trials. In
each trial, a recruitment goal was 450 patients and
these patients would be randomized to 3 groups
(placebo group, Ad5FGF-4 at a dose of 109 vp group,
and Ad5FGF-4 at a dose of 1010 vp group). In January
2004, enrollment was stopped (416 patients in AGENT
3 and 115 patients in AGENT 4) because interim data
analysis of AGENT 3 indicates that the studies will
provide insufficient evidence of efficacy. However, en-
rolled patients’ follow-up continues and final data will
be presented in the near future. 
Cell Based Therapy
Another alternative method for increasing coronary
vascularization is the transplantation of stem or pro-
genitor cells.34,35 These cells not only produce a variety
of growth factors and cytokines, but participate struc-
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turally in the formation of new vascular tissue and
myocyte. 
The promising results from experimental studies
promoted the initiation of clinical trials.36,38 Stem and
progenitor cells are being tested in patients with both
acute myocardial infarction and chronic ischemic
heart failure (Table 3 and 4).35,39-46 Improved wall mo-
tions or increased perfusion was demonstrated in
most of study patients. However, BOOST is the sole
randomized controlled clinical trial.42 Sixty patients
with ST-segment elevation myocardial infarction
Figure 5. Clinical feasible gene delivery routes.25
(Reprinted with permission of Nature Publishing Group.)
Intracoronary Inyection 
Angioplasty
Epicardial
Inyection
Epicardial
Inyection
Intraventricular
Inyection
Adventitial Delivery.
Cell Grafting or
ex Vivo Treatament of
Bypass Grafts
TABLE 1. Proteins That Stimulate Angiogenesis in
Preclinical Studies*,25
Growth factors
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PLGF
FGF-1, FGF-2, FGF-4, FGF-5
Angiopoietin-1, Angiopoietin-2
HGF, PDGF-BB
GM-CSF, neurotropin
IGF-1, IGF-2
Chemokines
MCP-1
Transcription factors
HIF-1, Egr-1, Prox-1
Others
Del-1,Cyr 61, PR39
Tissue kallikrein, Secreted frizzled-related protein
eNOS, iNOS
*VEGF indicates vascular endothelial growth factors. PLGF, placental growth
factors; FGF, fibroblast growth factors; HGF, hepatocyte growth factors;
PDGF, platelet derived growth factors; GM-CSF, granulocyte macrophage co-
lony stimulating factors; IGF, insulin like growth factors; MCP, monocyte che-
motactic protein; HIF, hypoxia inducible transcription factors; Egr-1, early
growth response factor-1; Prox-1, prospero-related homeobox-1; Del-1, deve-
lopmentally regulated endothelial cell locus-1; Cyr 61, cysteine-rich angioge-
nic inducer 61; PR 39, praline and arginine-rich peptide; eNOS, endothelial ni-
tric oxide synthetase; iNOS, inducible nitric oxide synthetase.
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were randomly assigned to either a control group that
received optimum post infarction medical treatment,
or a bone-marrow-cell group that received optimum
medical treatment and intracoronary transfer of au-
tologous bone marrow cells 4.8 days after percuta-
neous coronary intervention (PCI). After 6 months,
mean global left ventricular ejection fraction (LVEF)
had significantly increased in the bone-marrow-cell
group, compared to the control group. However, most
studies at present are limited by the small patient en-
rolment, and recently some papers reported that
bone-marrow-derived haematopoietic stem cells do
not transdifferentiate into cardiac myocytes in is-
chemic myocardium.47,48
PERCUTANEOUS MYOBLAST
TRANSPLANTATION 
Most preclinical experience has been reported on
transplantation of skeletal myoblasts in infarcted myo-
cardium.49-52 These studies demonstrated that trans-
planted skeletal myoblasts in damaged myocardium
are capable of cellular engraftment, myotube forma-
tion, and long-term graft survival. Several clinical per-
cutaneous myoblast transplantation trials, using both
the transendocardial and the transvenous approaches,
have been reported.
Transendocardial Approach
A pilot safety and feasibility study on percutaneous
transplantation of autologous skeletal myoblasts by
transendocardial injection in five patients with is-
chemic heart failure was reported by the group of Rot-
terdam.50 Autologous skeletal myoblasts were obtained
from the quadriceps muscle and cultured in vitro for
cell expansion. With a NOGA®-guided catheter sys-
tem, 196±105 million cells were transendocardially in-
jected into the infarcted area. After 3 months, LV ejec-
tion fraction increased and regional wall analysis by
magnetic resonance image (MRI) showed significant
increased wall thickening at the target area. In the light
of these preliminary favourable results, a multicenter
European uncontrolled investigation has been started.
Overall, 15 patients have been enrolled and treated
with transendocardial skeletal myoblasts injection.
TABLE 2. The Result of Controlled Phase II Clinical Trials Testing Angiogenic Factors to Treat Coronary Heart
Disease*,25
Trial Therapeutic Agent No. End Point Results
VIVA27 Recombinant VEGF protein 178 ETT (60 days) Negative
FIRST28 Recombinant FGF-2 protein 337 ETT (90 days) Negative
GM-CSF29 Recombinant GM-CSF protein 21 Invasive collateral flow index 
(2 weeks) Positive
AGENT30 Adenovirus-FGF-4 79 ETT (4 weeks) Positive
AGENT II 31 Adenovirus-FGF-4 52 MPI (8 weeks) Positive
KAT 32 Adenovirus-VEGF 165  103 MPI (6 months) Positive
Plasmid/liposome
VEGF165 (Adeno only)
Euroinject One 33 Plasmid VEGF165 74 MPI (3 months) Negative
*VEGF indicates vascular endothelial growth factors; FGF, fibroblast growth factors; ETT, exercise tolerance time; MPI, myocardial perfusion improvement.
TABLE 3. Stem/Progenitor Cell Therapy (Intracoronary Application) in Patients With Acute Myocardial
Infarction*,35
Reference Cell Type Patients Results
Strauer et al39 BMC (40 mL) versus control n=10 Hypokinetic area (LVA) ↓, contractility infarct 
region ↑, end-systolic volume ↓,
perfusion (tallium scintigraphy) ↑
TOPCARE-AMI40,41 BMC (50 mL) versus CPC (250 mL) n=20 Global and regional EF (LVA, echo, MRI) ↑,
end-systolic volume , viability 
(PET, MRI) ↑, coronary flow reserve ↑
BOOST (prospective BMC (120 mL) versus CONTROL n=30 EF (MRI) ↑
and randomised)42
*BMC indicates bone marrow cell; CPC, circulating progenitor cell; LVA, left ventricular angiogram; EF, ejection fraction; MRI, magnetic resonance image; PET, po-
sitron emission tomography.
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The results of this study will be presented in the near
future.
Transvenous Approach
A novel catheter-based endovascular system for di-
rect myocardial injection using IVUS guide needle
punctures via the coronary venous system (the
TRANSAccessTM) has been developed (Figure 6).53 In
the POZAN trial, 10 patients underwent intramyocar-
dial injection by using the TRANSAccess.54 The pro-
cedure was not successful in one patient but NYHA
class improved in all patients and ejection fraction in-
creased 3%-8% in 6 out of 9 cases during 6 month fol-
low-up.
Ventricular Arrythmia
After intramyocardial injection of skeletal myo-
blasts, ventricular arrhythmia was reported. Menasche
et al52 reported that implantable cardioverter-defibrilla-
tor (ICD) implantation for ventricular arrythmias was
required in 4 out of 10 patients after open chest autolo-
gus myoblast transplantation.50,52 One of the 5 patients
who were enrolled in the study on percutaneous
transplantation of autologous skeletal myoblasts by
transendocardial approach had also sustained episodes
of ventricular tachycardia and required ICD. This is
probably related to: a) heterogenecity of action poten-
tials between the native and the transplanted stem cells;
b) intrinsic arrhythmia potential of injected cells; c) in-
creased nerve sprouting induced by stem cell injection;
and d) local injury or edema induced by myocardial
puncture and inflammatory response.
FUTURE PERSPECTIVES TOWARDS
INVASIVE DETECTION OF VULNERABLE
PLAQUE
Lipid-Rich Atheromatous Core
IVUS provides an accurate tomographic view of the
coronary arteries and has shown a high correlation
with histology samples in in vitro validation studies.55-57
However, accurate plaque characterization with visual
interpretation of gray-scale IVUS, particularly of lipid
rich plaques, remains an unresolved issue.56 On the
contrary, spectral analysis of IVUS radiofrequency
data (IVUS-Virtual HistologyTM [IVUS-VH]) has
demonstrated potential to provide detailed quantitative
information on plaque composition and has been vali-
dated in studies of explanted human coronary seg-
ments (Figure 7).58
Angioscopic yellow plaques have been related to
atheromatous plaques in previous validation studies.59
However, this technique evaluates only the luminal
surface of the intima thus quantifiable values of lipid
core size are out of its scope. 
Raman spectroscopy is a technique that can cha-
racterize the chemical composition of tissues.60 In
vitro studies have demonstrated that diagnostic algo-
rithms allow the discrimination of coronary arterial
tissue in 3 categories: non-atherosclerotic, non-calci-
fied and calcified plaques.61 Nevertheless, this tech-
nique also lacks the ability to provide geometrical in-
formation of the vessel and has a shallow penetration
depth.
Intravascular ultrasound elastography and palpogra-
phy are techniques that allow the assessment of local
mechanical tissue properties (Figure 8).62,63 At a de-
fined pressure, soft tissue (lipid-rich) components will
deform more than hard components (fibrous-calci-
fied).64 However, they are unable to provide quantifia-
ble measurements of plaque components.
Finally, intravascular magnetic resonance (IVM-
RI) has recently emerged as a potential tool to iden-
tify TCFA since it can accurately determine the pre-
sence of lipid within the arterial wall.65,66 In vivo
feasibility remains to be proven and acquisition time
and extent of the scan analysis requires impro-
vement.
Thin-Fibrous Cap
The threshold to define the cap as “thin” has pre-
viously been set at <65 µm.67 However, it is well
TABLE 4. Stem/Progenitor Cell Therapy in Patients With Chronic Heart Failure*,35
Reference Cell Type Application Patients Results
Stamm et al43 CD133+BMC (85-195 mL) Injection during CABG n=6 EF in 4 patients (LVA) ↑, perfusion 
in 5 patients (SPECT) ↑
Tse et al44 BMC (50 mL) Intramyocardial/NOGA n=8 Wall motion and thickening ↑
Fuchs et al45 BMC Intramyocardial/NOGA n=10 Angina score and stress-induced 
ischemia improved
Perin et46 BMC (50 mL) Intramyocardial/NOGA n=14 EF ↑, end-systolic volume ↓
*CD indicates cluster of differentiation; BMC, bone marrow cell; CABG, coronary artery bypass grafting; EF, ejection fraction; LVA, left ventricular angiogram;
SPECT, single photon emission computed tomography; EF, ejection fraction.
en
T: tomo-
giogram;
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established that general tissue shrinkage can not be
avoided during dehydration.68 Shrinkage of up to
60%, 15% and 80% can occur during critical-point-
drying, free-drying, and air-drying respectively.69
Furthermore, post-mortem contraction of arteries fur-
ther contributes to deteriorate the pathological quan-
tification of atherosclerosis.70 Accordingly, we be-
lieve that the threshold should be higher than 65 µm.
Since the axial resolution of IVUS is between 100
and 150 µm, techniques such as IVUS-VH with the
capacity to quantify each plaque component and to
identify the location of the lipid core in relation to
the lumen have the potential to recognize all the 3
features of TCFA lesions.
Optical coherence tomography (OCT) is an imaging
technique that allows high-resolution (axial resolution
of 15 µm) imaging in biological systems (Figure 9).71
Accordingly, OCT has the capacity to allow in-vivo,
real time visualization of a thin fibrous cap. Recent in
vivo data suggest the possibility of detection of
macrophages in atherosclerotic plaques.72
The sensitivity and specificity of palpography to de-
tect vulnerable plaques has recently been assessed in
post-mortem human coronary arteries where vulnera-
ble plaques were detected with a sensitivity of 88%
and a specificity of 89%.63
Positive Remodeling
The expansive compensatory enlargement of the
coronary arteries in response to an increase in plaque
area is called positive or expansive remodeling.73
Several studies showed an increase in inflammatory
marker levels, larger lipid cores, and pronounced me-
dial thinning in positive remodeled vessels.74-76 Re-
cently, the relationship between vascular remodeling
and plaque composition was assessed using IVUS.77-79
In these studies, the remodeling index for soft lesions
Figure 6. Direct myocardial injection using IVUS guide needle punctu-
res via the coronary venous system.
Figure 7. Virtual histology image. Red: lipid core. White: calcium. Ye-
llow: fibrofatty. Green: fibrosis. Gray: media.
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Figure 8. Palpography image. Yellow,
high strain spot.
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was significantly higher than those for fibrous/mixed
and calcified lesions.77-79 Aside from gray-scale
IVUS, IVUS-VH can also accurately identify, as well
as lipid core size and TCFA, the geometry of the ves-
sel.
Pan-Coronary Syndromes
Several studies using angiography, IVUS, an-
gioscopy, and palpography identified a high inci-
dence of high-risk plaques throughout the coronary
tree.80-83 In the study conducted by Rioufol et al,81 at
least one plaque rupture was found away form the
culprit lesion in 80% of the patients, away from the
culprit artery in 71% and in the 2 non-culprit arteries
in 12.5%.81
Patients with acute myocardial infarction may pre-
sent additional complex non-infarct-related coronary
plaques. Furthermore, such multiple complex plaques
have been found independent predictors of future cli-
nical events.80
If the large number of high-risk plaques is detected
throughout the coronary tree by means of angiography,
angioscopy, IVUS, and palpography potential local
preventive strategies could not be cost-effective.8,80-83
On the contrary, a systemic “plaque stabilization” ap-
proach including statins or angiotensin converting en-
zyme (ACE) inhibitors could be capable of “cooling-
down” the inflammatory burden.84
CONCLUSIONS
Numerous percutaneous interventional treatments
and diagnostic tools have been developed to diagnose
the vulnerable plaque and to treat the large and in-
creasing number of patients with myocardial is-
chemia. The proliferation of these strategies, and the
need for multiple approaches in individual patients
indicate that the problem of myocardial ischemia is
not solved. Ongoing research on the use of drug elu-
ting stents, catheter based bypass graft, therapeutic
angiogenesis and myogenesis, and the catheter based
devices to detect the plaque vulnerability and compo-
sition may result in additional diagnostic and thera-
peutic options for patients with coronary artery dis-
ease.
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SUMMARY AND CONCLUSIONS
Part 1 Long term tissue growth inside and outside drug-eluting stent in humans
After drug-eluting stents (DES) implantation, vessel reaction inside and outside the stent 
is not identical. Chapter 2 presented vessel reaction after sirolimus-eluting stent (SES) 
implantation. In the first 2 years, the mean plaque volume and plaque compositional 
change expressed as mean percent (%) hypoechogenic tissue of the plaque behind the 
stent struts did not significantly change. However, significant plaque shrinking with an 
increase in plaque echogenicity was observed between 2 years and 4 years. The mean 
neointimal volume increased over 4 years. However no further statistically significant 
change occurred between 2 and 4 years. Chapter 3 showed that vessel reaction after 
paclitaxel-eluting stent (PES) implantation. Increased plaque outside the stent 6 months 
after PES implantation regressed completely in the slow release (SR) group and partially 
in the middle release (MR) group by 2 years. Neointimal suppression with both SR and MR 
PES is sustained up to 2 years. Whereas neointima decreased in the bare metal stent (BMS) 
group between 6 months and 2 years, neointima continued to increase in the SR and MR 
groups without impact on clinical events. Chapter 4 examined that vessel reaction after 
various doses and pharmacokinetic release of PES with an erodable polymer. Although 
type of polymer was different, vessel reaction inside and outside the stent was similar as 
PES with a durable polymer. Chapter 5 summarized vessel reaction after DES, including 
everolimus and ABT 578-eluting stents. Vessel reaction outside the stent was different 
between limus family (sirolimus, and everolimus) and paclitaxel. Significant expansive 
remodeling was observed only after paclitaxel release stents, but vessel regressed later 
time point. Neointima, in other words, vessel reaction inside the stent, regressed after 
implantation of BMS. However, neointima keeps growing after implantation of all kinds 
of DES. Although long term follow-up after DES implantation shows a sustained clinical 
benefit in several randomized trials, delayed neointimal growth beyond the first 6 to 9 
months has been reported in serial intravascular ultrasound system (IVUS) analyses in 
some trials. The issue of a delayed restenosis which was observed after brachytherapy 
has not been thoroughly evaluated with DES.
Part 2 Efficacy of drug-eluting stent for high risk patients
In the BMS era, long lesion, diabetes mellitus, let main coronary artery disease, chronic 
total occlusion, and bifurcation lesion are high risk for in-stent restenosis. Clinical effects 
of SES and PES on patients with these high risk factors were analyzed. In Chapter 6, 
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the medium-term clinical outcome and the potential for adverse effects when very long 
segments (i.e.≥64mm of stented length) were treated by DES implantation, an approach 
colloquially referred to as a “full metal jacket” were evaluated. The one-year target ves-
sel revascularization rate was 7.5% and the overall incidence of major adverse cardiac 
events was 18.0%. These results seemed better than full metal jacket, using BMS (The 
one-year target vessel revascularization rate was 21.6% and the overall incidence of ma-
jor adverse cardiac events was 38.0% in the historical control.) Outcomes in SES and PES 
groups did not differ statistically. In Chapter 7 and 8, patients with diabetes mellitus 
were evaluated. Routine utilization of SES for diabetic patients significantly reduced the 
rate of adverse cardiac events at 1 year compared to bare metal stents. (17.3% in the SES 
group versus 30.2% in the pre-SES group (hazard ratio, 0.54 [95% confidence interval, 
0.32-0.91]; p=0.02)) PES were associated with a nonsignificantly lower incidence of major 
adverse cardiac events at 1 year compared with SES (adjusted hazard ratio 0.68, 95% 
confidence interval 0.37 to 1.24, p = 0.21). Chapter 9 illustrated a patient with chronic 
total occlusion of left main coronary artery who was successfully treated with bifurcation 
stenting with SES. Chapter 10 and 11 analyzed patients with left main coronary artery 
disease, the cumulative incidence of major adverse cardiovascular events was lower in 
the DES cohort than in patients in the pre-DES group (24% versus 45%, respectively; haz-
ard ratio [HR], 0.52 [95% CI, 0.31 to 0.88]; P=0.01). Total mortality did not differ between 
cohorts; however, there were significantly lower rates of both myocardial infarction (4% 
versus 12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P=0.006) and target vessel re-
vascularization (6% versus 23%, respectively; HR, 0.26 [95% CI, 0.10 to 0.65]; P=0.004) in 
the DES group. PES may perform closely to SES both in terms of angiographic and long-
term clinical outcome, the cumulative incidence of major adverse cardiovascular events 
was comparable (25% in the SES vs. 29%, in the PES group; HR 0.88 [95% CI: 0.43-1.82]; 
p=0.74), reflecting similarities in both the composite death/MI (16% in the SES and 18% 
in the PES group) and target vessel revascularization (9% in the SES and 11% in the PES 
group). Angiographic in-stent late loss (mm) was0.32±74 in the main and 0.36±0.59 in 
the side-branch the SES vs. 0.46±0.57 and 0.52±0.42 in the PES, respectively (p=0.36 and 
p=0.41).In Chapter 12 and 13, we demonstrated the efficacy of DES implantation for the 
percutaneous treatment of chronic total occlusions when compared to BMS. Both SES 
and PES were associated with a low rate of target vessel revascularization. At one year, 
the survival-free of target vessel revascularization was significantly higher in the SES and 
PES groups compared with the BMS group (97.4% and 96.4% versus 80.8% respectively, 
p=0.01). Clinical and angiographic effects for patient with bifurcation lesions were ana-
lyzed in Chapter 14 and 15. Major adverse cardiac events (MACE) rates for both SES and 
PES were low compared with historical data of BMS. Our data suggests a higher need for 
target lesion revascularization for the PES compared with the SES, however further ran-
domized studies are needed to fully evaluate both stenting strategy, and any difference 
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between the stents (Survival-free of target lesion revascularization was 95.7% for SES 
versus 86.8% for PES, p=0.01.). Technique of stenting was not a predictor of either MACE 
or TLR. The most effective techniques for bifurcation stenting remain undefined.
Both SES and PES have almost similar clinical effect to reduce MACE compared to BMS, 
even if patients have high risk restenosis factors.
Part 3 Endothelial progenitor cell – alternative to drug-eluting stents
DES have dramatically reduced the incidence of in-stent restenosis. However, the inci-
dence of angiographic stent thrombosis in an unselected, complex DES population was 
1.0%, within the same range as the corresponding BMS population and concordant with 
previously published results from the BMS era. (Chapter 16) Other technology of re-
ducing the incidence of stent thrombosis is necessary to improve clinical outcome of 
coronary stenting. The acceleration of the endothelialization of stent is a key factor to 
reduce stent thrombosis. (Chapter 17) Recently, the existence of circulating endothelial 
progenitor cells (EPC) has been identified as a key factor for re-endothelialization. HEAL-
ING-FIM registry is the first clinical experience with implantation of a bio-engineered 
stent which is anti-CD34 coated stents, designed to capture circulating endothelial pro-
genitor cells. The results of the HEALING-FIM (Healthy Endothelial Accelerated Lining 
Inhibits Neointimal Growth - First In Man) registry showed that the EPC capture stent is 
safe and feasible: with no stent thrombosis (30 days or 6 months), MACE occurred in only 
one patient (6.3%), despite only 30 days of clopidogrel therapy. Further developments in 
this technology are warranted to evaluate the efficacy of this device for the treatment of 
coronary artery disease. (Chapter 18)
Part 4 Future direction to the interventional cardiology
Chapter 19 summarized that other approach for coronary artery disease, except DES. 
Ongoing research on catheter based bypass graft, therapeutic angiogenesis and myo-
genesis, and the catheter based devices to detect the plaque vulnerability and composi-
tion may result in additional diagnostic and therapeutic options for patients with coro-
nary artery disease.
In conclusion
Both SES and PES have significant effect to reduce major accident cardiac events, mainly 
due to reduce target lesion revascularization, even if patients have high risk factors for 
restenosis. Current issues of DES are long term effects of these devices and stent throm-
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bosis. Long-term follow-up after DES implantation shows a sustained clinical benefit in 
several randomized trials. In the intravascular ultrasound analyses of DES, neointima con-
tinued to increase without impact on clinical events. Although plaque outside the stent 
began to shrink beyond 1 year, longer term follow-up will be required to establish the 
natural history of local drug delivery by DES. In addition, the EPC capture stent which can 
rapidly endothelialize stainless steel stents has a possibility to reduce stent thrombosis in 
the first human study. Further developments in this technology are warranted to evalu-
ate the efficacy of this device and reduce the incidence of stent thrombosis. 
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SAMENVATTING EN CONCLUSIES
Deel 1 Lange termijn weefselgroei aan binnen-en buitenzijde van drug eluting 
stents in de mens
Na drug-eluting stent (DES) plaatsing, is de vaatreaktie aan binnen-en buitenzijde van de 
stent niet identiek. Hoofstuk 2 toonde de vaatreaktie volgend op sirolimus-eluting stent 
(SES) implantatie. Gedurende de eerste twee jaar toonde de gemiddelde hoeveelheid 
plaque en de veranderende plaque samenstelling uitgedrukt als gemiddeld percent-
age (%) echo-arm weefsel van de plaque achter de stent draden geen verandering van 
betekenis. Echter, plaque krimp van betekenis met een toename van plaque echo genic-
iteit werd gezien tussen twee en vier jaar. De gemiddelde neointimale hoeveelheid nam 
gedurende vier jaar toe. Echter, statistisch gezien werden geen belangrijke veranderin-
gen waargenomen tussen twee en vier jaar. Hoofdstuk 3 toonde vaatreaktie volgend 
op paclitaxel-eluting stent (PES) implantatie. Toegenomen plaque, welke zes maanden 
na PES implantatie aanwezig was aan de buitenzijde van de stent , verminderde volledig 
in de groep met de langzame afgifte (SR) en gedeeltelijk in de groep met de middel-
matige afgifte (MR) gedurende de volgende twee jaar. Neointimale onderdrukking via 
zowel SR als MR PES duurde tot twee jaar voort. Daar waar neointima in de Bare Metal 
Stent (BMS) groep afnam tussen 6 maanden en twee jaar, bleef neointima toenemen in 
de SR en MR groepen zonder van invloed te zijn op klinische gebeurtenissen. Hoofdstuk 
4 onderzocht de vaatreaktie op diverse doses- en farmacokinetische afgifte van PES met 
een erodeerbaar polymeer. Alhoewel sprake was van verschillende typen polymeer, de 
vaatreaktie aan binnen-en buitenzijde van de stent was gelijk aan PES met een stabiele 
polymeer. 
Hoofdstuk 5 vatte vaatreaktie na DES samen, inclusief everolimus en ABT 578-eluting 
stents. De vaatreaktie aan de buitenzijde van de stent was verschillend bij de limus fami-
lie (sirolimus en everolimus) en paclitaxel. Belangrijk positieve remodeling werd alleen 
bij paclitaxel afgevende stents waargenomen maar nam later weer af. 
Neointima, met andere woorden, vaatreaktie aan de binnenzijde van de stent, vermin-
derde na BMS implantatie.
Echter, bij alle soorten DES implantatie blijft neointima groeien. Hoewel lange termijn 
follow-up na DES implantatie een voortdurend klinisch voordeel aantoont in verschei-
dene gerandomiseerde studies, is vertraagde neointimale groei na de eerste zes tot ne-
gen maanden gerapporteerd in opeenvolgende intravasculair utrasound system (IVUS) 
analyses in enkele onderzoeken. De kwestie van de vertraagde restenosis, welk na bra-
chytherapie werd geobserveerd, is nog niet grondig geëvalueerd met behulp van DES. 
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Deel 2 Doeltreffendheid van drug-eluting stents for hoog-risico patienten
In het BMS-tijdperk, lange lesie, diabetes mellitus, linker coronair ziekte, chronische totaal 
occlusie en bifurcatie lesies zijn risicovol voor in-stent restenose. Bij patienten met deze 
hoog risico factoren werden de klinische effecten van SES en PES geanaliseerd. Hoofd-
stuk 6 Klinische resultaten op middellange termijn en het potentieel voor ongunstige 
resultaten werden geëvalueerd bij patienten waarbij lange segmenten ( dat wil zeggen 
≥ 64mm aan stent lengte ) werden behandeld met DES implantatie (populair “full metal 
jacket” genoemd). Het éénjarig coronaire revascularisatie percentage was 7,5% en het 
optreden van belangrijke cardiale eindpunten was 18%. Deze resultaten bleken beter 
dan “full metal jacket” met BMS (het éénjarig percentage revasculatisatie was 21,6% en 
het optreden van cardiale gebeurtenissen 38% in de historische controle). Resultaten 
in SES-en PES groepen toonden statistisch geen verschil. In hoofdstuk 7 en 8 werden 
patienten met diabetes mellitus geëvalueerd. In vergelijking met BMS reduceerde rou-
tinematig gebruik van SES voor diabetes patienten cardiale gebeurtenissen binnen een 
jaar aanzienlijk. (17.3% in de SES groep versus 30.2% in de pre-SES groep (risico percent-
age, 0.54 [95% vertrouwens interval, 0.32-0.91]; p=0.02)). PES werd geassocieerd met 
een non-significant optreden van cardiale gebeurtenissen binnen een jaar vergeleken 
met SES adjusted risico percentage 0.68, 95% vertrouwens interval 0.37 to 1.24, p=0.21). 
Hoofdstuk 9 illustreerde een patient met een chronische totale occlusie van de linker 
coronair welke succesvol behandeld werd met bifurcatie stenting met SES. Hoofdstuk 
10 en 11 analyseerde patienten met linker coronair ziekte, het cumulatieve vóórkomen 
van belangrijke cardiale eindpunten was lager in het DES cohort dan in de pre-DES pati-
enten groep (24% versus 45%, respectievelijk; risico percentage [HR] , 0.52 [95% CI, 0.31 
tot 0.88]; P=0.01). De totale mortaliteit tussen cohorten verschilde niet, echter, er waren 
aanzienlijk lagere percentages van zowel myocardinfarct (4% versus 12%, respectieveli-
jk; HR, 0.22 [95% CI, 0.07 tot 0.65]; P=0.006) als revascularisatie (6% versus 23%, respec-
tievelijk; HR, 0.26 [95% CI, 0.10 tot 0.65]; P=0.004) in de DES groep. PES benadert de werk-
ing van SES in termen van angiografische en lange termijn resultaten. Het cumulatieve 
vóórkomen van cardiale gebeurtenissen was vergelijkbaar (25% in de SES versus 29% in 
de PES groep; HR 0.88 [95% CI: 0.43 – 1.82]; p=0.74, overeenkomsten weergevend in het 
samengestelde geheel dood/MI (16% in de SES en 18% in de PES groep). Angiografisch 
in-stent late-loss (mm) was 0.32 ± 74 in het hoofd vat en 0.36 ± 0.59 in de zijtak de SES vs. 
0.46 ± 0.57 en 0.52 ± 0.42 in de PES, respectievelijk (p=0.36 en p=0.41). In hoofdstuk 12 
en 13 demonstreerden we de doeltreffendheid van DES implantatie voor de percutane 
behandeling van chronische totale occlusie in vergelijking met BMS. Zowel SES als PES 
werden geassocieerd met een laag percentage revascularisatie. Na één jaar was de over-
leving zonder noodzaak tot revascularisatie aanzienlijk hoger in de SES en PES groepen 
dan in de BMS groep (97.4% en 96.4% versus 80.8% respectievelijk, p=0.01). Klinische 
193
Samenvatting en conclusies 
en angiografische effecten voor patienten met bifurcatie lesies werden geanalyseerd in 
hoofdstuk 14 en 15. Cardiale eindpunten (MACE) percentages voor zowel SES als PES 
waren laag in vergelijking met historische BMS data. Onze bevindingen suggereren een 
grotere noodzaak voor revascularisatie voor de PES vergeleken met de SES, echter meer 
gerandomiseerd onderzoek is nodig om zowel stenting strategie als mogelijke verschil-
len tussen de stents (overleving vrij van revascularisatie was 95.7% voor SES versus 86.8% 
voor PES, p=0.01) te vergelijken. De stenting techniek was geen voorspeller van MACE 
of TLR. De meest effectieve technieken voor bifurcatie stenting blijven ongedefinieerd. 
Zowel SES als PES hebben bijna gelijke klinische effecten om MACE te reduceren in 
vergelijking met BMS, zelfs als patienten beschikken over hoog-risico factoren. 
Deel 3 Endotheliale voorlopercellen – alternatief voor drug-eluting stents
DES heeft het optreden van in-stent restenose spectaculair verminderd. Echter, het 
optreden van angiografische stent thrombose in een ongeselekteerde, complexe DES 
populatie was 1% en overeenstemmend met eerder gepubliceerde resultaten van het 
BMS tijdperk. Hoofdstuk 16 Andere technieken om het optreden van stent thrombose 
te verminderen zijn nodig om de klinische resultaten van coronair stenten te verbeteren. 
De versnelling van stent endothelialisatie is een belangrijke factor om stent thrombose 
te verminderen. Hoofdstuk 17 Recentelijk, het bestaan van circulerende endotheliale 
voorloper cellen (EPC) is ontdekt als een belangrijke factor voor re-endothelialisatie. De 
HEALING-FIM registratie is de eerste klinische ervaring met implantatie van een bio-en-
gineering stent (anti CD-34 gecoate stent) welke ontworpen is om circulerende endothe-
liale voorloper cellen te vangen. De resultaten van de HEALING-FIM (Healthy Endothelial 
Accelerated Linning Inhibits Neointimal Growth – First in Man) studie toonden aan dat 
de EPC stent veilig en bruikbaar is: geen stent thrombose deed zich voor (30 dagen of 6 
maanden), MACE trad enkel bij één patient op (6.3%), ondanks clopidogrel-therapie van 
slechts 30 dagen. Verdere ontwikkelingen in deze technologie zijn gewenst om de doel-
matigheid van deze stent te vergroten voor de behandeling van coronair lijden. Hoofd-
stuk 18. 
Deel 4 Toekomstige richting van de Interventie Cardiologie Hoofdstuk 19 geeft 
een samenvatting van alternatieve behandelingen van coronair lijden, behalve DES. Na-
der onderzoek naar met catheters te plaatsen bypass grafts, therapeutische angio-en 
myogenese, en de catheter gebaseerde instrumenten om hoge risico-plaque gevoelig-
heid en opbouw aan te tonen kunnen resulteren in aanvullende diagnostische en thera-
peutische opties voor patienten met coronair lijden.
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Samenvatting en conclusies 
In conclusie: Zowel SES als DES hebben grote invloed op de reductie van Cardiale eind-
punten (MACE), voornamelijk toe te schrijven aan de vermindering van revasculariza-
tie, zelfs als patienten hoge risico factoren voor restenose hebben. Huidige discussie-
punten van DES zijn lange termijn effecten van deze devices en stent thrombose. Lange 
termijn follow-up na stent implantatie toont een aanhoudend klinisch voordeel aan in 
diverse gerandomiseerde onderzoeken. In de intravasculaire ultrasound analyses van 
DES, bleef neointima groeien zonder dat het invloed had op klinische gebeurtenissen, 
hoewel plaque aan de buitenzijde van de stent na één jaar begon af te nemen. Langere 
termijn follow-up is nodig om het natuurlijke beloop van lokale drug afgifte door DES 
vast te stellen. Daarbij, de EPC capture stent heeft de mogelijkheid stent thrombose te 
reduceren in een eerste humane studie. Verdere ontwikkelingen in deze technologie zijn 
gewenst om de doelmatigheid van dit device te evalueren en het optreden van stent 
thrombose te reduceren.
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and four years, significant changes were noted (78.2� 8.9%
vs. 70.4 � 10.6%, p � 0.0001). A similar pattern was
observed for plaque at the proximal stent edge with a
significant reduction in percent hypoechogenic tissue at
four-year follow-up (p � 0.02). At the distal stent edge, no
significant changes in plaque echogenicity were observed
across time points (p � 0.78). Figure 3 is a representative
example of a patient with plaque shrinkage and reduction of
hypoechogenic plaque composition from two-year to four-
year follow-up.
Neointimal echogenicity. The echogenicity of the neoin-
tima increased over the four-year follow-up period (p �
0.0001) (Fig. 2B). On post-hoc testing with Bonferroni
corrections, the decrease in hypoechogenicity between four
Figure 1. (A) The adventitia is defined as tissue outside the external elastic membrane contour. For all non-shadowed adventitia pixels, the mean value and
standard deviation are calculated. To observe the suitability, a normal distribution curve based on the same mean and standard deviation histogram is
created. (B) Cross-sectional image of echogenicity and distribution graph of plaque echogenicity behind the stent struts. Hyperechogenic areas are colored
green. Hypoechogenic areas are colored red. ROI � region of interest.
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For SES, 80% of the drug load is eluted within 30 days of
stent implantation (1). However, concern has arisen about
long-term biological reactions to the non-biodegradable
polymer (5). Long-term exposure to these polymers may
cause chronic inflammation. Complete natural healing (i.e.,
re-endothelialization and a reduction in proteoglycan con-
tent) may take three to six months after bare metal stent
implantation (21). In this present study, plaque volume
behind the stent struts decreased between two and four
years, and this shrinkage was accompanied by a change in
plaque echogenicity, suggestive of a change in plaque
composition. This may indicate that the peri-stent area has
undergone a slower healing process after SES implantation
that results in a more fibrous content at four-year follow-up.
In animal experiments, it has been documented that the
exuberant proliferative process observed after stenting is
largely inhibited in the early stage with SES, but the normal
healing process is also delayed with persistence of fibrin
deposition and inflammatory cells (22). In humans, one
study reported the histologic findings of atherectomy spec-
imens of restenotic lesions after implantation of a paclitaxel
derivative-eluting polymer stent in which persistent fibrin
accumulation with smooth muscle cells and proteoglycan
and collagen type III-rich matrix with inflammation was
observed at 12 months (4,5). An autopsy performed on a
patient four years after SES implantation showed complete
healing, indicating that the delayed healing response had
abated, concurring with our findings (23).
In this study, neointimal volume continued to increase
over the four-year period. However, the increase between
two and four years failed to reach statistical significance (7.0
vs. 8.4 mm3, p � 0.25), and the change in neointimal
volume between two years and four years was significantly
less than between the post-procedure and two-year mea-
surements (1.4 vs. 7.0 mm3, p � 0.04), which possibly
indicates that the delayed tissue proliferation has subsided.
Carter et al. (24) reported long-term effects of SES in a
porcine coronary model. They found that inhibition of
neointimal hyperplasia was not sustained at 90 days com-
pared with the bare metal stent, and the mean neointimal
area was similar between 90 days and 180 days. These
results differ from observations seen in clinical trials, includ-
ing this study. Several trials have reported low target vessel
revascularization rates up to three years (25). This discrep-
ancy is likely explained by different monocyte and lympho-
cyte responses to similar concentrations of sirolimus in
human and porcine vessels, and the different anatomical
Table 3. Percent Hypoechogenic Tissue Component in the Plaque and Neointima
After
Procedure 4 Mo 1 Yr 2 Yrs 4 Yrs
ANOVA*
p Value
Post Hoc After
Procedure to
2 Yrs
Post Hoc
2 to 4 Yrs
Neointima, % — 74.9 � 12.7 68.9 � 17.1 66.7 � 19.1 57.0 � 22.6 0.0001† 0.03‡ 0.01
Plaque (stented segment), % 78.9 � 8.6 79.4 � 6.7 81.3 � 7.4 78.2 � 8.9 70.4 � 10.6 �0.0001 0.67 �0.0001
Plaque (proximal edge), % 88.7 � 6.9 87.2 � 6.5 87.1 � 6.0 87.7 � 7.9 81.7 � 9.3 0.02 0.67 0.008
Plaque (distal edge), % 86.1 � 9.8 86.8 � 6.0 87.0 � 10.4 88.5 � 9.5 85.9 � 9.4 0.78 — —
*Repeated-measures analysis of variance (ANOVA) was performed among five periods. Post-hoc analysis between after the procedure and two years, and between two and four
years were performed with Bonferroni corrections (significant level of p value is 0.025). †Repeated-measures ANOVA was performed among four periods, except after the
procedure. ‡Post-hoc analysis was performed between four months and two years.
Figure 3. A representative example of a patient with plaque compositional changes between two-year and four-year follow-up. Top row shows
cross-sectional vessel image at (A) post-procedure, (B) four months, (C) one year, (D) two years, and (E) four years. Red line indicates lumen. Light blue
line indicates stent. Green line indicates media. Dense blue line indicates adventitia. Bottom row shows cross-sectional echogenicity images.
Hyperechogenic areas are colored green. Hypoechogenic areas are colored red. (A’) Percent plaque behind stent hypoechogenicity was 84.0%
post-procedure, (B’) 85.3% at four months, (C’) 88.4% at one year, (D’) 84.2% at two years, and (E’) 74.8% at four years.
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intermediate coating with murine monoclonal anti-human
CD34 antibodies, attached to a stainless steel stent (R stent,
OrbusNeich, Fort Lauderdale, Florida) (Fig. 1). This anti-
body specifically targets CD34� cells (endothelial pro-
genitor cells are CD34 positive) in the vascular circula-
tion. This device was supplied in aqueous sodium azide
solution as a preservative to maintain bioactivity and
required hand crimping by the operator onto a percuta-
neous transluminal coronary angioplasty balloon catheter
before implantation.
Study procedures. Lesions were treated according to local
standard interventional techniques. Specifically, the decision
to predilate or direct stent was at the investigator’s discre-
tion, and post-dilation was performed as required to ensure
that the residual stenosis was �20% by visual assessment,
with a TIMI flow grade rate 3. In case of a dissection or
incomplete coverage of the lesion, implantation of addi-
tional EPC capture R stents was permitted.
Intravenous boluses of heparin were administered to
maintain an activated clotting time �300 s during the
implantation. Treatment with aspirin, at a dose of at least 80
mg/day, was initiated at least 12 h before the procedure and
continued for one month. In addition, a loading dose of 300
mg of clopidogrel was administered before the procedure,
followed by 75 mg daily for 28 days. Glycoprotein IIb/IIIa
inhibitors were used at the operator’s discretion. Angio-
graphic success was defined as the successful implantation of
the study device, with a stenosis of �20% of the vessel
diameter with TIMI flow grade 3.
Follow-up. All patients were scheduled for a clinical
follow-up at one, six, and nine months following the
implantation procedure to assess the anginal status and
the occurrence of major adverse cardiac and cerebrovas-
cular events (MACCE). An electrocardiogram was ob-
tained at each visit, and an angiographic and intravascular
ultrasound (IVUS) study was performed at a mean of 185
� 14 days.
Quantitative angiographic and IVUS analysis. Coronary
angiograms were obtained in multiple views after an intra-
coronary injection of nitrates. Offline quantitative analyses
of preprocedural, postprocedural, and six-month follow-up
angiographic data were performed. Restenosis was defined
as a reduction of 50% or more of the luminal diameter. Late
luminal loss was defined as the difference between the
minimal luminal diameter after procedure and at six
months. The target lesion was defined as the stented
Abbreviations and Acronyms
EPC � endothelial progenitor cell
HAMA � human antimurine antibody
HEALING-FIM � Healthy Endothelial Accelerated
Lining Inhibits Neointimal
Growth-First In Man
IVUS � intravascular ultrasound
MACCE � major adverse cardiac and
cerebrovascular events
MI � myocardial infarction
SMC � smooth muscle cell
TIMI � Thrombolysis In Myocardial
Infarction
Figure 1. Endothelial progenitor cell (EPC) capture coating technology.
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early functional endothelial lining can be expected in the
interstrut space, although the interstrut area in the animal
model (healthy coronary artery undergoing direct stenting)
was covered with functional endothelium within 48 h; this
situation differs substantially from a human pathologic
atherosclerosis vessel after balloon injury. In addition, the
bioactivity of these prototype EPC capture stents used in
HEALING-FIM registry was unstable and was easily
reduced by sterilization with gamma irradiation. It was
subsequently discovered through the use of a bioassay that
gamma irradiation lessened the immunoaffinity of EPC
capture prototype stents used in this trial. Therefore, it is
likely that the reduced bioactivity of EPC capture stents in
the HEALING-FIM registry may not have been enough to
inhibit neointimal hyperplasia after stent implantation.
The technology behind the creation of an EPC affinity
surface is achieved by attaching murine monoclonal antihu-
man CD 34 antibodies to the stent. An immunoreaction
against the murine monoclonal antibody may occur in
patients who have human ant-murine antibody (HAMA).
In addition, production of HAMA may result in the
neutralization of the EPC capture surface. In this registry,
increased HAMA levels were not observed in the four
patients who underwent serial HAMA testing, and no
patients exhibited systemic symptoms of immunoreaction.
This safety issue was in agreement with other trials, evalu-
ating immunologic treatment using murine antibody for
ovarian cancer (10).
Because of the small sample size and single-center en-
Table 4. Evolution of Endothelial Progenitor Cell Capture
Stent: Improvement From HEALING-FIM (H1) to
HEALING II (H2)
Device
H1 - Wet, hand-crimped
H2 - Dry, premounted
Stability
H1 - Wet; supplied in sodium azide preservative; required rinsing
before use
H2 - Dry, formulated to preserve antibody structure & activity
Sterilization
H1 - Gamma irradiation; 15 to 25 kGy
H2 - Gamma irradiation; �15 kGy
Bioactivity
H1 - Significant reduction in activity with sterilization
H2 - Stable with sterilization
Figure 2. Overview (A) and details (left: B, C; mid:D, E; right: F) of the atherectomy specimen obtained six months following stent placement. Histology
shows a mixture of myxoid (B, C) and fibrous material (F) consisting of smooth muscle cells (C, E) within variable amounts of extracellular matrix. Some
fragments contained thrombus remnants (Th) (D, E) and calcifications (Ca) (F). A � elastin stain; B, D, F� hematoxylin eosin; C, E �
immunocytochemistry for smooth muscle cell-specific alpha actin.
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established that general tissue shrinkage can not be
avoided during dehydration.68 Shrinkage of up to
60%, 15% and 80% can occur during critical-point-
drying, free-drying, and air-drying respectively.69
Furthermore, post-mortem contraction of arteries fur-
ther contributes to deteriorate the pathological quan-
tification of atherosclerosis.70 Accordingly, we be-
lieve that the threshold should be higher than 65 µm.
Since the axial resolution of IVUS is between 100
and 150 µm, techniques such as IVUS-VH with the
capacity to quantify each plaque component and to
identify the location of the lipid core in relation to
the lumen have the potential to recognize all the 3
features of TCFA lesions.
Optical coherence tomography (OCT) is an imaging
technique that allows high-resolution (axial resolution
of 15 µm) imaging in biological systems (Figure 9).71
Accordingly, OCT has the capacity to allow in-vivo,
real time visualization of a thin fibrous cap. Recent in
vivo data suggest the possibility of detection of
macrophages in atherosclerotic plaques.72
The sensitivity and specificity of palpography to de-
tect vulnerable plaques has recently been assessed in
post-mortem human coronary arteries where vulnera-
ble plaques were detected with a sensitivity of 88%
and a specificity of 89%.63
Positive Remodeling
The expansive compensatory enlargement of the
coronary arteries in response to an increase in plaque
area is called positive or expansive remodeling.73
Several studies showed an increase in inflammatory
marker levels, larger lipid cores, and pronounced me-
dial thinning in positive remodeled vessels.74-76 Re-
cently, the relationship between vascular remodeling
and plaque composition was assessed using IVUS.77-79
In these studies, the remodeling index for soft lesions
Figure 6. Direct myocardial injection using IVUS guide needle punctu-
res via the coronary venous system.
Figure 7. Virtual histology image. Red: lipid core. White: calcium. Ye-
llow: fibrofatty. Green: fibrosis. Gray: media.
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Figure 8. Palpography image. Yellow,
high strain spot.
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